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Abstract
The ZNF217 transcription factor is an oncogene found within the 20q13 amplicon
and is amplified and overexpressed in many cancers including breast and ovarian.
Overexpression of ZNF217 leads to increased cell proliferation, survival, and causes
resistance to TGFβ's anti-proliferative effects.
ZNF217 is a core constituent of a transcriptional complex that includes CoREST,
HDAC1/2, LSD1, and the CtBP1/2. In this study, I have combined genome-wide
biochemical approaches to identify genes directly regulated by ZNF217. I have identified
the tumor suppressor and cell cycle inhibitor, p15ink4b, as a direct target of the ZNF217
complex and demonstrated that ZNF217 represses the p15ink4b gene by promoting a
repressive chromatin environment and facilitating promoter DNA hypermethylation that
involves a novel interaction with DNMT3A.
Furthermore, treatment of cells with TGFβ triggers DNA demethylation of the
p15ink4b promoter and the release of ZNF217/CoREST/DNMT3A complex. Subsequently,
a novel activation complex is recruited that consists of SMAD2/3, CBP, and the DNA
glycosylase TDG which precedes increases in p15ink4b protein expression. Knockdown of
TDG, or its functional homolog MBD4, prevents TGF-β-dependent demethylation of the
p15ink4b promoter suggesting that the demethylation occurs through an active mechanism
and is required for TGFβ dependant activation of gene expression. DNA
immunoprecipitation experiments indicate that 5mC undergoes conversion to 5hmC in
response to TGFβ treatment. AID/APOBEC2 deaminases are also required for the DNA
demethylation by TGFβ supporting a mechanism whereby 5mC is hydroxylated to 5hmC
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and then deaminated to 5hmU which is reverted to the unmethylated cytosine by the BER
enzymes.
Overexpression of ZNF217 inhibits promoter demethylation and expression of the
p15ink4b gene in response to TGFβ by preventing recruitment of SMAD2/3/TDG complex.
These findings suggest that the coregulator balance at promoters of genes is an important
determinant of gene regulation and oncogenic amplifications such as ZNF217 can upset
this balance causing deregulation of many genes. Taken together, these results establish
the ZNF217 complex as a negative regulator of the p15ink4b gene and may constitute an
important link between amplification of ZNF217, increased cell proliferation and loss of
TGFβ responsiveness in cancer.
Keywords: ZNF217, p15ink4b, Active DNA Demethylation, TGFβ, Cancer, TDG,
MBD4, LSD1, CoREST, HDAC.
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Chapter 1: General Introduction

2

1.1 Overview
Cell-specific phenotypes resulting from embryonic development are dictated
through a succession of signals that trigger elaborate and accurate patterns of gene
expression. Gene expression can be regulated in many ways that can be understood
through consideration of the central dogma (Figure 1.1). The central dogma describes
how the message encrypted in the deoxyribonucleic acid (DNA) is decoded and begins
through the production of ribonucleic acid (RNA) molecules complementary to the DNA
molecule, referred to as transcription, and then the production of linked amino acids
(peptides) translated from the RNA to make complex proteins, referred to as translation
(Bustamante et al., 2011; Franklin and Vondriska, 2011). In eukaryotes, RNA is
synthesized in the nucleus through an enzyme, RNA polymerase (RNA-pol), followed by
processing of the RNA such as addition of poly Adenosine tail and splicing. The RNA is
then exported out to the cytoplasm to be translated. Translation of the RNA molecule to
generate individual proteins is performed by a large protein complex, the ribosome
(Rodrigo-Brenni and Hegde, 2012). The ribosome is composed of both protein and RNA
subunits that can recruit structures called transfer RNAs (tRNA), structural RNA
molecules that carry a specific amino acid. Within the ribosome the tRNA molecules
recognize triple nucleotide base units of the messenger RNA (mRNA), referred to as
codons. A catalytic unit of the ribosomal RNA catalyzes a peptide linkage to the
carboxyl-terminal end of a growing peptide chain which will, following completion and
proper folding, become a functional protein (Jackman and Alfonzo, 2012). The translated
proteins then become the building blocks for structural integrity and enzymes that carry
out many complex reactions in the cell.

Figure 1.1: The central dogma.
In the nucleus, DNA is transcribed by RNA polymerase to pre-RNA which is then
processed by addition of a poly-A tail, 5'cap and the removal of introns to yield the
mature RNA. The RNA is then transported out of the nucleus into the cytoplasm where it
is translated by the ribosome into a functional protein.
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1.2 Eukaryotic Transcription
Transcription can be divided into three major phases, initiation, elongation and
termination. The control of transcription initiation is considered a critical and rate
limiting step in determining cell protein composition. In eukaryotes, there are three major
classes of proteins that dictate transcription initiation: (1) Sequence specific transcription
factors (TFs), many of which are expressed in a tissue specific fashion and can serve as
activators or repressors (Garcia-Huerta et al., 2012; Sharon et al., 2012), (2) the basal
transcriptional machinery consisting of core proteins that include the ubiquitously
expressed RNA polymerase II (RNA-pol-II) and general transcription factors (GTFs) that
facilitate the loading of the polymerase onto the DNA, and (3) transcriptional
coregulators, that can either directly interact with the basal transcriptional machinery or
that can modify the promoter region to indirectly facilitate or inhibit the loading of the
transcriptional machinery. These three classes of proteins work in concert to determine
the amount and types of crucial cellular contituents (proteins, RNA etc.) produced that
ultimately dictate the phenotype of the cell (Figure 1.2).
1.2.1 DNA
Proteins within a cell are strategically synthesized through specific instructions
contained in the genetic “blue print” of the cell, the DNA. DNA consists of two long
chains of linear polymers, which make up the individual chromosomes, and each chain is
composed of nucleotides. A nucleotide contains three components; a negatively charged
phosphate group, a pentose sugar molecule and a nucleotide base. The pentose sugar
molecule is linked to the phosphate group by a phosphoester bond to the 5’ carbon and

Figure 1.2: Transcription initiation.
This diagram depicts the regulation of gene expression through the concerted actions of
many cis-regulatory elements which consists of core promoter elements, proximal
promoter elements and elements located at further distances from the TSS such as
enhancers, and silencers. Transcription is initiated by binding of GTFs to the core
promoter in the following sequence; TBP binds to the TATA box followed by the binding
of TFIIB, TFIIF and RNA-pol-II complex, TFIIE, and TFIIH. Two additional protein
complexes can also regulate transcription initiation in eukaryotes; TAFs interact directly
with activators that bind proximal promoter elements and Mediator complex is
responsible for facilitating the interaction between long range activators, which bind to
enhancer elements, and the GTFs. CpG islands are also located near the TSS that can
recruit SP1 to facilitate transcription.
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the 1’ carbon is linked to the base through a glycosidic bond. Adjacent nucleotides are
linked through a phosphodiester bond created between the phosphate group and the 3’
hydroxyl of the pentose sugar. Four different bases make up the DNA; the purines,
adenine (A) and guanine (G), pairs with the pyrimidines, thymine (T) and cytosine(C),
respectively. Unique combinations of the four bases can form “factors”, as coined by
Gregor Mendel, which are units of information, referred to as genes (Reid and Ross,
2011). A gene is a hereditary unit resulting in identifiable traits and is the simplest unit
that can produce a functional protein. Most eukaryotic genes contain introns, which
consist of DNA sequence that is excluded from the resulting protein, and exons, DNA
sequence containing the necessary information to make a complete protein (Figure 1.1).
The DNA chains are arranged in an anti-parallel orientation, held together by
complementary base pairing to form a double helix molecule of approximately 22-26
angstroms (Watson and Crick, 1953, 2003). The resulting double helix also contains two
unequally sized grooves, the major groove and the minor groove. The mammalian
genome consists of 23 homologous chromosomes pairs and 2 sex chromosomes and
contains more than 25 000 protein coding genes.
1.2.2 RNA and Amino Acids
During transcription, DNA is read from 3’ to 5’ direction by the RNA-pol and
generates the complementary RNA molecule in the 5’ to 3’ direction. The resulting RNA
molecules are single strand linear polymers and, unlike DNA, contain a ribose instead of
a deoxyribose sugar (Cheatham and Kollman, 1997). RNA molecules also contain the
base uracil (U) in place of T. Many types of RNAs are transcribed from the eukaryotic
genome. Ribosomal RNA molecules (rRNA) are part of the ribosomal protein-RNA
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translational machinery and are transcribed by RNA polymerase I (RNA-pol-I) (Reeder,
1990). tRNAs are structural RNAs that carry the necessary amino acid to the ribosome
during translation (Lambowitz and Perlman, 1990). Recently, many non-coding RNA
(ncRNA) molecules involved in structural and functional roles within the cell have been
identified. One such RNA molecule is the micro RNA (miRNA) which regulate
transcription of genes through downregulation of mRNAs (Leonardo et al., 2012).
The mRNAs are transcribed from protein coding genes by RNA-pol-II (Figure
1.1). In prokaryotes, transcription and translation occur simultaneously and the resulting
RNA is translated without further processing (Mitchell et al., 1997). In eukaryotes, the
transcribed RNA molecule (pre-mRNA) is processed by an RNA-protein complex called
the spliceosome which removes introns and splice together exons corresponding to an
individual gene (Bonnal et al., 2012; Nielsen and Staley, 2012). In many cases, unique
combinations of exons can be formed, called splice variants, that results in multiple
protein isoforms being derived from a single gene (Herbert and Rich, 1999). Further
processing of the pre-mRNA involves the addition of a 5’ cap and a poly-adenylated 3’
tail, which are important determinants of mRNA stability. The resulting mRNA is loaded
onto the ribosome and is read in the 5’ to 3’ direction one codon at a time and each codon
dictates the amino acid added to the growing polypeptide chain (Figure 1.1)(Nakamoto,
2009).
There are 20 amino acids that make up the individual eukaryotic proteins and
amino acids can be represented by several codons (Nakamoto, 2009). The backbone of
every amino acid has a simple configuration, consisting of an alpha-carbon joined to an
amino group and a carboxyl group (NH2-CH-COOH). During translation, a peptide bond
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is formed between the carboxyl group and the amino group of an adjacent amino acid.
The resulting peptide contains an amino-terminal end (N-terminal) and a carboxyl
terminal end (C-terminal). The side chains that are attached to the alpha-carbon defines
the unique properties of the amino acids. Importantly, the side chains can participate in
protein-protein interactions, can be covalently modified (phosphorylation, methylation,
ubiquitination, acetylation and sumoylation), function as proton donors/acceptors during
enzymatic reactions, and/or influence the secondary structure and function of the protein
(Gray, 2003; Moreira et al., 2007).
1.2.3 RNA Polymerase
RNA-pol-II is the fundamental complex that catalyzes that the transcription of
mRNA precursors as well as microRNAs. Eukaryotic RNA-pol-II contains 10-12
subunits, Rpb1 to Rpb12. The subunits are structurally and functionally conserved
between yeast and humans and the core eukaryotic RNA-pol-II also shares similarity with
prokaryotic RNA polymerase (Cramer et al., 2000). Initial binding of RNA-pol-II to
DNA is performed by the Rpb1 subunit that is also capable of identifying a
transcriptional start site (TSS). Rpb1 and Rpb2, together, form the active site of the
enzyme, where ribonucleoside triphosphates (NTPs) are polymerized. Structural studies
indicate that Rpb5 on one side and Rpb1 and Rpb9 on the other act as a mechanical jaw
to help position DNA for transcription and Rpb1, Rpb2 and Rpb6 act as a sliding clamp
allowing DNA to pass through the RNA-pol while also stabilizing the DNA-RNApolymerase complex (Cramer et al., 2008). The remaining subunits contribute to various
transcriptional processes such as TSS identification (or binding) transcriptional
elongation and interaction with additional activator proteins. For example, Rpb4 and
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Rpb7 appear to function as stress responsive dissociable subunits and display tissue
specificity (Khazak et al., 1998). DNA assumes a non-linear structure when bound by
RNA-pol-II forming a sharp bend at the site of interaction, which is speculated to provide
torsional stress to the double helix hence lowering the energy required to break the
hydrogen bonds between the complementary strands (Coulombe and Burton, 1999). The
growing nascent RNA strand is fed through two pores that are formed by the Rpb1 and
Rpb2 subunits.
1.2.4 Eukaryotic RNA-pol-II Regulator DNA Regions
Regulation of gene expression occurs through the concerted actions of short DNA
sequences known as cis-regulatory elements that are found within promoters, enhancers
and introns. Cis-regulatory elements bind TFs that function as activators, repressors or
insulators (Figure 1.2) (Gaszner and Felsenfeld, 2006; Petrykowska et al., 2008).
Core promoters consist of DNA sequence immediately upstream (5’) of TSSs and
contain diverse sequence elements that direct transcription initiation (Butler and
Kadonaga, 2002). Variability in core promoter sequence is crucial for transcription
regulation since it provides a gene specific function for activators and repressors.
Eukaryotic core promoters of protein coding genes can contain three different promoter
elements that dictate RNA-pol-II loading; the TATA box, the initiator element (Inr), and
the GC-rich elements (Figure 1.2). The TATA box was identified as early as 1979 when
promoter regions of Drosophila melanogaster, mammals and viral RNA-pol-II protein
coding sequences were compared and analyzed (Breathnach and Chambon, 1981). The
TATA box has a consensus sequence that is TATAXAAX (X represents A, T, C or G)
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and is found 25-35 bp upstream of the TSS (Carninci et al., 2006; Hahn et al., 1989).
Recent comparative sequence analysis of many D. melanogaster core promoters has
found that as many as 32-43% of promoters contain a TATA box (Kutach and Kadonaga,
2000; Ohler et al., 2002). In humans, a similar analysis of 1031 core promoters revealed
that 32% contain the TATA box (Suzuki et al., 2001). Depending on the tissue type,
mutations within the TATA box can result in a drastic reduction in transcription (Duan et
al., 2002). TATA box acts to position RNA-pol-II at the TSS and because the TATA box
consensus sequence is not symmetrical, it also confers directionality of transcription
(Singh et al., 1997).
Some eukaryotic genes contain an Inr element which is found at the TSS and
consists of a degenerative consensus sequence Y-Y-A (+1)-N-T/A-Y-Y-Y-3’, where Y
represents any pyrimidine and N represents (A,G,C or T) (Figure 1.2) (Javahery et al.,
1994). Pyrimidines at position -2, +4, and +5 are essential for Inr activity and increasing
the number of pyrimidines around this position correlates with increased transcription
(Kutach and Kadonaga, 2000). The Inr sequence functions independently of other
regulatory elements and transcription from Inr-containing promoters is comparable to
TATA box regulated promoters (Corden et al., 1980; Grosschedl and Birnstiel, 1980).
Some eukaryotic promoters contain both the TATA box and the Inr element where both
elements function synergistically (Malecova et al., 2007). An Inr element is found in
approximately 69 % of core D. melanogaster promoters but the prevalence of these
elements in mammals is yet to be determined (Kutach and Kadonaga, 2000).
Promoters of some eukaryotic genes lack both the TATA box and the Inr element
and do not contain a well-defined TSS. These genes may have multiple TSSs that span
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between 20-200 bp, giving rise to mRNAs that vary in size. These genes often contain
CG dinucleotide repeats, also known as CpG islands. CG dinucleotide repeats can serve
as specificity protein 1 (SP1) binding sites and studies have demonstrated that
transcription often begins 40-80 bp downstream of SP1 binding. This suggests that SP1
may direct the transcriptional machinery to these sites (Figure 1.2) (Kwon et al., 1999).
The human genome is estimated to have approximately 29,000 CpG islands and half of
the protein coding genes contain at least one CpG island in the vicinity of the TSS
(Antequera and Bird, 1993; Suzuki et al., 2001). Interestingly, it has been found that
when an Inr element is inserted downstream of an SP1 binding site, higher levels of
transcription can be attained (Butler and Kadonaga, 2002; Smale, 2001). Combinatorial
effects of the proximal promoter elements can thus confer multiple transcriptional states
of genes, adding complexity and control of gene transcription (Petrykowska et al., 2008).
The promoter may also contain other cis proximal promoter elements that can
activate or repress transcription. In addition, regulatory elements may also be found many
kilobases away, within enhancer regions (Figure 1.2) (Lenhard et al., 2012). Enhancers
are DNA sequences consisting of one or more binding sites for a variety of TFs that can
regulate transcription independent of their position within the genome, distance or
direction (Banerji et al., 1981). In fact, enhancers have been known to activate
transcription of genes located on a separate chromosome (Geyer et al., 1990; Lomvardas
et al., 2006). It has been shown that TFs bound at enhancers can directly interact with the
core transcriptional machinery by a mechanism involving looping out of the intervening
sequences (Schoenfelder et al., 2010).
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1.2.5 Transcription Factors
TFs are proteins that bind to cis-regulatory elements and regulate gene expression
by facilitating the loading of RNA-pol-II and activating transcription, or hindering its
binding and repressing transcription (Petrykowska et al., 2008). The activity of a single
TF bound to DNA may regulate transcription alone or may be affected by the presence of
other TFs that bind to adjacent sites. For example, Yin Yang 1 (YY1) is a transcriptional
repressor or activator depending on the presence of specific factors. This suggests that the
context in which the TFs are found is an important determinant of gene regulation
(McKenna and O'Malley, 2002; Shi et al., 1997). The human genome encodes
approximately 2000 distinct TFs representing approximately 5 % of the human genome
(Tupler et al., 2001). TFs can be classified into many different families according to their
DNA binding domains or the class of genes they regulate. For example, the
homeodomain protein family contains domains that can specifically bind and regulate
homeotic genes, which determine the development of body plan (Blyth, 2012; Verzi et
al., 2012). Helix-loop-helix (HLH) proteins and leucine-zipper proteins function as
dimers and contain the hydrophobic amino acid leucine at every seventh position that is
required for the dimerization (Baxevanis and Vinson, 1993; Oshaben et al., 2012; Zhao et
al., 2012).
The largest class of TFs are the zinc finger (ZNF) family of proteins (Laity et al.,
2001). ZNF proteins use zinc ions to contour a relatively short, 23-50 amino acids,
polypeptide to form compact projected structures. Two major classes of ZNF proteins are
present in eukaryotes, referred to as the C4 ZNF and C2H2 ZNF proteins (Iuchi, 2001;
Seo et al., 2012). The C4 ZNF proteins contain four conserved cysteines within a short
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stretch of polypeptide that can coordinate a zinc ion and bend the polypeptide to form the
fingers. The C4 ZNF proteins contain only two such fingers and generally bind to DNA
as a dimer. This class of TF encompasses the nuclear hormone receptors that are
regulated by ligand binding (Knegtel et al., 1995). The C2H2 class of ZNF proteins
contains two conserved cysteines adjacent to two conserved histidines that bind and
coordinate a zinc ion to form the individual fingers. This class of proteins can contain
several adjacent fingers which wrap around the double helix DNA and insert into the
major groove (Iuchi, 2001; Quinlan et al., 2007).
Several mechanisms exist for the regulation of TFs that provides an additional
level of transcriptional control. Many TFs, such as the steroid hormone receptors are
sequestered in the cytoplasm thus preventing access to a DNA binding site. Additionally,
TFs are subject to post-translational modifications such as phosphorylation, acetylation
and methylation, that may also result in alterations to subcellular localization, activity and
ability to recognize binding sites on DNA (Zhang and Reinberg, 2001).
1.2.6 Mechanism of Eukaryotic Transcription Initiation
Transcription initiation is considered to be an integrative process and is the result
of the combinatorial binding of TFs to the core promoter, proximal promoter elements
and enhancers (Figure 1.2). In vitro experiments have demonstrated that RNA-pol alone
is sufficient for transcription but the eukaryotic RNA-pol-II requires additional proteins,
such as TFs, to be targeted to the promoter region of genes in vivo. These proteins can
form a complex with RNA-pol-II and is referred to as the pre-initiation complex (PIC)
(Walter, 1967; Sekine et al., 2012). In addition, the PIC also assists in strand separation,
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dictates start site selection and provide directionality to transcription. DNA foot-printing
and electro-mobility shift assays have been used to characterize the proteins of the PIC
that bind to DNA, referred to as the general transcription factors (GTFs) (Orphanides et
al., 1996). Transcription is initiated by binding of the TATA box binding protein (TBP)
through its C-terminal region. TBP is highly conserved between yeast and humans and its
structure resembles a saddle with both non-identical halves of the protein exhibiting a
dyad symmetry (Kays and Schepartz, 2000). Interestingly, much like a saddle, TBP
interacts with the minor groove of the DNA double helix with each half of the protein on
both sides of the DNA and this interaction causes a significant bend in the DNA.
Transcription factor IIB (TFIIB) then binds to TBP, through its C-terminal end, and
makes direct contact with the TATA box (Sainsbury et al., 2012). TFIIB demonstrates
directionality with its N-terminal domain extending towards the TSS. This is followed by
recruitment of a preformed complex consisting of transcription factor IIF (TFIIF) and
RNA-pol-II and the catalytic site of RNA-pol-II is positioned over the TSS. Before the
DNA double strand can be separated to expose the template strand, two other proteins
must bind, transcription factor IIE (TFIIE) and transcription factor IIH (TFIIH) (Kim et
al., 2000; Kim et al., 1997). TFIIH has helicase activity and uses the energy derived from
adenine triphosphate (ATP) breakdown separate the double stranded DNA providing an
open template for RNA-pol-II to initiate transcription (Kim et al., 2000).
Two additional protein complexes can also regulate transcription initiation in
eukaryotes; TBP associated factors (TAFs) and Mediators (Figure 1.2). TAFs serve as
scaffolds for the assembly of the PIC and play a critical role in promoter recognition
(D'Alessio et al., 2009). A multi-subunit complex consisting of TBP and approximately
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12 TAFs, generally referred to as transcription factor IID (TFIID), is often found as part
of the eukaryotic PIC. Eukaryotic genes can be characterized as TAF dependent or
independent and genes requiring TAFs achieve specificity through differential tissue
specific expression of TAF proteins (D'Alessio et al., 2009; Kuras et al., 2000; Raha et
al., 2005). TAFs can also interact directly with activators that bind proximal promoter
elements thus increasing gene expression (Shen and Green, 1997).
The Mediator is a large multi-protein complex containing as many as 20 subunits.
Seven Mediator complexes have been identified in humans (Kim et al., 1994; Myers and
Kornberg, 2000). Mediator complex is responsible for facilitating the interaction between
long range activators, which bind to enhancer elements, and the GTFs. This increases the
formation of the PIC at TSS and enhances gene transcription (Ptashne and Gann, 1997;
Scafe et al., 1990). The Mediator has also been shown to increase basal transcription by
approximately 10-fold and promote phosphorylation of the C-terminal domain (CTD) of
RNA-pol-II. The CTD consists of up to 52 repeats with a consensus Tyr-Ser-Pro-ThrSer-Pro-Ser and is an essential component of the RNA pol II that plays an important role
in transcription initiation, RNA capping and splicing (Kim et al., 1994; Lee et al., 1997).
Transition from the initiation phase to the elongation phase involves the
dissociation of RNA-pol-II from the majority of the GTFs associated with the PIC.
However, certain factors that facilitate the elongation by RNA-pol-II, remain associated.
In addition, the transition into the elongation phase requires several covalent
modifications to the CTD of RNA-pol-II such as phosphorylation (Wade and Struhl,
2008). RNA-pol-II then transcribes towards the 3’-end of the gene, effectively elongating
the mRNA as it proceeds. Termination of transcription can occur in several ways but one
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accepted mechanism involves the addition of the poly A tail to the nascent mRNA. This
allows for the recruitment of RNA binding proteins that can promote the dissociation of
the RNA-pol-II/RNA complex from the DNA(Kuehner et al., 2011).
In summary, the PIC is required for the loading of RNA-pol-II and in many cases,
TAFs are required as part of the PIC for promoter recognition and, along with Mediators,
facilitate the activation by long range enhancers. Although GTFs, TAFs and Mediators
are essential for transcription initiation, the regulation of their binding and activity is
controlled by epigenetic mechanisms.

1.3 Epigenetic Regulation of Gene Expression: Overview
Epigenetic regulation is defined as “the structural adaptation of chromosomal
regions so as to register, signal or perpetuate altered activity states” of genes (Bird,
2007). One component of epigenetic regulation occurs as a result of the packaging of
DNA into chromatin, a nucleoprotein complex that allows for gene regulation through
nucleosome remodelling and post-translational covalent modifications (Gu and Roeder,
1997). Another component of epigenetic control involves DNA methylation at cytosine
within CpG dinucleotides and CNG trinucleotides resulting in the formation of 5methylcytosine (5mC). DNA methylation is generally considered to be repressive to
transcription and is important for the maintenance of chromosome stability. (Bird, 1986;
Deaton and Bird, 2011). These two forms of epigenetic control are major determinants of
the transcriptional state of the cell and are largely defined by a repertoire of proteins with
enzymatic activity that are targeted to specific sites throughout the genome.
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1.3.1 Chromatin: General Features
The nucleosome is the fundamental repeating unit of chromatin and consists of an
octamer of core histones containing two copies each of histone H3, H4, H2A and H2B,
interacting with each other through globular domains (Figure 1.3) (Eickbush and
Moudrianakis, 1978; Luger et al., 1997). Approximately 147 bps of DNA is wrapped
around each nucleosome in 1.7 helical turns and the nucleosomes are connected by 10-16
bps of linker DNA (Kornberg and Thomas, 1974).

Each histone has an amino-terminal tail consisting of 20 to 37 amino acids, and

although the molecular structure of the tails have not been determined, it is believed that
the histone tails protrude out from the surface of the nucleosome (Szerlong and Hansen,
2011). A fifth histone, the histone H1, interacts with nucleosomes and serves as a linker
between successive nucleosomes to stabilize and promote a higher order structure of
chromatin. Histone H1 has been implicated in promoting transcriptional repression by
blocking nucleosome repositioning, obstructing activator binding and promoting
heterochromatization (Caterino and Hayes, 2011; Shen and Gorovsky, 1996).
Chromatin is packaged into two general states that are highly dynamic and
contribute to the maintenance of cellular identity, heterochromatin and euchromatin.
Heterochromatin consists of highly dense regions and contains genes which are not being
transcribed. Euchromatin consists of less dense regions of the genome which contains
many genes that are either being actively transcribed or are poised for transcription
(Figure 1.3). Euchromatin represents the first order of compaction and when examined by
electron microscopy, appears as a 11 nm fiber composed of DNA wrapped around many

Figure 1.3: The chromatin structure.
The top represents chromatin packaging which is dynamic and generates two states,
heterochromatin which is a highly dense region, and euchromatin, a less dense region of
the genome. Euchromatin consists of approximately 147 bp of DNA wrapped around
each nucleosome and the nucleosomes are connected by 10-16 bp of linker DNA. The
bottom depicts a nucleosome which consists of an octamer of core histones containing
two copies each of histone H3, H4, H2A and H2B. Each histone has an amino-terminal
tail that protrudes out from the surface of the nucleosome. Adapted from (Russ et al.,
2012).
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repeating nucleosomes which resemble “beads on a string” (Figure 1.4) (Szerlong and
Hansen, 2011). The second level of compaction consists of the 30 nm fiber which is
found in heterochromatin (Gu and Roeder, 1997). Though the crystal structure of the
11nm fiber has been solved the exact structure of the 30nm fiber remains unclear
(Kornberg and Thomas, 1974). Chromatin is also able to undergo several levels of higher
order compaction and it has been hypothesized that long-range interactions between
nucleosomal arrays is thought to play a role in additional compaction although the
dynamics remains unclear (Li and Reinberg, 2011). Chromatin itself plays an extremely
important role in the regulation of gene transcription because the winding of DNA around
nucleosomes, as well as the higher order packaging of chromatin renders the DNA
largely inaccessible. Consequently, transcription requires that genes become accessible to
both sequence specific TFs and the transcriptional machinery (Narlikar et al., 2002;
Urnov and Wolffe, 2001).
In order to accomplish this, eukaryotic cells utilize coregulator proteins which
alter chromatin structure and make the DNA more accessible. Coregulator proteins can
be divided into two categories. The first are the ATP-dependent nucleosome remodeling
proteins, which often exist as part of multi-protein complexes and utilize the energy
derived from the hydrolysis of ATP to reposition nucleosomes. The second category
consists of coregulators that modify the chemistry of histone proteins by catalyzing posttranslational modifications to the amino terminal tails of the histones (Turner, 1993).
Both types of coregulator proteins can induce transcriptional changes important for gene
regulation.

Figure 1.4: Transmission electron image of euchromatin.
An image generated using Transmission Electron Microscope of Chicken erythrocyte
nuclei that were allowed to decondense. Decondensed chromatin appears as a 10nm fiber
composed of DNA wrapped around many repeating nucleosomes which resemble a
“beads on a string” model. The black arrows point to nucleosomes and the white arrows
point to the linker region between nucleosomes.
Figure adapted from The Cell (An image library; http://www.cellimagelibrary.org/images
/709).
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The ATP-dependent chromatin remodeling complexes can restructure chromatin
to make DNA more accessible for transcription, or can generate highly compact
chromatin structures that repress transcription. All of the chromatin remodeling
complexes contain a subunit that belongs to the superfamily 2 (SF2) of helicases and
contains an intrinsic ATPase domain which is required for separating DNA from
nucleosomes (Narlikar et al., 2002). The ATPase subunit associates with additional
subunits and each of the individual subunits possess specific activities that contribute to
the function of the complex, such as regulating the ATPase activity, mediating
interactions with chromatin, and/or protein-protein interactions (Clapier and Cairns,
2009).
The two major classes of ATP-dependent chromatin remodelers are the, switching
defective/sucrose non-fermenting (SWI/SNF) and imitation SWI (ISWI), based on the
homology of their ATPase domain to yeast and D. melanogaster proteins, respectively
(Figure 1.5) (Gangaraju and Bartholomew, 2007). Complexes within the SWI/SNF class
of remodelers consist of eight to fifteen subunits, while the ISWI class of remodelers are
smaller and consist of two to five subunits (Lall, 2007). More recently, two additional
families of chromatin remodelers have been identified, the chromo-ATPase/HelicaseDNA binding domain (CHD) and inositol requiring 80 (INO80) (Clapier and Cairns,
2009).
Despite similar biochemical properties it has been shown that the chromatin
remodeling complexes can generate distinct rearranged products of the nucleosomes. For
example, the SWI/SNF class of remodelers can generate stable protruding loops of DNA
around nucleosomes and this is postulated as a mechanism to expose DNA at promoters

Figure 1.5: ATP-dependent chromatin remodelers.
The diagram represents two major classes of ATP-dependent chromatin remodelers;
SWI/SNF and ISWI. Complexes within the SWI/SNF class of remodelers consist of eight
to fifteen subunits, while the ISWI class of remodelers is smaller and consist of two to
five subunits. The ATPase subunits also contain domains such as the bromo-domain and
SANT domain which are chromatin binding domains. Adapted from (Narlikar et al.,
2002).
SWI/SNF: SWItch/Sucrose NonFermentable. RSC: Remodels structure of chromatin.
ISW1/2: Imitation switch 1/2. RSF: Remodeling and spacing factor. ACF: Assembly and
chromatin remodeling factor. CHRAC: Chromatin accessibility complex. NURF:
Nucleosome remodeling factor.
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within chromatin dense regions to facilitate transcription. SWI/SNF remodelers can also
transfer nucleosomes to different regions of the DNA as well as remove H2A/H2B
dimers or entire nucleosomes (Fan et al., 2004; Narlikar et al., 2002). Both of these
mechanisms have been implicated in generating nucleosome free regions of DNA.
Alternatively, the ISWI class of remodelers can generate evenly spaced nucleosomes over
long stretches of DNA which generally promotes higher order chromatin structures and
represses transcription (Cairns, 2005; Cryderman et al., 1999; Gangaraju and
Bartholomew, 2007).
Human SWI/SNF complexes include the Brahma-related gene 1 (BRG1)/Brahma
(BRM) associated factors (BAF) chromatin remodeler that contain the BRG1/BRM
proteins as the ATPase subunit along with eight other subunits (Figure 1.5) (Steinberg et
al., 2012; Wu, 2012). An example of the human ISWI is the remodeling and spacing
factor (RSF) which consists of sucrose non-fermenting 2 homolog (Snf2h) as the ATPase
domain and one other subunit (Figure 1.5) (LeRoy et al., 1998). Chromatin remodelers
can be targeted to gene promoters by interacting with TFs, such as the the glucocorticoid
receptor which binds to the human BAF chromatin remodeling complex to promote
transcriptional activation in response to glucocorticoids (Hsiao et al., 2003) Alternatively,
they can be targeted to the genome by interacting with the chromatin through intrinsic
chromatin binding domains contained within specific subunits (Clapier and Cairns,
2009).
The second class of coregulators catalyzes the post translational modifications of
the histones. Due to their accessibility outside of the core nucleosome the amino acids on
the histone tails are highly amenable to covalent modifications (Figure 1.6). These

Figure 1.6: Chromatin tail modifications.
The diagram represents histone modifications that occur on histones H3, H4, H2A and
H2B. Each histone has an amino-terminal tail consisting of 20 to 37 amino acids. The
modifications include methylation, phosphorylation, acetylation, and ubiquitination.
Adapted from (Kato et al., 2010).
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modifications include the acetylation of lysines, methylation of lysines and arginines, as
well as phosphorylation of serines (Strahl and Allis, 2000). The consequences of histone
covalent modifications varies depending on which amino acid is modified, as well as the
type of modification but tend to result in two possible consequences. First, the
modification can alter the charge on the specific amino acid which can influence
interactions between histones and DNA leading to changes in chromatin structure.
Second, histone modifications can affect the recruitment or repulsion of non-histone
effector molecules resulting in downstream transcriptional effects. With respect to
transcription, histone modifications are grouped into two categories: those resulting in
transcriptional activation and those resulting in transcriptional repression (Strahl and
Allis, 2000). It has been postulated that the type, number and combination of specific
histone modifications, generate a type of code known as “the histone code” that dictate a
downstream transcriptional event and consequently a biological outcome (Strahl and
Allis, 2000; Turner, 2000, 2007).
Chromatin modifications are mediated by enzymes that add or remove specific
moieties at the histone tails. To gain access to their histone substrates these enzymes must
be recruited to the DNA and one mechanism involves recruitment by specific TFs (Kang
et al., 2004). This mode of recruitment provides a degree of selectivity of gene expression
because only the genes that are targeted by these enzymes will be regulated by the
corresponding histone modification. Enzymes that catalyze the addition or removal of
certain chromatin marks on histone tails with a transcriptional outcome are referred to as
co-activators or co-repressors. (Turner, 1993).
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1.3.2 Lysine Acetylation
The presence of acetylated histones in locations of active transcription was noted
as early as 1978 when chromatin was found to be less resistant to DNAase I digestion
after treatment with sodium butyrate, a potent histone deacetylase (HDAC) inhibitor
(Simpson, 1978). Since then, it has been shown that lysine acetylation plays a
fundamental role in many cellular processes such as DNA replication where histones are
acetylated before the assembly into the newly synthesized strand, and importantly in
transcriptional regulation (Sawan and Herceg, 2010; Strahl and Allis, 2000). Lysine
acetylation has been detected in vitro and in vivo. In addition, in vitro reconstitution of
DNA in the context of chromatin have confirmed the requirement for lysine acetylation
in transcriptional activation (Loyola et al., 2001). Lysine acetylation has been
characterized most frequently at residue 9, 14, 18, 23 and 56 on histone H3 (H3K9, 14,
18, 23, 56) as well as residues 5, 8, 12, and 16 of histone H4. Acetylation at these
residues has been associated with transcriptional activation of genes. Acetylation may
facilitate transcription by neutralizing the positive charge on the lysine residues, which
normally contributes to interactions between the chromatin and DNA (Hansen, 2002).
This mechanism is controversial since acetylation can only neutralize approximately 30%
of the charge which may not be sufficient to release the DNA from histones (Struhl,
1998). Alternatively, acetylated lysines can serve as binding sites for the bromodomain
(BRD), a consensus motif found in many transcriptional regulatory proteins (Struhl,
1998). The BRD is a well conserved left handed helix bundle consisting of four helices,
more commonly referred to as the BRD fold. Within the human genome, 46 BRD-

33

containing proteins have been identified and many of these proteins contain multiple
BRD domains (Schultz et al., 2000).
BRD-containing proteins can facilitate transcription in many ways. For example,
BRD1 and BRD2 proteins can enhance transcription on nucleosomal templates in vitro
that is dependent on histone acetylation. The ability of BRD1 and BRD2 to facilitate
transcription was attributed to their capability to bind acetylated histones and their
intrinsic chaperone activity which was found to temporarily remove histones to allow the
progression by RNA-pol-II (LeRoy et al., 2008).
Acetylation is catalyzed by the histone acetyl transferases (HATs), also known as
lysine acetyltransferases (KATs). HATs transfer an acetyl group from the co-factor
acetyl-CoA to the terminal amino group of the side chain (ε-amino group) on lysines
(Figure 1.7) (Wiegand and Brutlag, 1981). There are two types of HATs in eukaryotic
cells, type A and B. Type B-HATs are exclusively cytoplasmic and are mainly involved
in the acetylation of histone H4 prior to incorporation into the newly synthesized
DNA(Brownell and Allis, 1996). Type A-HATs are directly involved in transcriptional
regulation and chromatin assembly (Ruiz-Garcia et al., 1997).
The first HAT was cloned from Tetrahymena thermophila and is homologue to
the yeast transcriptional adaptor/coactivator protein, general control nonrepressed
(GCN5p). Using free nucleosomes as substrates, it was subsequently shown that
recombinant GCN5p possesses intrinsic HAT activity (Brownell et al., 1996). These
experiments established an important link between acetylation and transcriptional
activation by adaptor proteins (Georgakopoulos and Thireos, 1992). Additionally, it was

Figure 1.7: Acetylation/methylation of lysines.
HATs transfer an acetyl group from the co-factor acetyl-CoA to the terminal amino group
of the side chain on lysines. HDACs can catalyze the removal of acetyl groups from
proteins by an ion exchange mechanism utilizing the co-factors zinc or NAD+.
Methylation is also added to the amino terminal of the lysine side chain and this is
catalysed by the MLL proteins using S-adenosyl-methionine (H-SAM) as the methyl
donor. Methyl-lysines can be demethylated by LSD1 which utilize FAD to oxidize
methyl-lysine to an imine intermediate which is then hydrolyzed to yield unmethylated
lysine and formaldehyde. The JHDM enzymes can also demethylate lysines and this class
of enzymes uses iron and α-ketoglutarate as co-substrates and demethylation results in
the generation of formaldehyde and succinate. Molecules indicated in red represent
modifications to lysine.
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found that GCN5p contains a BRD, implicating this domain in targeting of HATs to
genes (Sanchez and Zhou, 2009). Many additional HATs have been identified in
eukaryotes, such as cAMP response element-binding protein and its close homologue,
binding protein 300 (CBP/p300), TAT interacting protein (TIP60), and p300/CBPAssociated factor (P/CAF) (Bararia et al., 2008; Sartorelli et al., 1999; Verreault et al.,
1998). Many of these HATs exhibit specificity towards their substrates through
recognition of consensus motifs (Peserico and Simone, 2011). For example, GCN5p
contains a consensus motif for H3K14 consisting of GKXP, where X represents any
amino acid (Rojas et al., 1999).
The CBP/p300 proteins, are ubiquitous HATs that are utilized by many classes of
TFs. For example, p300 was found to be an important component of the estrogen receptor
(ER) nuclear receptor activation complex that is targeted to specific genes following βestradiol treatment (Hanstein et al., 1996). CBP/p300 is also required for the
transcriptional response induced by the transforming growth factor β (TGFβ) (Feng et al.,
1998; Janknecht et al., 1998; Nishihara et al., 1998; Pouponnot et al., 1998).
Homozygous deletion of p300 or CBP in mice is embryonic lethal and exhibit numerous
developmental defects such as defects in neural tube closure, reduced cell proliferation
and disrupted cardiac development (Oike et al., 1999; Yao et al., 1998).
Acetyl groups are removed from lysine residues by histone deacetylase (HDACs)
class of enzymes. HDACs catalyze the removal of acetyl groups by an ion exchange
mechanism utilizing the co-factors zinc or NAD+ (Figure 1.7) (Dokmanovic et al., 2007).
In mammals, there are four major classes of HDAC enzymes based on sequence
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homology. Class I (HDAC 1-3, 8), class IIa (HDAC 4, 5, 7, 9), class IIb (6, 10), class III
(SIRT 1-7) and class IV (HDAC11). Class I, II and IV are zinc dependent while Class III
is NAD+ dependent (Bali et al., 2005). Deacetylation by HDACs plays a critical role in
regulating histone as well as non-histone proteins. For example, HDAC6 is primarily
cytosolic and deacetylates heat shock protein 90 (HSP90) which is required for HSP90 to
bind ATP and associate with its client proteins (Bali et al., 2005).
In mammals, the class I enzymes (HDAC1 and HDAC2) share the most sequence
identity (65%) with the yeast reduced potassium dependency 3 (RPD3p) being the major
deacetylase that regulates histone acetylation in yeast (de Ruijter et al., 2003; Kurdistani
et al., 2002). HDAC1 and 2 are ubiquitously expressed and share 87% amino acid
similarity in mammals (Yang and Seto, 2008). Deletion of HDAC1 in mice causes
defects in cell proliferation and growth, resulting in embryonic lethality, whereas deletion
of HDAC2 causes prenatal lethality resulting from cardiac defects (Montgomery et al.,
2007). With respect to deacetylation of histones, HDAC1 and HDAC2 are considered to
be functionally redundant. However they also possess different non-histone substrates
which could account for the differences in the phenotypes of the individual knockouts
(Jurkin et al., 2011). For example, during differentiation of neuronal precursors
knockdown of both HDACs, but not individual knockdowns, result in severe brain
abnormalities (Sun et al., 2011). HDAC 1 and 2 are found in the nucleus as components
of multiprotein repressor complexes such as Sin3A, nucleosome remodelling and histone
deacetylase complex (NuRD) and the corepressor of
(Peserico and Simone, 2011).

REST (CoREST) complex
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Alterations in HATs and HDACs have been identified in numerous cancers. For
example, disruption of CBP or p300 resulting from missense mutations, or mutations
leading to p300 truncations are associated with colorectal, gastric and other epithelial
cancers (Giles et al., 1998; Goodman and Smolik, 2000). Overexpression of the
transcriptional repressor lymphoma-associated zinc finger-3/B-cell lymphoma 6
(LAZ3/BCL6) in non-Hodgkin's lymphom causes aberrant recruitment of HDACs
resulting in deregulated transcriptional repression (Dhordain et al., 1998). The fusion
gene acute myeloid leukemia-1 and the eight-twenty-one corepressor (AML1-ETO)
recruit HDACs and acts as a potent repressor of transcription that associates with acute
myloid leukaemia (Wang et al., 1998).
Interestingly, many structurally diverse HDAC inhibitors have been developed
that inhibit cell proliferation in vitro and in vivo by inducing cell cycle arrest,
differentiation and/or apoptosis (Marks et al., 2001; Munster et al., 2001).

HDAC

inhibitors have provided a valuable tool to study the physiological role of HDACs and are
being tested therapeutically to treat specific cancers such as those mediated by the
AML1-ETO fusion proteins (Wang et al., 1998).
1.3.3 Histone Lysine Methylation
Histone methylation was first identified and characterized as early as 1968
(Murray, 1964). Much like acetylation, methylation of histone tails is an important
regulator of transcription (Figure 1.6). However, unlike acetylation, methylation does not
alter the charge of the histone tail, suggesting that this modification does not play a direct
role in DNA histone interactions (Hansen, 2002; Martin and Zhang, 2005). Furthermore,
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methylation of histone tails can be mono-, di-, or tri-methylated and, depending on the
residue that is methylated, can be associated with either transcriptional activation or
repression (Greer and Shi, 2012). Notably, methylation at H3K4 is generally linked to
transcriptional activation and the degree of methylation at H3K4 confers varying states of
transcription. In vertebrates H3K4me3 and H3K4me2 are often colocalized and associate
with the 5’ regions of actively transcribed genes (Bernstein et al., 2002; Sims and
Reinberg, 2006; Wysocka et al., 2005b). H3K4me2 is also found in the coding regions of
active genes and H3K4me1 appears to be mostly localized to the 3’ region of transcribed
genes (Heintzman et al., 2007; Santos-Rosa et al., 2002).

In contrast, di and tri-

methylation of H3K9 and H3K27 are considered hallmarks of transcriptionally repressed
genes (Young et al., 2010; Zee et al., 2010). Interestingly, in some contexts the presence
of H3K4me3 can co-occupy the same promoter regions of genes as the repressive
methylation mark, H3K27me3 (Heintzman et al., 2007; Orford et al., 2008; Santos-Rosa
et al., 2002). This phenomenon is known as bivalency and is generally found at lineage
specific genes within pluripotent cells, such as embryonic stem cells. The presence of
transcriptionally repressive marks are thought to maintain lineage commitment genes in
the off position while the activation marks hold the promoters in a “poised” state,
prepared for rapid activation upon appropriate differentiation signals (Bernstein et al.,
2006).
Methylation can also occur at arginine residues (Figure 1.6). Arginines can be
mono- or di-methylated, and di-methylation of arginines can occur in two conformations,
symmetric or asymmetric which can result in distinct phenotypic outcomes (Chen et al.,
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2011). Methylation at histidines is rare in eukaryotes and only the mono-methylation at
these residues has been reported (Paik et al., 2007).
Histone methylation is mediated by three classes of enzymes. The DOT1-like
proteins (DOT1L) methylate H3K79, and have been implicated in telomeric silencing and
transcriptional regulation (Feng et al., 2002). The protein arginine methyl transferase
(PRMT) family methylate an array of histone tail arginine residues and are associated
with many cellular outcomes and transcriptional states (Wolf, 2009).
The

SET

domain-containing

proteins

are

a

large

family

of

lysine

methyltransferases that regulate transcription of many genes (Figure 1.7 and Figure 1.8)
(Rea et al., 2000). The SET domain is the catalytically active component of the enzyme
and amino acids surrounding the SET domain dictates the amino acid motif recognized
by the enzyme (Bannister and Kouzarides, 2011). One of the first SET domain methyl
transferases identified is the suppressor of variegation 3-9 (SUV39) which specifically
methylates H3K9. Many additional proteins within this family have been identified. This
includes G9a/GLP1 which can di- and tri-methylate H3K9. A unique feature of this
enzyme is that it contains an ankyrin domain which can specifically bind to the H3K9
modification and as a result, this enzyme is capable of propagating the H3K9me mark
from a narrow region to extended regions of the genome (Chen et al., 2012). In addition,
enhancer of zeste (Ez) proteins (Ezh1 and Ezh2), are part of polycomb repressor complex
2 (PRC2) that can trimethylate H3K27 (Ezhkova et al., 2011). PRC2 establishes long
term repression at homeobox genes to maintain stem cell identity and plasticity, and trimethylation of H3K27 mediated by Ezh1/2 is one of the critical marks required for this
repression (Richly et al., 2011).

Figure 1.8: Histone methyltransferases/demethylases.
The diagram lists the enzymes that catalyse the addition or removal of methyl groups
from histone H3 lysines. The methyltransferases are listed on the top and demethylases
are listed at the bottom of the histone mark they are associated with. Adapted from
(Kondo, 2009).
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The majority of SET domain containing proteins recognize and methylates H3K4, a
covalent modification that is associated with transcriptional activation. The first H3K4
methyltransferase to be discovered was SET1 in Saccharomyces cerevisiae (Miller et al.,
2001). SET1 is assembled into a multi-subunit complex called complex proteins
associated with Set1 (COMPASS), which consists of approximately seven subunits that
are essential for regulating SET1 activity. SET1 is capable of mono-, di-, or trimethylating H3K4 and its specificity is dependent on the subunit composition of the
COMPASS complex. For example, the absence of brefeldin-A sensitivity protein 2
(Bre2/Csp60) subunit from the COMPASS complex prevents H3K4-trimethylation and
the presence of Cps25 is required for di- and tri-methyaltion of H3K4 (Takahashi et al.,
2011).
There are six human orthologues (MLL1 – MLL4, SET1A and SET1B) to the
yeast SET1, and all six belong to the mixed lineage leukemia (MLL) family of proteins
(Milne et al., 2002). Similar to the yeast COMPASS complex, all of the human MLL
proteins are constituents of multi-subunit complexes and the methyltransferase activity of
MLL proteins is also regulated by the associated subunits (Patel et al., 2009). In addition,
the MLL complexes associate with many other activating complexes such as the MOF (a
MYST family histone acetyltransferase) complex which also contains a HAT capable of
acetylating H4K16, a mark that is also associated with transcriptional activation (Dou et
al., 2005; Glaser et al., 2006; Milne et al., 2002). Collectively, the existence of many
histone methyltransferases that uniquely modify a specific histone tail amino acid,
represents the variety of ways eukaryotic cells can fine tune transcriptional regulation.
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1.3.4 Readers of Histone Methylation
Lysine methylation serves as a marker for the recruitment of effecter proteins
containing methyl-lysine binding domains that convert this modification to an appropriate
biological outcome. Several classes of methyl-lysine binding domains have been
identified in mammals and include WD40 repeats, plant homeodomain (PHD) fingers,
CW domains, PWWP domains and ankryin repeats. Proteins belonging to the Royal
super family also bind methylated histones. All of these proteins contain domains such as
chromobarrels, chromodomains, double chromodomains, Tudor domains, and malignant
brain tumor (MBT) repeats which have varying affinities for different methylated lysines
(Taverna et al., 2007).
Heterochromatin protein 1 (HP1) contains a chromodomain that can bind
H3K9me3 and repress transcription by stabilizing macromolecular complexes between
nucleosomes, as well as preventing transcriptionally activating histone variants, such as
histone H3.3, from being deposited (Cheutin et al., 2003; Jacobs and Khorasanizadeh,
2002; Janicki et al., 2004). In contrast, CHD1 is an ATP-dependent chromatin remodeler
and contains two chromodomains which specifically binds H3K4me3 (Pray-Grant et al.,
2005). CHD1 promotes transcriptional activation by altering chromatin structure through
the SWI/SNF ATPase domain and interacting with coactivator complexes such as the
histone Spt-Ada-Gcn5 acetyltransferase (SAGA) and SAGA-like (SLIK) complex (PrayGrant et al., 2005; Simic et al., 2003). Collectively, these studies suggest that there are
many lysine methylation readers capable of propogating this modification and
determining a specific transcriptional outcome.
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1.3.5 Histone Lysine Demethylation
Lysine methylation is also a reversible modification and the first demethylase
discovered was lysine specific demethylase 1 (LSD1), also referred to as KDM1A (Shi et
al., 2004). LSD1 is a flavin adenine dinucleotide (FAD)-dependant amine oxidase which
catalyzes the demethylation of mono- and di-methylation of H3K4 and H3K9. This is
accomplished by utilizing FAD to oxidize methyl-lysine to an imine intermediate which
is then hydrolyzed to yield unmethylated lysine and formaldehyde (Figure 1.7) (Shi et al.,
2004). LSD1 was initially identified as a component of the repressor element silencing
transcription factor (REST) complex that is recruited to RE1 elements found at many
neuron-specific genes (Lee et al., 2005; You et al., 2001). Purified recombinant LSD1 is
capable of demethylating H3K4me1 and H3K4me2 in peptides and bulk histones, but not
from nucleosomes. However, LSD1 is capable of demethylating H3K4me2 from
nucleosomes as a component of the REST complex (Shi et al., 2005). Downregulation of
LSD1 using small-interfering RNAs (siRNA) demonstrates an over-all increase in
H3K4me2, mainly at neuronal specific genes (Amente et al., 2010). For this reason,
LSD1 was initially implicated in transcriptional repression.
However, LSD1 is also required in many hormone dependent processes, such as
estrogen and androgen receptor signaling where it acts as a H3K9 demethylase (mono or
di) and is associated with transcriptional activation of many genes (Krig et al., 2010;
Metzger et al., 2005). This dual mode of action by LSD1 is speculated to be context
dependant such that specific protein associations alter the chemistry of the active site, to
yield distinct specificities (Wysocka et al., 2005a). LSD1 has been identified as an
integral component of several transcription complexes such as C-terminal binding protein
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1 (CtBP1), NuRD and ZNF217 complexes (Cowger et al., 2007; Wang et al., 2007;
Wang et al., 2009). LSD1 is also essential for mammalian development and homozygous
knockout of LSD1 causes embryonic lethality by E7.5 (Wang et al., 2007).
Demethylation of mono, di or tri-methylated lysines is accomplished by a second
class of lysine demethylases, the jumonji C (JmjC) domain-containing iron-dependent
dioxygenases (Figure 1.8) (Takeuchi et al., 2006). This class of enzymes use iron and αketoglutarate as co-substrates and demethylation results in the generation of
formaldehyde and succinate (Figure 1.7) (Klose et al., 2006). There are six JmjC domain
containing families of demethylases within this class; JmjC domain containing
demethylase I (JHDM1), jumonji domain containing protein 2 (JMJD2), jumonji at-rich
interactive domain (JARID1), Lysine demethylase 6 (KDM6), KDM7 and KDM8 (Zhang
et al., 2012). The first JmjC domain containg demethylase was identified in S. cerevisiae
and was named the Jmjc domain containing histone demethylase-2 (JHD2P) which is
capable of demethylating H3K4me2 or H3K4me3 (Liang et al., 2007). The mammalian
homologues of JHD2P includes the JARID1 family members, JARID1a,b,c and d
(Christensen et al., 2007).
JmjC domain containing demethylases are targeted to specific genes for
transcriptional regulation. Interestingly, JMJD2 is found in a complex also containing
LSD1 and mediates androgen receptor signaling. Within this complex, JMJD2 and LSD1
cooperate to demethylate H3K9 and activate androgen responsive genes (Wissmann et
al., 2007). JARID1B represses many developmentally important genes by demethylating
H3K4 and is crucial for the differentiation of embryonic stem (ES) cells towards a neural
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lineage (Schmitz et al., 2011). JMJD5, part of the KDM8 family of demethylases,
demethylates H3K36 and knockout in mice demonstrated the upregulation of the tumor
suppressor gene p53 resulting in embryonic lethality (Oh and Janknecht, 2012).

1.4 Cytosine Methylation: Overview
DNA methylation is an epigenetic modification that plays a pivotal role in many
biological processes such as silencing of transposable elements, defense against viral
sequences, gene imprinting during development and X-inactivation. Importantly, the loss
of normal DNA methylation patterns in mice often results in embryonic lethality and is a
hallmark of all cancers (Li et al., 1992; Okano et al., 1999; Severson et al., 2012).
DNA methylation was discovered nearly 66 years ago, and it was immediately
proposed to be involved in the regulation of gene expression (McCarty, 1946). Shortly
after, it was demonstrated that DNA methylation occurs exclusively at the cytosine
nucleotide (Hotchkiss, 1948). However, it was not until 40 years later that a correlation
between DNA methylation and gene transcription was established (Compere and
Palmiter, 1981). Although methylated cytosine only accounts for 1-4 % of the nucleic
acids, it was shown to markedly affect transcription of many genes and numerous studies
have found a high degree of correlation between DNA methylation and transcriptional
silencing (Bird, 2002; Ehrlich et al., 1982).
Cytosine methylation occurs within the sequence context CG (CpG) dinucleotide
or CNG trinucleotide. There are approximately 28 million CpG dinucleotides
(http://genome.ucsc.edu/) in the human genome and 60-90 % of the CpGs are methylated
(Siegfried and Cedar, 1997; Xie et al., 2009). The majority of CpGs are found within
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repetitive DNA sequences and intergenic regions that contain transposable and/or
retroviral elements. Approximately 45 % of the human genome contains transposable
elements that are kept silenced by DNA methylation. This methylation dependent
suppression is critical because active transposable elements can cause mutations and gene
disruptions that are deleterious to the cell (Giordano et al., 2007; Lee et al., 2012).
CpG dinucleotides are also found at a much higher frequency within dense
clusters referred to as CpG islands. Approximately 70 % of human genes have a CpG
island associated with their promoter region and many are highly conserved between
mice and humans (Figure 1.2) (Deaton and Bird, 2011). The majority of CpG islands at
promoters are not methylated in somatic cells although some CpG islands become
methylated during development (Feltus et al., 2003). An interesting feature of CpG
islands is that they are commonly found in areas where there are fewer nucleosomes, and
the nucleosomes which are found in these areas, usually contain histone tail
modifications associated with transcriptional activation (Choi, 2010). Collectively, these
observations suggest that CpG islands are involved in transcriptional regulation of genes.
Cancer cells exhibit drastically altered patterns of DNA methylation that includes
a global hypomethylation along with hypermethylation of many promoter CpG islands.
Promoter regions that are normally unmethylated in somatic cells are found
hypermethylated in tumor cells and this is associated with silencing of many tumor
suppressor genes (Das and Singal, 2004; Esteller, 2002; Teng et al., 2011). However,
CpG methylation is also found within gene bodies and is less predictive of transcription.
Infact, in some cases, it has been demonstrated, to be associated with gene expression
(Aran et al., 2011; Mohn et al., 2008).
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1.4.1 Molecular Determinants of DNA Methylation
Cytosine methylation is catalyzed by the DNA methyltransferases (DNMT1,
DNMT3A, and DNMT3B) which transfer a methyl group from the cosubstrate S-adenyl
methionine (SAM) to the 5’ position of cytosine (5mC). All of the DNMTs contain a
carboxy-terminal methyltransferase domain and a cysteine rich zinc binding domain
(CXXC), both of which are conserved between mouse and human (Xie et al., 1999).
Mouse knockouts of DNMTs demonstrate the importance of these enzymes during
development. Deletion of DNMT3A, 3B or DNMT1 is embryonic lethal and in all cases,
hypomethylation was observed (Li et al., 1992; Okano et al., 1999).
DNMT1 is the maintenance methyltransferase that recognizes hemi-methylated
DNA and during DNA replication, methylates the unmethylated daughter strand. This
allows the 5mC mark to be stably conveyed following subsequent cell divisions (Figure
9A). DNMT1 contains six additional domains within the N-terminal portion of the
protein which facilitate protein-protein interactions and targeting of DNMT1 to
replication foci which are locations within the genome where the DNA is actively being
replicated (Jurkowska et al., 2011). Interestingly, embryonic stem cells remain viable
following knockout of DNMT1, however, upon differentiation massive cell death was
observed suggesting that methylation is required for proper differentiation (Li et al.,
1992).
DNMT3A and DNMT3B are highly homologous proteins, based on amino acid
sequence, and are responsible for establishing de novo patterns of methylation, the
majority of which occurs during early development (Reik et al., 2001). The N-terminus of

Figure 1.9: DNA demethylation mechanisms.
A. Passive DNA demethylation. Top branch represents maintenance of DNA methylation
on the newly synthesized strand by DNMT1. Bottom branch represents inhibition of
methylation by DNMT1 which leads to passive DNA demethylation following
subsequent DNA replications. Black lines represent parental DNA strands, red lines
represent newly synthesized strands after first division and blue lines represents newly
synthesized strands after second division. Me represents methylation. B. Active DNA
demethylation pathways. The pathway indicated in green involves deamination of 5mC
by the AID/APOBEC deaminase enzymes to T which is excised by TDG or MBD4. The
pathway indicated in blue involves oxidation of 5mC by the TET proteins to 5hmC, 5fC
and 5CaC which is then recognized and cleaved by TDG. The pathway indicated in
brown involves hydroxylation by TETs to 5hmC followed by deamination by
AID/APOBECs to 5hmU which is cleaved by TDG or MBD4.

The cleavage by

TDG/MBD4 glycosylases results in an aprunic/aprymidinic site which is repaired by the
BER machinery and replaced with the unmethylated cytosine. The generation of the
5hmC has also been observed to facilitate replication dependent passive DNA
demethylation.
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DNMT3A/B contains a PHD-like ADD domain that binds histone H3, and a PWWP
domain which is involved in direct DNA binding and targeting of DNMT3A/B (Ge et al.,
2004; Otani et al., 2009; Qiu et al., 2002; Shirohzu et al., 2002; Zhang et al., 2010).
DNMT3A/B have also been found as part of multi-protein repressor complexes that are
targeted to specific genes. For example, DNMT3A associates with the PRC complex to
establish de novo methylation at many gene promoters (Mohammad et al., 2009; Vire et
al., 2006). Alternatively, the underlying chromatin structure may also contribute to
DNMT3A/B binding. DNMT3A/B possesses higher affinity towards unmethylated rather
than methylated H3K4 and binds to this moiety through the ADD domain (Otani et al.,
2009; Zhang et al., 2010). It is likely that both of these mechanisms are functional in
eukaryotic cells to establish selective de novo DNA methylation patterns. Recently, it was
demonstrated that the deletion of DNMT3A in hematopoietic stem cells resulted in the
loss of differentiation emphasizing the important role of methylation during
differentiation (Challen et al., 2012).
An additional member of this family, the DNMT3-like (DNMT3L) protein, is also
involved in DNA methylation. DNMT3L is homologous to DNMT3A/B but lacks the
catalytic domain. DNMT3L has been shown to dimerize and enhance the activities of
DNMT3A or DNMT3B and is required for genomic imprinting, compaction of the X
chromosome, and silencing of retroviral transposons (Hata et al., 2002).
1.4.2 Consequences of DNA Methylation
Although it is well accepted that DNA methylation is associated with
transcriptional silencing, it is not clear whether methylation is an instructive modification

53

that dictates transcriptional repression, and if so, how the methyl marks confer this
repression (Jones, 2012). One theory is that 5mC could directly prevent the binding of
TFs that are required to initiate and/or facilitate transcription (Tate and Bird, 1993).
Alternatively, many proteins selectively bind 5mC and can inhibit transcription by
physically interfering with activators, or by associating with histone modifying proteins
such as HDACs that promote localized chromatin condensation (Kavalali et al., 2011;
Lewis et al., 1992).
There are three classes of proteins that bind methylated CpGs in mammals. First,
ubiquitin-like containing PHD and RING finger domain (UHRF) proteins direct DNMT1
to hemi-methylated DNA (Achour et al., 2008). Second, a subclass of zinc finger proteins
selectively bind methylated DNA. For example, the TF Kaiso binds to two consecutively
methylated CpG dinucleotides (Daniel et al., 2002).

Finally, methyl-CpG binding

domain (MBD proteins) containing proteins recognize and bind methylated CpGs
indiscriminately. Seven such proteins have been identified in mammals, MeCP1, MeCP2,
MBD1, MBD2A/B, MBD3 and MBD4 (Hendrich and Bird, 1998; Lewis et al., 1992).
MeCP1/2, MBD1 and MBD2 can directly bind methylated CpGs and recruit additional
repressor proteins through an intrinsic transcriptional repression domain (TRD). For
example, MBD proteins directly interact with HDACs through their TRD domain and
recruit HDACs to methylated promoters, resulting in a hypoacetylated and more stably
silenced state of genes (Kavalali et al., 2011; Nan et al., 1998; Sarraf and Stancheva,
2004). MeCP1/2 have been biochemically purified and are components of transcriptional
corepressor complexes which also contain HDACs1/2 and Sin3A (Kavalali et al., 2011).
It has also been demonstrated that MeCP2 can promote heterochromatin formation (Nan
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et al., 1997). Mecp2 null mice are viable but have neurological disorders that mimic Rett
syndrome resulting in death at 6 and 12 weeks postnatal (Chen et al., 2001; Guy et al.,
2001). Knockout of the various Mbd genes did not have any obvious developmental
defects with the exception of Mbd3 which is embryonic lethal (Hendrich et al., 2001;
Martin Caballero et al., 2009; Zhao et al., 2003).
1.4.3 DNA Demethylation
In mammals, 5mC has long been regarded as a stable, heritable, epigenetic mark.
In dividing cells, DNA can be demethylated through a passive mechanism whereby the
newly synthesized sister strand is not remethylated by DNMT1, following DNA
replication (Figure 1.9A) (Bird and Wolffe, 1999). This would result in the dilution of the
methylation marks after subsequent divisions. In contrast, a much more rapid DNA
demethylation mechanism has been described that occurs in response to specific signals
and is DNA replication independent. This is known as active DNA demethylation and
was first described in plants involving DNA glycosylases (Zhu, 2009).
Although orthologues of plant DNA glycosylases have not been identified,
numerous studies have provided evidence for the existence of active DNA demethylation
in mammals. Following fertilization the paternal genome, but not the maternal, is rapidly
demethylated before the onset of DNA replication, indicative of an active process (Mayer
et al., 2000; Oswald et al., 2000). In addition, there have been several examples of active
demethylation at specific loci in somatic cells. The interleukin-2 promoter region is
rapidly demethylated within 20 minutes following T-cell (T-lymphocytes) activation by
anti-CD3 plus anti-CD28 and the observed demethylation was independent of DNA
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replication (Bruniquel and Schwartz, 2003). Depolarization of post-mitotic neurons with
KCl resulted in DNA demethylation of the brain-derived neurotophic factor (bdnf) gene
promoter with subsequent increases in gene expression (Martinowich et al., 2003).
Binding of the estrogen receptor to the pS2 promoter is rapid and cyclical and is
accompanied by rapid cycles of methylation and demethylation (Kangaspeska et al.,
2008).
Although the mechanism of active DNA demethylation in mammals is unclear,
current evidence points to the involvement of the BER pathway. In mammals, the
deamination of C and 5mC can occur spontaneously to generate U and T, respectively. If
not corrected, the resulting G:U and G:T mispairs can lead to mutations following
subsequent rounds of DNA replication. In fact, it has been estimated that over one third
of mutations arising in cancer are a result of spontaneous deamination of cytosine and 5
mC (Jones et al., 1992). To correct this spontaneous decay, mammalian cells have
developed repair mechanisms that recognize and correct this lesion. During BER the G:T
and G:U mispairs

are

initially recognized by DNA glycosylases that cleave the

thymine/uracil base from its sugar back bone at the glycosidic bond. Two DNA
glycosylases are known for this function, thymine DNA glycosylase (TDG) and MBD4
also known as MED1 (Cortellino et al., 2003; Robertson et al., 2009). Both of these
enzymes produce an apurinic/apyrimidinic (AP) site which is cleaved by AP
endonuclease (APE) and this allows DNA polymerase β to incorporate the correct
nucleotide (Robertson et al., 2009).
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1.4.4 The DNA Glycosylases TDG and MBD4
TDG belongs to the Escherichia coli mismatch-specific uracil-DNA glycosylase
(MUG) superfamily of enzymes that are capable of excising uracil from single strand or
double strand DNA and are implicated in the processing of G:T/G:U mispairs arising
from spontaneous mutations (Lee et al., 2011). In addition, numerous studies have
implicated TDG in gene transcription involving two mechanisms which may be
interrelated; as a coactivator for various TFs and in active demethylation of 5mC.
A direct role for TDG in transcription was initially inferred when it was
identified, by yeast two-hybrid screening, as an interacting partner for the ligand bound
retinoic acid receptor (RAR) (Um et al., 1998). Since then it has been shown to directly
interact with other nuclear receptors such as the ligand bound estrogen receptor alpha
(ERα) and is recruited to ERα responsive gene promoters (Chen et al., 2003). In addition,
TDG interacts with coactivators such as steroid receptor coactivator 1 (SRC1) and CBP
(Lucey et al., 2005; Tini et al., 2002).

TDG's interaction with CBP/p300 greatly

enhanced the transcriptional activation by CBP. This study further demonstrated that
CBP acetylated TDG at the amino terminus and that the acetylation promoted the
dissociation of CBP from TDG. Interestingly, the CBP-TDG complex still retained the
ability to cleave the mispaired G:T or G:U (Tini et al., 2002). Collectively these studies
implicate TDG in transcriptional activation although the exact mechanism remained
unclear.
TDG knockout mice have recently been generated in order to evaluate the
contribution of TDG to DNA demethylation in vivo. Knockout of TDG in mice is
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embryonic lethal caused by cardiovascular defects. Importantly, TDG knockout resulted
in increased promoter DNA methylation which was attributed to the loss of TDG's
glycosylase activity, coinciding with aberrant transcriptional repression of genes that are
developmentally regulated and genes involved in retinoic acid receptor signaling
(Cortazar et al., 2011; Cortellino et al., 2011). TDG was also required for recruiting the
histone acetyltransferase CBP/p300 and the MLL proteins to target genes (Cortazar et al.,
2011; Cortellino et al., 2011). This was consistent with the loss of active chromatin marks
such as H3K4me3, and increases in repressive marks, H3K27me3 and H3K9me3 in the
TDG null mice (Cortazar et al., 2011). Surprisingly, loss of TDG in ES cells or mouse
embryonic fibroblasts (MEFs) did not show any significant differences in cell survival
and mutation frequency in response to ionizing radiation or treatment with H2O2,
suggesting that TDG's contribution to BER is relatively minor (Cortellino et al., 2011).
These findings suggest that TDG plays a central role in gene-specific transcription and in
epigenetic stability.
The human MBD4 protein was initially isolated through its interaction with the
mut L homolog 1 (MLH1), a mismatch repair (MMR) protein, in a yeast two-hybrid
screen (Bellacosa et al., 1999). MBD4 belongs to the MBD-containing proteins and
consists of an N-terminal MBD and a C-terminal glycosylase domain (Sjolund et al.,
2012). Although MBD4 is not homologous to TDG, it does possess similar activities
towards U:G and T:G mispairs resulting from deamination of cytosine and 5mC,
respectively (Hendrich and Bird, 1998). Surprisingly, Mbd4 knockout (Mbd4-/-) mice are
viable and develop normally, however, mutation analysis demonstrated that Mbd4-/showed a threefold increase in mutation rate compared to wild type (Millar et al., 2002).
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In addition, when Mbd4-/- mice were crossed with mice containing heterozygous mutated
Adenomatous polyposis coli (Apc) allele (Apcmin/+), that is prone to intestinal
tumourgenesis, to generate a double mutant mice (Mbd4-/-/Apcmin/+), an increase in
intestinal tumor formation was observed compared to the Apcmin/+ background alone.
Further examination of the tumors showed an increase in C:G to T:A transitions within
the Apc allele suggesting that MBD4 functions as a tumor suppressor by preventing C to
T transitions and its deletion/mutation can promote tumors in a cancer prone background
(Wong et al., 2002).
One study demonstrates that MBD4 mutations were observed in approximately
20% of colorectal carcinomas, endometrial carcinomas and pancreatic primary tumours
that also demonstrate microsatellite instability (MSI) (Riccio et al., 1999; Sjolund et al.,
2012). MSI arises often through mutations in a stretch of poly A DNA sequence that
either shortens or lengthens the sequence contributing to genomic instability (Giannini et
al., 2002). Collectively these studies demonstrate that inactivation of MBD4 in human
cancers can increase mutation frequency and can accelerate tumor progression in certain
genetic background (Sjolund et al., 2012).
It has been reported that, MBD4 localizes to heterochromatinized regions of the
genome and has been proposed to function in transcriptional repression (Hendrich and
Bird, 1998). MBD4 represses transcription of p16ink4a and Mlh genes in methylation
dependent manner through direct association with Sin3a and HDAC1 (Kondo et al.,
2005).
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In contrast, recent studies using zebrafish as a model system have implicated
MBD4 in active DNA demethylation. It was found that the glycosylase activity of MBD4
was essential for demethylating and activating an ectopically introduced methylated
cDNA containing plasmid that involved recognizing and cleaving G:T mispairs. In
addition, the zebrafish MBD4 could be functionally compensated by the human version
suggesting the conserved nature of MBD4 function (Rai, Huggins et al. 2008).
Collectively these studies demonstrate the versatility of MBD4 and it is possible that
MBD4 functions redundantly in a variety of roles described in a context dependent
manner.
The mechanism of active demethylation involving BER has become an area of
intense research. However, it is becoming apparent that active DNA demethylation
cannot be explained by a single unified mechanism but involves a cascade of enzymes
that utilize different pathways (Figure 1.9B). One pathway involves the deaminase
enzymes that convert 5mC to T to generate a T:G mispair that is excised by TDG or
MBD4 and the BER machinery. The second pathway involves the metabolism of 5mC
into various oxidation products by the ten-eleven translocation (TET) family of enzymes.
Many of these oxidation products are recognized and excised by TDG and the BER
enzymes.
1.4.5 Active Demethylation involving Deamination of 5mC
The deamination of 5mC to T, generates a G:T mismatch that is excised and
replaced with cytosine by the concerted actions of DNA glycosylases (TDG or MBD4)
and the BER pathway (Figure 1.9B) (Hashimoto et al., 2012a; Hashimoto et al., 2012b).
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In mammals, deamination is mediated by the activation induced deaminase
(AID)/apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like (APOBEC), a
large family of zinc-coordinating enzymes involved in purines and pyrimidine
metabolism. AID, a 24kDa protein, was initially shown to play a role in inducing
variability in immunoglobulins, a process by which the mRNA generated from the
immunoglobulin gene is deaminated to cause C to U transitions (Muramatsu et al., 2000).
This provides functionally different products to generate high affinity antibodies during a
process referred to as affinity maturation (Muramatsu et al., 2000; Muramatsu et al.,
1999). The APOBEC family of proteins consists of four members, APOBEC 1-4 (Smith
et al., 2012). The structure of both AID and APOBEC proteins are highly similar,
consisting of alternating α helices and β sheets. The second and the third α helices are
positioned to form a pocket consisting of histidine and two cysteines that hold a zinc ion
crucial for the deamination of cytidine bases (Conticello et al., 2005).
Genome wide analysis demonstrated that knockdown of AID in primordial germ
cells (PGCs) resulted in three times the methylation found in wild-type cells (Popp et al.,
2010). The AID protein is required for the reprogramming of somatic cells towards
pluripotency, which occurs in the absence of DNA replication, and is mediated by DNA
demethylation and activation of key pluripotency genes such as Oct4 and Nanog (Bhutani
et al., 2010). In zebra fish AID/APOBEC2 function in a complex containing MBD4 and
the growth arrest and DNA damage inducible 45 alpha (GADD45α) protein to
demethylate an ectopically introduced methylated cDNA that involves deamination of
5mC to T (Rai et al., 2008). More recently, coimmunoprecipitation studies have
demonstrated that AID, GADD45α and TDG interact when overexpressed in HEK293
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and p19 cells suggesting that all three proteins function together as a DNA demethylase
(Cortellino et al., 2011).
1.4.6 Oxidation of 5mC by the TET proteins
A second mechanism of active DNA demethylation involve the metabolism of
5mC to 5'-hydroxy-methylcytosine (5hmC) that is mediated by the TET family of
enzymes (Figure 1.9B) (Ito et al., 2010). 5hmC is a reaction intermediate that is not
recognized by either TDG or MBD4. However 5hmC is oxidized further by an interative
process involving the TET proteins to 5’formyl-cytosine (5fC) and then to 5’carboxylcytosine (5CaC) (Figure 1.9B) (Ito et al., 2011). Alternatively 5hmC can be deaminated
to 5-hydroxymethyluracil (5hmU) (Figure 1.9B) (Cortellino et al., 2003). 5fC, 5CaC and
5hmU are all efficient substrates for TDG in vitro (Cortellino et al., 2003; Maiti and
Drohat, 2011).
It has been shown in mESCs that TDG knockdown results in an accumulation of
5caC (He et al., 2011). However the amount of 5caC, under TDG-depleted conditions, is
still well below the level of 5fC found under normal conditions. This finding is somewhat
paradoxical given the high efficiency of TET proteins to convert 5fC to 5caC (He et al.,
2011). If TDG is the only enzyme capable of processing 5caC, one would predict that
5caC to accumulate at a much higher level under TDG depleted conditions. This suggests
that additional enzymes that possess 5caC processing activity may exist in mammalian
cells.
Although derivatives of 5mC are generally regarded as metabolic intermediates,
accumulation of these derivatives in some tissues have been observed and a very recent
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study using quantitative mass spectrometry in combination with affinity purification has
identified proteins which bind selectively to 5mC, 5hmC, 5fC and 5caC, suggesting that
these products may represent novel epigenetic marks (Spruijt et al., 2013). In the adult,
levels of 5hmC vary between tissues with high levels found in the central nervous
system, accounting for 0.3 to 0.7 % of all cytosines (Kriaucionis and Heintz, 2009; Penn
et al., 1972). 5hmC is also believed to play a role during development. High levels of
5hmC are observed immediately after fertilization but drops sharply as the embryo
develops (Lee et al., 2002; Oswald et al., 2000; Wossidlo et al., 2011). Levels of 5hmC
are elevated once again as the embryo reaches the blastocyst stage (~E11.5 to E12.5) and
in particular, the inner cell mass contains high levels of 5hmC. The changes in the levels
of 5hmC observed during development, inversely correlates with the expression of the
TET enzymes. Surprisingly, TET1 or TET2 knockout mice are viable and grow normally
whereas knockout of TET3 is embryonic lethal (Tan and Shi, 2012).
All three TET enzymes contain a C-terminal dioxygenase domain and are capable
of converting 5mC to 5hmC, in the presence of ATP and alpha-ketogluterate (αKG) as
co-substrates (Ficz et al., 2011; Ito et al., 2010; Ko et al., 2010; Szwagierczak et al.,
2010). However, only TET1 and TET3 contain an amino terminal CXXC domain that
possesses DNA binding activity and can target TET1/3 to gene promoters (Xu et al.,
2012). In mESCs TET1 and 5hmC colocalize to many promoter CpG islands at
promoters and maintain pluripotency through promoter DNA demethylation and
expression of key genes such as Oct4 and Nanog (Ito et al., 2010; Williams et al., 2011;
Xu et al., 2011). Consistently, downregulation of TET1 resulted in reduced 5hmC levels
coinciding with the loss of stem cell identity (Freudenberg et al., 2012).
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The metabolism of 5mC by TET proteins also plays an important role in cancer.
Mutations in TET2 have been identified in a subset of myeloid leukemias and correlate
with DNA hypermethylation and low levels of 5hmC in patients (Ko et al., 2010).
Furthermore, mice that have a conditional knockout of Tet2 demonstrate an increase in
hematopoietic stem cell self renewal and myeloid transformation (Moran-Crusio et al.,
2011; Tefferi et al., 2009). Isocitrate dehydrogenase 1 and 2 (IDH1/2) convert isocitrate
to αKG which is the major co-substrate for TET proteins. Studies have shown that
IDH1/2 are mutated in approximately 80% of adult glioblastomas and in acute myeloid
leukemias (Figueroa et al., 2010; Gross et al., 2010; Yan et al., 2009). These mutations
are restricted to specific residues that cause the IDH proteins to acquire novel enzymatic
activity and converts αKG to D-2-hydroxyglutarate (D2HG) in a reaction that reduces
NADP to NADPH. D2HG acts as a competitive inhibitor of αKG dependent enzymes,
such as the TETs, and results in elevated 5mC levels in DNA, generating a genome-wide
hypermethylation signature characteristic of transformed cells (Gross et al., 2010; Ward
et al., 2010). Furthermore, TET1 was shown to be downregulated in prostate and breast
cancer tissues and downregulation of TET1 causes invasion, tumor growth, and cancer
metastasis in prostate xenograft models (Hsu et al., 2012).

1.5 The Cell Cycle and the Restriction Point
Cell division, the generation of two identical daughter cells from a parent cell, is
divided into four stages that are sequentially orchestrated by cyclins and cyclindependent-kinases (CDKs). The cell cycle consists of two gap phases, G1 and G2,
interspersed between two main phases, synthesis (S) and mitosis (M), during which the
chromosomes are replicated and segregated, respectively (Vermeulen et al., 2003). Proper

64

regulation of cell division is essential for development and de-regulated cell division is
an underlying cause of cancer (Mitra et al., 2012). A major point of cell cycle regulation
exists within the G1 phase of the cell cycle referred to as the restriction (R) point.
Following mitosis, cells require constant stimulation by mitogens, such as growth factors,
to continue past the R point and once the cell cycle passes this point, the cells are fully
committed to cell division. Alternatively, the lack of mitogen stimulation or growth
inhibitory signals can cause the cells to exit the cell cycle prior to the R point and enter a
quiescent (G0) stage (Zetterberg et al., 1995).
The retinoblastoma protein (Rb) is critical for maintaining cells in G0. Rb belongs
to the pocket protein family which also contains p107 and p130. The Rb family of
proteins binds to E2F TFs and prevents the transcription of genes necessary for S-phase
entry. Upon mitogen stimulation, Cyclin-cyclin dependent kinase (CDK) complexes are
activated which result in the phosphorylation of Rb. This releases E2Fs and activates
E2F-dependent transcription. Conversely, growth inhibitory signals can prevent cell
division by upregulating CDK inhibitors and downregulating CDK activators (Weinberg,
1996). Common inhibitors of CDKs (ink) are p15ink4b, p16ink4a, p27kip1 (Kinase interacting
protein 1), p57kip2 and p21cip1 (CDK-interacting protein 1), Activators of of CDKs include
the cell division cycle 25 A (CDC25A). The p15ink4b and p16ink4a proteins are cyclin DCDK4/6 inhibitors that bind the catalytic site of the kinase and prevent phosphorylation
of Rb. p27kip1, p57kip2 and p21cip1 can inhibit a wide range of cyclin-CDK complexes by a
similar mechanism (Sherr and Roberts, 1995). CDC25A is a protein phosphatase that
dephosphorylates CDK2 and CDK1 promoting progression through the cell cycle
(Draetta and Eckstein, 1997).
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Cell division can be regulated by many external signals. For example, many
growth factors bind to their respective receptors on the cell surface to activate Ras which
initiates a kinase cascade that results in the transcriptional upregulation of cyclin D1
(Jiang et al., 2011; Liu et al., 1995). Ras, or components of the Ras-pathway, are often
mutated and/or constitutively activated in many cancers (Downward, 2003). Conversely,
the TGFβ cytokine can activate a critical tumor suppressor pathway, leading to the
expression of many cell cycle inhibitors that can cause cell growth arrest at G1 phase
(Planas-Silva and Weinberg, 1997; Su et al., 2007).

1.6 The TGFβ Signalling Pathway
TGFβ is a family of secreted growth factors that consists of over 30 types of
ligands in humans that are subdivided into two major subfamilies, TGFβ-activin-nodal
and bone morphogenic proteins (BMP) (Greenwald et al., 2003).
TGFβ ligands bind to TGFβ Receptor I (TGFβRI) and TGFβRII which belong to
the serine/threonine kinase receptor family of proteins. In mammals, there are seven type
I receptors and five type II receptors that can dimerize in various combinations to activate
two pathways, a SMAD-dependent and SMAD-independent pathway (Manning et al.,
2002; Massague, 2012). The SMAD-dependent pathway consists of eight SMAD proteins
(SMAD1-8) which are structurally similar consisting an N-terminal mad homology 1
(MH1) and a C-terminal MH2 domains linked by an unstructured region. The MH1
domain interacts with DNA, and the MH2 domain can interact with many proteins such
as the activated TGFβ receptor or nuclear pore proteins which mediate the translocation
of SMADs into the nucleus. SMADS 1-3, 5 and 8 also contain an SXS motif at the C-
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terminal end and phosphorylation of this motif promotes complex formation with
SMAD4 (Abdollah et al., 1997; Shi and Massague, 2003).
Binding of TGFβ ligand promotes the heterodimerization of TGFβRI with
TGFβRII (Figure 1.10). The TGFβRII then phosphorylates and activates the kinase
domain of TGFβRI which, in turn, phosphorylates receptor regulated SMADs (RSMADs) promoting heterodimerization with SMAD4. The Nodal/Activin class of TGFβ
ligands activates SMAD2 and SMAD3 and the BMP subfamily of TGFβ ligands activate
SMAD1, SMAD5 and SMAD8 (Massague, 2012). Two additional proteins complete the
SMAD family, SMAD 6 and 7, which are inhibitory SMADs that negatively regulate
TGFβ signaling. SMAD7 prevents the phosphorylation of R-SMADs by competitive
TGFβRI binding. SMAD6 binds to SMAD4 and inhibits its interaction to the R-SMADs
(Itoh et al., 2001).
The R-SMADs/SMAD4 complex translocate into the nucleus where it binds to
specific regions of the genome to regulate gene transcription (Figure 1.10) (Shi and
Massague, 2003). SMADs can be targeted to genes indirectly by associating with tissuespecific proteins, such as tripartite motif containing 33 (TRIM33) and inhibitor of DNA
binding 1 (ID1) (Massague et al., 2005; Young, 2011). Alternatively, the SMADs can
directly bind to DNA through a SMAD binding element (SBE) consisting of a consensus
CAGAC sequence. The DNA bound SMAD complex also associates with various
coregulators such as CBP/p300 to activate transcription (Pouponnot et al., 1998).
Alternatively SMAD complexes can repress some genes by associating with HDACs
and CtBP1/2 (Massague et al., 2005).

Figure 1.10: TGFβ signaling leading to cell growth arrest.
The model depicts the signaling events that result from activation of the cell surface
TGFβ receptors to transcriptional activation by the SMAD complexes. TGFβ1 ligand
binding promotes the formation of TGFβRII/TGFβRI heterodimerization. The kinase
domain of TGFβRII phosphorylates TGFβRI resulting in TGFβRI kinase activation.
TGFβRI then specifically phosphorylates SMAD2/3 which heterodimerizes with SMAD4
and localizes to the nucleus. SMAD7 can inhibit the interaction of SMAD2/3 with
TGFβRI and SMAD6 can inhibit heterodimerization between SMAD4/SMAD2/3. In the
nucleus, SMAD4/SMAD2/3 complex interacts with co-regulators such as CBP/p300 and
regulate transcription of genes. The TGFβ cytostatic program includes the increased
expression of the CDK inhibitors p15ink4b and p21cip1 through the binding of SMAD
activation complex and release of MYC repression from the promoters. Upregulation of
p15ink4b and p21cip1 leads to the binding and inhibition of cyclin D-CDK4/6. This
promotes the release of p27kip1 from the cyclin D-CDK4/6 complex and p27kip1 can
inactivate cylin E-CDK2. These events ultimately lead to cell growth arrest at G1 phase.
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TGFβ can also regulate gene expression independent of SMADs. For example, in
some cells, the activated TGFβRs initiate the mitogen activated protein (MAP) kinase
signaling cascade involving Ras and Raf that leads to the activation of the extracellular
signal regulated kinase (ERK) protein. ERK then translocates into the nucleus and
mediates transcription of many genes (Lafontaine et al., 2011; Zhang, 2009).
The TGFβ signaling pathway is essential for mammalian development and is
required for an array of cellular responses, such as axis formation and the subsequent
patterning to generate tissues during embryogenesis (Little and Mullins, 2006; O'Connor
et al., 2006). Genetic ablation of the TGFβ signaling proteins, such as TfgβrII, Smad2 or
Smad4 leads to embryonic lethality in mice (Goumans and Mummery, 2000; Larsson et
al., 2001; Oshima et al., 1996; Weinstein et al., 1998). In the adult, TGFβ maintains
homeostasis by playing a role in a wide variety of cellular processes which includes cell
differentiation, growth, apoptosis and migration (Derynck and Akhurst, 2007; Massague
et al., 2000).
In addition, TGFβ is a potent anti-proliferative cytokine and coordinates this
function through transcriptional regulation of genes that primarily target cell growth
arrest at the G1 phase of the cell cycle (Figure 1.10) (Hanahan and Weinberg, 2000;
Laiho et al., 1990). In many cell types, TGFβ upregulates the expression of cyclin
dependent kinase inhibitors p15ink4b and p21Cip1 and downregulates the expression of
proteins that promote cell division, including CDC25A, myelocytomatosis viral oncogene
homolog (MYC), ID1, ID2 and ID3 (Brown and Bhowmick, 2004; Feng et al., 2000;
Kang et al., 2003).
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G1/S phase transition requires the actions of cyclin D-CDK4/6 and cyclin ECDK2 complexes to phosphorylate Rb. The TGFβ induced CDK inhibitors, p15ink4b and
p21Cip1, bind and inhibit these CDKs (Besson et al., 2008). In dividing cells, CDK
inhibitor p27kip1 is bound to cyclin D-CDK4/6 and the p27kip1-cyclin D-CDK4/6 complex
still retains its kinase activity. The binding of p15ink4b to cyclin D-CDK4/6 complex
dislodges p27kip1 allowing it to bind and repress cyclin E-CDK2 complex promoting
complete repression of the CDKs (Figure 1.10) (Blain et al., 1997).
The TGFβ anti-proliferative response is also dependant on MYC levels. MYC
acts as a repressor of the msx interacting zinc finger 1 (MIZ1) which is bound to the
p15ink4b and p21cip1 promoter and is required for the activation of p15ink4b and p21cip1
genes. TGFβ causes downregulation of MYC and this relieves its repression of MIZ1 and
allows activation of p15ink4b and p21cip1 gene.
MYC is an activator of ID2 transcription and downregulation of MYC by TGFβ
also leads to ID2 silencing. The ID proteins promote growth by preventing differentiation
through inhibition of the basic helix-loop-helix (bHLH) TFs and ID2 promotes cell
division by physically interacting and sequestering Rb. TGFβ also stimulates the
expression of activating transcription factor 3 (ATF3) and ATF3 interacts with the SMAD
complex to repress ID1 transcription (Kang et al., 2003).
The anti-proliferative effects of TGFβ are often lost during cellular transformation
and this feature is considered a hallmark of cancer (Hanahan and Weinberg, 2000; Reiss,
1997). The link between TGFβ signaling and cancer was demonstrated using mouse
genetic studies. Overexpression of a dominant negative TfgβrII or deletion of Smad4 in
mice resulted in increased tumor frequency compared to wild type. Treatment of these
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mice with carcinogens lead to increased accumulation of tumors compared to the wild
type mice (Barcellos-Hoff and Ewan, 2000; Go et al., 2000; Tang et al., 1998; Xu et al.,
2000). Frequent mutations of TGFβRs and SMADs have been identified in specific types
of cancers (Goggins et al., 1998; Grady et al., 1999). Bi-allelic loss of SMAD4 has been
observed in approximately 50 % of pancreatic cancers and one third of metastatic colon
tumors (Hahn et al., 1996; Miyaki et al., 1999). TGFβRII mutations have been identified
in human colorectal and gastric carcinomas (Markowitz et al., 1995). Deletion/mutations
of TGFβRI have been identified with ovarian, breast, pancreatic, biliary, and colon
cancers (Chen et al., 1998; Goggins et al., 1998; Pasche et al., 1999; Wang et al., 2000).
In summary, during the early stages of transformation the cytostatic and apoptotic
functions of TGFβ help restrain growth of mammalian cells and TGFβ acts as a tumour
suppressor. However in later stages of cancer the TGFβ pathway is disrupted resulting in
hyperproliferation and tumor promotion (Kang et al., 2005). How specific oncogenic
signals attenuate the tumor-suppressor functions of TGFβ and turn this cytokine into a
tumor promoter is currently unclear.

1.7 Zinc Finger 217 Protein
ZNF217 is a Kruppel-like TF of approximately 1100 amino acids and contains 8
Cys2 – His2 zinc fingers. ZNF217 mainly localizes to the nucleus and binds directly to
DNA (Nunez et al., 2011; Vandevenne et al., 2013). Two consensus sites for ZNF217
have been identified. Using an in vitro approach the consensus CAGAAY (Y represents
C or T) was isolated, and using a sequence comparison analysis of global ZNF217
targets, the consensus ATTCCNAC (N represents any nucleotide) was identified
(Cowger et al., 2007; Krig et al., 2007). Recent crystal structures demonstrate that
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ZNF217 interacts with DNA through the 6th and 7th zinc fingers to the consensus
sequence, CAGAAY (Nunez et al., 2011). Subsequently, an extended version of this
consensus

sequence

was

identified

which

conferred

stronger

binding,

(T/A)(G/A)CAGAA(T/G/C) (Vandevenne et al., 2013). Mutation of this site only
resulted in a modest decrease in ZNF217 binding and it was demonstrated that a lower
affinity non-specific interaction between DNA and ZNF217 in solution also exists. In
vitro assays demonstrate that ZNF217 is a transcriptional repressor and is a component of
a 1.5 MDa repressor complex (Cowger et al., 2007; Vandevenne et al., 2013). This
complex also consists of CoREST and several histone modifying enzymes, including
HDACs (1 or 2), LSD1 and the CtBP1 (Cowger et al., 2007; Kuppuswamy et al., 2008;
You et al., 2001; Zhang et al., 2001). ZNF217 directly interacts with both CoREST and
CtBP1 through its N-terminal and C-terminal portions, respectively. Both motifs are
essential for conferring the transcriptional repressor properties of ZNF217 (Cowger et al.,
2007; Quinlan et al., 2006a).
CoREST contains two SANT domains (SWI3, adaptor 2 (ADA2), nuclear
receptor co-repressor (N-CoR), TFIIB) which are domains capable of binding unmodified
histone tails. However in the context of CoREST, the SANT domain is involved in
protein-protein interaction. CoREST interacts with HDAC1/2 through the amino terminal
SANT domain and LSD1 through the linker region between the two SANT domains (Shi
et al., 2005; You et al., 2001). In vitro experiments have shown that CoREST acts as an
auxiliary protein and enhances the activity of LSD1 on methylated nucleosomes (Shi et
al., 2005).
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CtBP1 and CtBP2 are proteins that share a high degree of amino acid sequence
similarity and function primarily as adaptor proteins by facilitating the formation of
multi-protein complexes (Chinnadurai, 2002; Sewalt et al., 1999; Shi et al., 2003; Siles et
al., 2013). CtBP proteins contain two hydrophobic binding pockets at each end of the
protein which bind many PXDLS (where X represents any amino acid) motif containing
proteins such as early region 1A (E1A) (Quinlan et al., 2006b). These interactions are
further enhanced by the RRT binding surface housed between the PXDLS pockets
(Kuppuswamy et al., 2008). It has been reported that CtBP proteins possess NADHdependant dehydrogenase activity and undergo NAD(H) dependent dimerization
although its dehydrogenase function is controversial (Kumar et al., 2002; Schaeper et al.,
1995). ZNF217 also contains the PXDLS and RRT motifs within the C-terminal end,
where CtBP1 was observed to bind (Quinlan et al., 2006a). CtBP2, and not CtBP1, is
crucial during development and overexpression of CtBPs in cancers correlates with
increased tumor growth and epithelial to messenchymal transition (Chinnadurai, 2009;
Hildebrand and Soriano, 2002).
Interestingly ZNF217 has also been shown to activate transcription in some
contexts. ZNF217 directly binds and activates the promoter of the ERBB3 receptor
tyrosine kinase (V-ERB-B2 avian erythroblastic leukemia viral oncogene homolog 3)
gene that can as an oncogene. In contrast, CtBP2 represses ERBB3, but ZNF217 and
CtBP2 are both found at the ERBB3 promoter suggesting a complex mechanism of
transcriptional regulation. However, the mechanism by which ZNF217 functions as an
activator still remains unclear (Krig et al., 2010).
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ZNF217 is found at the 20q13 chromosomal region which is found amplified in a
number of different cancer types including ovarian and breast (Collins et al., 1998).
Cancers possessing the 20q13 amplification are associated with reduced patient survival,
increased cell proliferation and increased tumor aggressiveness and grade (Tanner et al.,
1995). Positional cloning of the 1 MB region at 20q13 allowed for the isolation of a
highly amplified central 260 Kb region and identified ZNF217 as the strongest candidate
within the maximally amplified region (Collins et al., 1998).
ZNF217 amplification and overexpression has been shown to correlate with lower
patient survival in many cancer types such as ovarian, colon and breast (Collins et al.,
1998; Ginestier et al., 2006). ZNF217 amplification in breast tumors is associated with
increased tumor grade and aggressiveness with poor prognosis (Tanner et al., 1995).
Recently it was demonstrated that ZNF217 is overexpressed in 71.2% of Glioblastoma
multiforme (GBM) an aggressive type of brain tumor that arises from a subpopulation of
Glioma stem cells (GSCs). It is postulated that ZNF217 contributes to this cancer type as
a consequence of its ability to prevent differentiation of GSCs and its sustained
expression in hypoxic conditions (Mao et al., 2011). ZNF217 overexpression was also
found to have increased self-renewal capacity, expression of mesenchymal markers,
motility, and metastasis (Rahman et al., 2012). Consequently ZNF217 overexpression
represents a strong prognostic marker associated with poor clinical outcome (Littlepage
et al., 2012).
Numerous studies have provided strong evidence that ZNF217 overexpression
contributes to the transformed phenotype. Transduction of finite life-span human
mammary epithelial cells (HMEC) with a retrovirus consisting of a construct that
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overexpresses ZNF217, gives rise to immortalized cells with increased telomerase
activity coinciding with stable telomere length, increased cell proliferation and resistance
to TGFβ growth inhibition which are all key characteristics of transformed cells
(Hanahan and Weinberg, 2000; Nonet et al., 2001). Transduction of ovarian epithelial
cells with a ZNF217 overexpressing retrovirus showed similar characteristics, as well as
increased survival in reduced serum conditions and anchorage independent cell growth.
Furthermore, silencing of ZNF217 in the ovarian epithelial cells using siRNA caused
growth arrest demonstrating that the sustained proliferation was due to ZNF217 (Li et al.,
2007). In addition to a proliferative advantage, many cancer cell types which have
ZNF217

overexpression

also

develop

resistance

to

apoptotic

signals

and

chemotherapeutic drugs such as doxorubicin (Song et al., 2005). Furthermore, ZNF217
was demonstrated to function together with the TGFβ-SMAD signaling pathway to
promote epithelial to messenchymal transition (EMT). Coincidently, overexpression of
ZNF217 promoted migration and invasion in breast cancer cells, increased lung/node
metastasis in mice and correlates with poor prognosis (Vendrell et al., 2012).
In summary, ZNF217’s oncogenic potential is compelling but the molecular
mechanisms employed by ZNF217 to drive and sustain oncogenic properties, such as
increased proliferation survival, and resistance to TGFβ, remain elusive.

1.8 Hypothesis and Summary of Objectives
Strong evidence suggests that overexpression of ZNF217 causes patterns of
cellular deregulation that are consistent with oncogenesis. However, its molecular
mechanism of action remains poorly understood. I have conceptualized a global
hypothesis which encompasses the entire scope of my study as follows; Overexpression
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of ZNF217, as has been found in cancers, causes disruption of transcriptional regulation
resulting in aberrant expression of specific target genes which provides a growth
advantage to the host cell. Ultimately, my goal was to identify gene targets for ZNF217
that would provide insight into its molecular mechanisms of action as well as to better
understand its oncogenic potential.
In chapter 2 of my thesis, I utilized a modified chromatin immunoprecipitation
(ChIP)-on-chip approach known as chromatin immunoprecipitation with directed
selection and ligation (ChIP-DSL) to identify targets on a 20,000 gene promoter array.
This was done in conjunction with microarray gene expression analysis following
ZNF217 knockdown. By comparing the results of both approaches, I identified a group of
genes directly regulated by ZNF217. Among the genes identified, I focused on the
p15ink4b CDK inhibitor because it was known that ZNF217 overexpression was associated
with increased cell proliferation and TGFβ resistance; functions that are tightly linked to
p15ink4b activity. Furthermore, the transcriptional activation of 15ink4b has been well
characterized, and so it provided me with an ideal model system to study the molecular
mechanisms of transcriptional regulation employed by ZNF217. I showed that there is a
good correlation between recruitment of the ZNF217 complex and repression of p15ink4b.
Using ChIP, I mapped the ZNF217 binding site to the proximal promoter region of
p15ink4b and I established a good correlation between the presence of ZNF217, specific
histone marks and TGFβ signaling. I demonstrated a coregulator exchange following
TGFβ treatment that involves the release of ZNF217 and the binding of SMADs at the
p15ink4b promoter.
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In chapter 3 I extended the findings from chapter 2 in several ways. First, I have
used ChIPseq which has much greater resolving power than ChIP-DSL and this allowed
me to identify binding sites genome-wide. Additionally, I have performed the ChIPseq
analysis for two components of the ZNF217/CoREST complex, ZNF217 and CTBP1
which was not done in chapter 2. I have performed some analysis on this data to define
binding sites of these proteins within the genome. This demonstrated a significant overlap
between ZNF217 and CtBP1, which confirms previous biochemical observations
regarding the association of ZNF217 and CtBP1 in the same complex (Cowger et al.,
2007; Quinlan et al., 2006a). I have also performed knockdown experiments in order to
examine a requirement for specific components of the ZNF217 complex. I also conducted
additional experiments regarding the downstream events resulting from the
ZNF217/p15ink4b association, such as effects on the cell cycle and Rb status.
Chapter 3 also broadened the mechanistic aspects which began in chapter 2 by
examining the dynamics of DNA methylation at the p15ink4b promoter. I observed a
strong correlation between DNA hypermethylation of p15ink4b promoter and silencing of
the p15ink4b gene in MCF7 cells, and based on my preliminary observations in chapter 2, I
formulated a secondary hypothesis as follows: In addition to coregulator exchange, TGFβ
stimulation causes active DNA demethylation and this mechanism is inhibited by
ZNF217 overexpression. I was able to verify this hypothesis experimentally at the
p15ink4b promoter in HaCAT cells. I identified a novel activator complex consisting of
SMAD2/3, TDG and CBP which bound the p15ink4b promoter in close proximity to the
region occupied by the ZNF217 complex and mediated the TGFβ induced active DNA
demethylation. Finally, overexpression of ZNF217 using adenovirus, abrogated the active
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DNA demethylation imposed by TGFβ, by preventing the binding of the demethylase
protein complex, coinciding with repression of the p15ink4b gene.
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Chapter 2: Genome Analysis Identifies the p15ink4b Tumor
Suppressor as a Direct Target of the ZNF217/CoREST
Complex
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2.1 Introduction
ZNF217 is a candidate oncogene found at the core of the 20q13.2 amplicon
(Collins et al., 1998). Amplification and overexpression of ZNF217 has been found in a
significant proportion of tumours and transformed cell types of epithelial origin including
those of the breast, colorectal, ovarian and prostate, ranging in amplification frequency
from 10 to 40% (Suzuki et al., 2004; Tanner et al., 2000; Watanabe et al., 2002; Weiss et
al., 2003). Several studies have also established correlations between amplification and
overexpression of ZNF217 and clinical outcome, with increased ZNF217 expression
correlating with a poor prognosis (Bar-Shira et al., 2002; Chin et al., 2006; Hidaka et al.,
2000; Tanner et al., 2000; Weiss et al., 2003).
Insights into the oncogenic role of ZNF217 have come primarily from studies
using finite lifespan human epithelial cells. Forced expression of ZNF217 by retroviral
gene transfer in human mammary epithelial cells promotes loss of senescence,
immortalization, and resistance to growth inhibition by TGFβ (Nonet et al., 2001). In
addition, prolonged growth of ZNF217-immortalized cells display chromosomal
instability, as well as telomere crisis and telomerase reactivation (Chin et al., 2004). More
recently, transduction of finite lifespan ovarian cells with a ZNF217 retrovirus has also
been shown to promote cellular immortalization, increased cellular proliferation and
telomerase activity, as well as anchorage independent cell growth (Kwon et al., 2007).
ZNF217 overexpression was also shown to suppress spontaneous and doxorubicininduced apoptosis, suggesting that ZNF217 may promote oncogenic transformation by
increasing cell survival (Huang et al., 2005).
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The ZNF217 protein contains 8 Kruppel-like zinc fingers suggesting that it most
likely functions as a transcription factor. Molecular mapping studies using a
transcription-based reporter assay and various regions of ZNF217 fused to the GAL4
DNA binding domain have identified two repression domains located within the carboxy
terminus (Cowger et al., 2006; Quinlan et al., 2006). Biochemical purification studies in
combination with mass spectrometry have identified ZNF217 as a constituent of severalrelated transcriptional repressor complexes (Cowger et al., 2006; Hakimi et al., 2003; Lee
et al., 2005; Shi et al., 2004; Shi et al., 2005; You et al., 2001). Comparative analysis of
each of the purified complexes suggests that the ZNF217 complex is very similar to the
CoREST complex previously implicated in neuronal differentiation (You et al., 2001),
and consists of 3 core proteins: the histone deacetylase 2, the lysine demethylase I
(LSD1) and the Corepressor of Rest (CoREST). In addition, the carboxy terminus of
ZNF217 interacts directly with the CtBP 1/2 corepressor and this interaction is, in part,
essential for the repressor function of ZNF217 (Cowger et al., 2006; Quinlan et al.,
2006).
CASTing (Cyclic amplification and selection of targets) analysis, using
degenerate oligonucleotides and the region of ZNF217 encompassing the sixth and
seventh zinc fingers has identified a core recognition sequence consisting of CAGAAY
(where Y is A, G orT) (Cowger et al., 2006). This sequence has been identified within the
E-cadherin promoter and chromatin immunoprecipitation (ChIP) assays have shown that
the ZNF217 complex is present on the E-cadherin promoter in breast cancer cells
(Cowger et al., 2006). More recently, a bioinformatics approach in conjunction with ChIP
analysis was used to identify a consensus ZNF217 binding site (ATTCNAC), in ZNF217
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target genes. Interestingly, 65% of the genes identified in the ChIP screen also contained
the CAGAAY motif suggesting that ZNF217 may use multiple zinc fingers to bind
specific target genes (Krig et al., 2007).
In the present study, we have used a two-step approach to identify ZNF217
targets. First, we employed siRNA-mediated gene silencing of ZNF217 coupled with
microarray screening to identify genes with altered expression. Secondly, we used
chromatin immunoprecipitation with directed selection and ligation (ChIP-DSL) to
identify promoters directly bound by ZNF217. By comparative analysis of genes
identified using both approaches, we have identified a subset of genes directly regulated
by the ZNF217 complex. Our analysis has focused on the p15ink4b tumour suppressor
gene as a critical ZNF217 target. ChIP analysis in both MCF7 and HaCAT cells
confirmed that the ZNF217 complex occupies a region of p15ink4B promoter that is
critically important for transcriptional activation. Stimulation of HaCAT cells with TGFβ
resulted in a rapid release of ZNF217 and a concomitant recruitment of SMAD2 protein
to the p15ink4b gene promoter, which preceded increases in protein expression.
Importantly, ZNF217 downregulation and TGFβ stimulation have similar affects on the
chromatin modifications surrounding the p15ink4b promoter suggesting that ZNF217 and
TGFβ are functioning through convergent mechanisms. Our results suggest that a
coactivator/corepressor balance may constitute an important parameter regulating p15ink4b
expression and establishes a possible link between overexpression of ZNF217 and the
loss of TGFβ stimulation at selected targets.
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2.2 Materials and Methods
2.2.1 Plasmids, antibodies, reagents and culture conditions.
The affinity purified anti-ZNF217 antibody was generated as previously described
(Cowger et al., 2006). A complete list of primers used can be found in Table 2.1.
Antibodies used in this study are listed in Table 2.2. TGFβ was purchased from R&D
systems.

The

siRNA

was

purchased

from

Dharmacon.

ZNF217

siRNA1:

GCAAAUAACCUCAUCUGUAUU, ZNF217 siRNA2: GAACAGAACCUCCCAAGG
AUU. Control siRNA: scrambled pool siRNA (sequence not revealed by manufacturer).
MCF7 (breast cancer cells) and HaCAT cells (Immortilized skin keratinocytes) were
grown in humid 37°C incubators containing 5% CO2. HaCAT cells were grown to
approximately 75% percent confluence and were passaged once every 3 days. MCF7
cells were grown to full confluence and were passaged once every 3 days.
2.2.2 RNA isolation and real-time PCR.
Total cellular RNA was isolated using RNA EZ kit (Qiagen). The quality and
quantity of RNA were evaluated by measuring OD 260/280. In addition, RNA quality
was evaluated by agarose gel electrophoresis. RNA knockdown was conducted using
Oligofectamine

(Invitrogen

Cat

#

12252-011)

according

to

manufacturer's

recommendations. For real-time PCR analysis, 0.2 µg of RNA was reverse-transcribed
with TaqMan reverse transcriptase (Applied Biosystems) using random hexamers to
generate cDNA. All amplicons were detected using the 5’ nuclease (Taqman) assay with
5’ TAMRA- labelled probes. Probes were already predesigned and quality tested
(Applied Biosystems). Reactions were performed according to the manufacturer's
recommendations (Applied biosystems) and were run in replicates of two, in a 96-well
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Table 2.1: Primers used in ChIP experiments. Primer sequences are derived from
1Kb upstream region of genes.
Gene
ABCA12
EFNB2
GJA1
NOTCH1
VAV3
RAC3
SF3A1
MAN1A1
MCM8
CDC25C
ink4b

p15
Standard
PCR
Primer Set 4
Primer Set 3
Primer Set 1
Realtime PCR
Primer Set 4
Primer Set 3
Primer Set 2
Primer Set 1

Forward Primer 5' - 3'

Reverse Primer 5' - 3'

GAGCCTGAAACAATG CTATGTTGGCCAGG
TGG
TCC
GTCGCTGTTTCCACGT CGGGCTGACAGGTG
C
AGC
CTCTCTAGTGGGCTT CCATGTCTCCAGAA
GAG
AACTAAG
GCGCCAGCGGCAGAT TCGCGGACGGATTG
C
TGC
GCGCAAAAGTTCTGG GCCGTTGCTGTTCT
GG
GG
GGCGACTGTTGGTGG AACGCGCTGTATTT
TGT
CCAAAC
TGGTGAAACCCCGTC GCGATCTTGACTCT
TCTAC
CTGCAA
GGCGGGAGAGACATA GAAGCACGGCTTTA
CAAGT
CTCCAG
TGGACGGCCAGATAT GTGCCATTCTTGGC
GAAAT
TCTCTC
TCCCAAAGTGCTGGG AATTCCGTTGCAGG
ATTAC
GAAAG

CTCGGTCACAAGGGA
GC
GCACACGCAAAACAT
GATTC
CCTAGGAAGATTAGG
AAGG

AATGCTGGCTGCAC
TGC
GCGACAGCTCTGCA
CC
CCCACTTTGTCAGG
TATC

CCAACGTCTCCACAG
TGAAA
CATGATTCTCGGGAT
TTTTCTC
CCTGACAAAGTGGGT
TTAAATAGG
AGGAAGATTAGGAAG
GGGAAA

AATGCTGGCTGCAC
TGCT
GACAGCTCTGCACC
TGTCAT
GAATCATGTTTTGC
GTGTGC
CCCACTTTGTCAGG
TATCTTATTTT

Region
amplified
-769/-588
-848/-717
-934/-776
-738/-509
-632/-536
-632/-484
-583/-451
-693/-505
-996/-870
-791/-638

-359/-203
-578/-420
-950/-779

-340/-204
-566/-426
-775/-578
-947/-786

114

Table 2.2: Antibodies used for immunoblotting and chromatin
immunoprecipitation.
Antibodies
EHF
MAP2
p15INK4B
EFNB2
GJA1
LSD1
CoREST
SMAD2/3
Anti-AcetylLysine 9/14 H3
Anti-dimethylLysine 4 H3
Anti-trimethylLysine 27 H3

Company
Lab Vision
Santa Cruz
Santa Cruz
Santa Cruz
Sigma
Bethyl Laboratories
Bethyl Laboratories
Santa Cruz

Catalogue Number
RT-1912
sc-20172
sc-612
sc-15397
c6219
A300-216A
A300-130A
sc-6032

Upstate

06-599

Upstate

05-790

Upstate

07-449
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format. Each reaction included 18S RNA as a control for normalization, and reactions
lacking cDNA served as negative controls. Two independent experiments were
performed for each gene, and a mean value was obtained and compared to the mean
expression level of each gene from cells transfected with control siRNA. Applied
Biosystems 7500 Real Time PCR System software was used to identify cycle threshold
(Ct) for each reaction.
2.2.3 RNA microarray analysis.
Total RNA was extracted from MCF7 cells transfected with ZNF217 siRNA or
mock. Independent biological triplicates were performed for each siRNA, and including
control transfections, brought the number of independent transfection experiments to
nine. cDNA was prepared from control and each siRNA-transfected sample, labelled and
hybridized to HgU133A + 2 human affymetrix DNA microarray and a list of genes was
then created for all 9 experiments. The hybridization, washing, scanning and analysis of
genechips were performed at the University of Western Ontario, Robarts Genomic Centre
(London, Ontario, Canada).
An average intensity of siRNA knockdowns (RNAi (1 and 2) was compared to
control non treated sample. Three biological replicates were done for each array and the
data was transformed using Robust Multi-Array normalization (Bolstad et al., 2003) and
values below 0.01 were set to 0.01. Each measurement was normalized by dividing all
measurements in that sample by the 50th percentile. Ratios were then calculated for all 9
samples against the median of the control samples (1, 4, and 9).

A student t-test

statistical analysis was conducted and false positives were reduced using Benjamini and
Hochberg false discovery rate.
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2.2.4 Western blot analysis.
Cells were washed twice in phosphate buffered saline (PBS) harvested and lysed
in lysis buffer (~300 ul/10 cm plate) consisting of 20 mM Tris (pH7.9), 300 mM KCl,
0.1% NP40, 10% glycerol, 0.1 mM DTT, 0.5 mM EDTA, 0.5 mM EGTA and protease
inhibitor cocktail (Thermo Scientific Cat# 1862209). For experiments involving detection
of p15ink4b, RIPA buffer was used to prepare the cell extracts consisting of 50 mM Tris
(pH 8.0), 150 mM NaCl, 1% NP-40 and 0.1% SDS. Extracts were centrifuged for 10 min
at 16,000xg at 4°C and the soluble extracts were retained. Samples were normalized for
protein content and were separated by SDS-PAGE, transferred to nitrocellulose or PVDF
membrane and blocked overnight in PBS containing 0.1% TWEEN20 and 5% nonfat
dried milk. The appropriate antibodies were then diluted (according to manufacturer's
recommendations) in blocking buffer and the membrane was probed for 2 hr at room
temperature with rocking followed by the appropriate secondary antibody (1/10 000
dilution) for 1 hr. Proteins were detected using ECL according to the manufacturers
recommendations (Amersham). ZNF217 antibody was diluted at 1/3000 dilution.
2.2.5 Purification of the ZNF217 complex.
ZNF217 was purified from MCF-7 cells essentially as previously described (13).
Approximately 20 mg of nuclear extract was loaded onto a 10 ml phosphocellulose P11
column. The column was then washed using buffer A (20 mM Tris [pH 7.9] 0.5 mM
EDTA, 10% glycerol, and 0.5 mM DTT and 100 mM KCl) and ZNF217 was eluted with
buffer A containing 0.3M KCl. The ZNF217-containing fraction was assayed by western
blotting and then loaded, and reloaded five times, onto an anti-ZNF217 immunoaffinity
column that was generated by crosslinking affinity purified ZNF217 antibody to protein
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A Sepharose according to standard procedures (Harlow and Lane, 1999). The column
was then washed with buffer A containing 0.3 M KCl and 0.1% NP40. Bound proteins
were eluted with 100 mM glycine (pH 2.8) containing 100 mM KCl and analyzed for
various proteins by western blotting.
2.2.6 Chromatin immunoprecipitation assay.
MCF-7 cells were cross-linked with 1% formaldehyde at room temperature for 10
min. Cross-linking was quenched by immediately washing cells twice with ice-cold PBS.
Cells were washed twice with ice-cold PBS containing 0.5 mM EDTA and harvested.
Cells pellets were lysed in 0.3 ml of cell lysis buffer (50 mM Tris-HCl [pH 8.1], 10 mM
EDTA, 1% SDS, and protease inhibitors) and incubated on ice for 10 min. Cell lysates
were sonicated to yield DNA fragments ranging in size from 300- to 1,000-bp.
Approximately 450µg of the cross-linked, sheared chromatin solution was used for
immunoprecipitation (IP) with. A small portion of each IP was saved as input DNA (5%).
Supernatants were diluted 10-fold in dilution buffer (20 mM Tris-HCl [pH 8.1], 1%
Triton X-100, 2 mM EDTA, 150 mM NaCl, and protease inhibitors) and precleared with
60 µl of 50% slurry protein A-Sepharose containing 2.5 µg of sheared salmon sperm
DNA for 2 h at 4°C. IP was performed overnight at 4°C with 1.5-4 μg of the antibodies.
60 µl of protein A-Sepharose containing 2.5 µg of salmon sperm DNA per ml was added
to the solution and incubated for 1 h at 4 °C. The beads were washed one time with wash
buffer I (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris-HCl, 150mM NaCl),
wash buffer II (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris-HCl, 500mM
NaCl), wash buffer III (0.25 M LiCl; 1% NP-40; 1% Na-Deoxycholate; 1 mM EDTA; 10
mM TrisHCl) and twice with TE buffer. Immunocomplexes were extracted twice with
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200 μl elution buffer (1% SDS-0.1 M NaHCO3). NaCl was added to a final concentration
of 200 mM and the cross-linking was reversed by heating at 65 °C overnight. The DNA
was purified using Qiagen PCR purification spin columns. For analysis by conventional
PCR, conditions were as follows: initial denaturing cycle of at 94 °C for 3 min, followed
by 35 cycles of 94 °C for 30 sec, 52 °C for 30 sec and 72 °C for 1 min, and a final
elongation step of 72 °C for 10 min. For experiments involving TGFβ treatment, HaCAT
cells were plated to approximately 90% confluence and treated with 150 pM TGFβ for 90
min prior to ChIP analysis.
For some experiments, DNA isolated from ChIP experiments was subjected to
quantitation by real time PCR using Brilliant SYBR green master mix (Stratagene;
600548). Primers were identified using the Primer Express program (Stratagene) and
tested to establish optimum reaction conditions. Reactions were performed in a 25ul
volume according to manufacturer’s recommendations. The reaction was carried out and
measured using Mx3000P realtime instrument. Standard curves were generated using
total input DNA (copy number range: 8X105 to 8X101). The IP and IgG DNA copy
number was calculated by extrapolating their respective Ct value from the standard curve.
The nonimmune IgG copy number was subtracted from IP DNA copy number. The
resulting IP copy number was normalized against the total input DNA by dividing the IP
by input and expressing the IP as a percentage of the input DNA. All measurements were
done in duplicates and an average Ct value was used to calculate copy number. Two
independent realtime reactions were done for each experiment.
2.2.7 ChIP-DSL assay.
Chromatin immunoprecipitation coupled to DNA selection and Ligation (ChIP-
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DSL) was used to assess global promoter occupancy by ZNF217. MCF7 cells were crosslinked with formaldehyde and subjected to standard ChIP assay using affinity purified
anti-ZNF217 antibody. The procedure for oligonucleotide annealing, solid phase
selection ligation and PCR amplification were performed exactly as described (Aviva
Systems Biology; H20K, Cat# AK-0504). The antibody-enriched DNA and the total
input were biotinylated followed by annealing to the 40mer oligonucleotide pool. The
DNA-oligonucleotide complexes are then selected by binding to streptavidin-conjugated
magnetic beads, while the non-annealed oligonucleotides are washed away. Correctly
paired 40mers are then ligated to form the corresponding 80mer which is flanked by both
universal primer annealing sites (T3 and T7) giving rise to a complete amplicon. A PCR
reaction was then conducted on the amplicons using fluorescently labeled T7 and regular
T3 primers. Total input DNA was PCR amplified using Cy5 (green) labelled T7 primer
and the IP sample was amplified using Cy3 (red) labeled T7 primer. The PCR products
are co-hybridized to the 40mer array (Hu20K) to derive an enrichment ratio for each
target. After hybridization and washing, array slides were scanned on a One Virtek (BioRad) Chip Reader, and the ArrayVision (v6.0) software package (Genomic Centre,
London, Ontario, Canada) was used to quantify fluorescence intensity. The Chip on chip
intensity values were normalized using a Lowess curve, which was fit to the log intensity
versus log-ratio plot and 20% of the data was used to calculate the Lowess fit at each
point.

Following normalization, a two-sided student's T-test was conducted where

standard deviation of the replicates was used to calculate a p-value. Fold change was
calculated for each gene using a mean value that was calculated from all three biological
replicates.
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2.2.8 Ingenuity Pathways Systems analysis.
Ingenuity Pathways Systems (http://www.ingenuity.com) analysis was employed
to group statistically significant genes. Genes that had at least a single enrichment were
imported into the Ingenuity systems. Only 1215 genes were found in the system database
and only those genes were used for further analysis. The significance value associated
with a function is expressed as a p-value, which is calculated using the right-tailed Fisher
Exact Test. This is done by comparing the number of genes from the gene expression
profile that participate in a given function, relative to the total number of occurrences of
those genes in all functional annotations stored in the Ingenuity Pathways database.

2.3 Results
2.3.1 Purification of ZNF217 from MCF-7 breast cancer cells.
Using protein purification in combination with mass spectrometry, we, and others,
have recently shown that ZNF217 is a component of a core complex consisting of
CoREST, LSD1 CtBP1 and HDAC2 (Cowger et al., 2006; Hakimi et al., 2003; Lee et al.,
2005; Shi et al., 2004; Shi et al., 2005; You et al., 2001). To assess the integrity of the
ZNF217 complex in MCF7 breast cancer cells we purified ZNF217 by immunoaffinity
chromatography using a similar approach (Figure 2.1A). SDS-PAGE analysis of the
immunopurified ZNF217 followed by silver staining indicated that the profile of proteins
was similar to the ZNF217 complex we recently purified (Cowger et al., 2006) and
contains at least three additional polypeptides that were not present in the control
immunopurification using rabbit IgG (Figure 2.1B).Western blot analysis using selected
antibodies indicated that CoREST, LSD1, HDAC2 and CtBP1 all copurified with

Figure 2.1: Purification of the ZNF217 complex from MCF-7 nuclear extracts.
(A) Purification scheme used to purify the ZNF217 complex from MCF7 cell nuclear
extracts. ZNF217 was partially purified by passing MCF7 cell nuclear extracts through a
P11 phosphocellulose column prior to immunoaffinity chromatography using ZNF217
antibody. (B) Silver stain SDS-PAGE gel of the purified proteins. A 15 µl aliquot of the
purified ZNF217 complex was analyzed by SDS-PAGE followed by silver staining. IgG;
represents affinity purification using a rabbit IgG nonimmune affinity column. (C)
Western blotting of various proteins found in the ZNF217 complex. A 15 µl aliquot of
the purified ZNF217 complex was analyzed by SDS-PAGE followed by western blotting
using various antibodies indicated on the left of the figure.
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ZNF217 (Figure 2.1C). These results suggest that the ZNF217 complex found in MCF-7
cells is similar to the complex previously identified in HeLa cells (Cowger et al., 2006).
2.3.2 Identification of gene expression changes in ZNF217-depleted MCF-7 cells.
To identify genes that are regulated by ZNF217 we initially performed expression
array analysis on ZNF217-depleted cells. Two small interfering RNAs (siRNA1 and
siRNA2), which recognize distinct regions of the ZNF217 transcript, were transfected
into MCF7 cells. The use of multiple siRNAs minimizes potential off target effects
associated with individual siRNAs. Western blot analysis of cell lysates prepared 72 hr
after transfection confirmed that ZNF217 protein levels were significantly reduced
(Figure 2.2A). cDNA from three independent cultures of control and siRNA-treated
MCF7 cells were prepared, fluorescently labelled and hybridized to Affymetrix arrays. In
our initial analysis, we identified genes displaying statistically significant changes in
expression in 3 out of 3 replicates for each siRNA. From this preliminary list of genes we
identified those genes which were common to both siRNAs. Using this approach, we
identified 176 genes which were significantly upregulated and 875 genes which were
downregulated following ZNF217 knockdown (Figure 2.2B, Thillainadesan et al. 2008;
Supplementary Table 3). In our initial analysis, we focused on those genes which are
upregulated by ZNF knockdown. This is based on the observation that ZNF217 is
generally believed to function as a transcriptional repressor and depletion of ZNF217
should result in derepression of target genes. To confirm the results of the expression
screen, quantitative real-time PCR analysis and western blotting was performed on
randomly selected genes (Figure 2.2C and 2.2D) which indicated significant upregulation
following ZNF217 depletion. Realtime PCR analysis and western blotting was also

Figure 2.2: Genome-wide expression screen to identify changes in gene expression
associated with ZNF217 depletion.
(A) Western blot of ZNF217-depleted MCF7 cells. MCF7 cells were transfected with
siRNA recognizing two different regions of ZNF217 (siRNA1 or siRNA2). Cells were
incubated for 72 hr prior to analysis of whole cell extracts by western blotting using
ZNF217 antibody. (B) Venn diagrams depicting the overlap in genes upregulated or
downregulated from cells transfected with either siRNA1 or siRNA2. (C) Real-time PCR
analysis of selected genes identified as significantly upregulated following ZNF217 or
LSD1 knockdown using siRNA. Each bar represents the mean relative expression as
compared to the expression in cells transfected with control siRNA. (D) Western blot of
selected genes significantly upregulated following ZNF217 or LSD1 gene knockdown
using siRNA. MCF7 cells were transfected with siRNA targeting either ZNF217 or
LSD1. After 72 hr, whole cell extracts were prepared and proteins were analyzed by
SDS-PAGE followed by western blotting using the antibodies indicated on the left of
each panel.
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performed on LSD1-depleted MCF7 cells to examine whether gene expression was
dependent on other components of the ZNF217 complex. For the majority of genes
examined, upregulation was observed in response to LSD1 knockdown although the
levels of upregulation were generally lower than those observed following ZNF217
downregulation most likely resulting from our inability to fully downregulate LSD1.
2.3.3 Genome-wide identification of human promoters bound by ZNF217.
To determine which of the genes identified in the expression analysis are directly
bound by ZNF217, we used a genome-wide chromatin immunoprecipitation assay based
on DNA selection and ligation (ChIP-DSL) (Garcia-Bassets et al., 2007; Kwon et al.,
2007). A standard ChIP assay was performed on MCF-7 cells using affinity purified
ZNF217 antibody. The resulting ZNF217-enriched and input DNA were then biotinylated
and combined with 20,000 predesigned oligonucleotides pairs, each representing one-half
of an 80mer sequence, corresponding to promoter regions of target genes and flanked by
a T3 and T7 primer. After annealing, the biotinylated DNA was purified using
streptavidin-conjugated magnetic beads. Adjacent oligonucleotides, that have annealed to
the immunoprecipitated DNA, are ligated creating complete amplicons which are then
amplified with fluorescently labelled primers and hybridized to a 20,000 gene promoter
array. We first validated the functionality of the platform by demonstrating a normalized
distribution of the intensity values (Figure 2.3A). From three independent analysis we
identified 1431 promoters which are directly bound by ZNF217 (Figure 2.3A and 2.3B
and Supplementary Table 4 from Thillainadesan et al. 2008). To identify the nature of the
target genes identified, the targets were analyzed using the Ingenuity Analysis program
(http://www.ingenuity.com/). Based on this analysis we found that approximately 25% of

Figure 2.3: ChIP-DSL analysis of ZNF217 target genes in MCF7 cells.
(A) Scatterplot of specific ChIP (y axis) versus total X axis of averaged values from three
independent biological replicates demonstrating a normal cluster distribution. Data in red
indicates genes significantly enriched. (B) Venn diagram depicting the overlap in genes
enriched from three independent ChIP-DSL experiments (Rep 1-3). 1-fold change and a
P value < 0.05(calculated using student’s T-test) yielded 1431 genes common to all three
replicates. (C) Ingenuity functional analysis revealed majority of genes whose promoter
regions are bound by ZNF217 to be involved in various diseases. Genes were scored
with a significance value which is a log p-value calculated using the Fishers exact test
measuring the uniqueness of a gene within a function. (D) Targets corresponding to
molecular function were also categorized revealing approximately 25% of ZNF217 target
genes are transcription factors.
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the targets identified are transcription factors suggesting that ZNF217 may play a
prominent role in various differentiation processes (Figure 2.3D). Interestingly, in terms
of biological function, genes uniquely related to various aspects of cancer were ranked as
the most significant, and approximately 73 genes were found to be consistently present in
more than one cancer category (Supplementary Table 5 from Thillainadesan et al. 2008;).
Additionally, a significant number of genes related to cell morphology and various
aspects of the cell cycle were also identified. Network analysis revealed two highly
significantly networks of interacting genes (Figure 2.4) with many of the genes within
each network linked to tumour suppressor activity.
By comparing the ZNF217 target genes, with genes undergoing a significant
change in expression following ZNF217 knockdown, we identified 9 genes directly
bound by ZNF217 which were found to be significantly upregulated (are repressed by
ZNF217), and 45 genes which were significantly downregulated (are activated by
ZNF217) (Table 2.3). The results of the ChIP-DSL screen were confirmed by standard
ChIP using ZNF217 antibody and oligonucleotide primers corresponding to specific
regions within selected promoters (Figure 2.5A and 2.5B, Figure 2.6). Surprisingly, for
the vast majority of the target genes identified, no change in expression levels was
observed in ZNF217-depleted MCF7 cells. The reason for this are not entirely clear, but
our results are consistent with several recent ChIP-chip studies published for other human
transcription factors and coregulators suggesting that loss of a single factor may not be
sufficient to alter the expression of a gene, perhaps as a result of secondary repressive
modifications which are not alleviated following ZNF217 knockdown (Bracken et al.,
2006; Carroll et al., 2006; Cawley et al., 2004; Scacheri et al., 2006).

Figure 2.4: ChIP-DSL data analysis.
Network (1 and 2) diagram highlighting interrelationships between specific genes
identified in the ZNF217 ChIP-DSL analysis.
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Network 1

Network 2

Table 2.3: List of genes directly regulated by ZNF217.
Comparative analysis of ChIP-chip data and expression analysis following ZNF217
depletion in MCF7 cells allowed for the identification of ZNF217 target genes.
a

KSHV, Kaposi’s sarcoma-associated herpesvirus.
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Direction of
regulation and
protein name

Accession

Description

Genes repressed
by ZNF217
MGC45400

AI743979

VAV3

AF118886

cell motility

ABCA12

AL080207

membrane transporter

p15INK4b

AW444761

cdk inhibitor

FLJ39370

AI110850

paired like homedomain 2

MAN1A1

BG287153

Glycosylase

EFNB2

BF001670

transmembrane ligand

THY28

NM_014174

thymocyte nuclear protein

FLJ11280

AL561943

Fam 63A

transcription elongation factor 8

Genes activated
by ZNF217
FAM35A

NM_019054

hypothetical protein MGC5560

DAZAP1

BF512907

DAZ associated protein 1

LOC55971

AA496034

C18orf25

AI823360

insulin receptor tyrosine kinase substrate
mRNA sequence of wh53b02.x1 NCI_CGAP_Kid11 Homo sapiens
cDNA

GAJ

AY028916

meiotic nuclear divisions 1 homolog (S. cerevisiae)

C13orf3

AI829603

Chromosome 13 open reading frame 3

SF3A1

BF129339

splicing factor 3a, subunit 1, 120kDa

KLIP1

AA460299

KSHVa latent nuclear antigen interacting protein 1

BRCA1

NM_007295

breast cancer 1, early onset

ETF1

NM_004730

eukaryotic translation termination factor 1

TCF3

M31523

transcription factor 3

MCM8

BC005170

minichromosome maintenance deficient 8

LBR

NM_002296

lamin B receptor

CaMKIINα

NM_018584

calcium/calmodulin-dependent protein kinase II

PFKFB3

NM_004566

6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3

ZNF395

AK021850

papillomavirus regulatory factor PRF-1

SUSD2

Z92546

sushi domain containing 2

XPO4

BF968638

exportin 4

SF3A1

NM_005877

splicing factor 3a, subunit 1, 120kDa

AD-017

NM_018446

glycosyltransferase AD-017

FLJ90022

AW264102

PIR51

BE966146

hypothetical protein FLJ90022
mRNA sequence of wh53b02.x1 NCI_CGAP_Kid11 Homo sapiens
cDNA

RAC3

NM_005052

rho family, small GTP binding protein

IRX2

AI928035

iroquois homeobox protein 2

POP7

BC001430

processing of precursor, S. Cerevisiae

FLJ11029

BG165011

Hypothetical Protein

CDC25C

NM_001790

cell division cycle 25C

TUBB2

W72331

tubulin, beta, 2

CECR5

NM_017829

ZBTB8

AW006067

cat eye syndrome chromosome region, candidate 5
wz92a02.x1 NCI_CGAP_Brn25 Homo sapiens cDNA clone
IMAGE:2566250 3', mRNA sequence.

DCXR

NM_016286

dicarbonyl/L-xylulose reductase

FLJ11127

NM_019018

Hypothetica protein

CDCA8

BC001651

cell division cycle associated 8

FGFRL1

AF312678

fibroblast growth factor receptor-like 1

Figure 2.5: ChIP analysis of selected ZNF217 targets.
(A) Direct ZNF217 targets which were found significantly upregulated following
ZNF217 depletion. Proliferating MCF7 cells were crosslinked with 1% formaldehyde and
ChIP was performed with either control IgG or αZNF217 antibody. The recovered DNA
was then assayed by PCR using oligonucleotide primers corresponding to the promoter
region of specific genes identified in the ChIP-DSL analysis. (B) Direct ZNF217 targets
which were found significantly downregulated in ZNF217-depleted MCF7 cells.
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Figure 2.6: ChIP PCR analysis of the MAN1A1 and RAC3 target genes.
ChIP experiments were performed in MCF7 cells using ZNF217 antibody MAN1A1 and
RAC3 genes were analyzed using specific oligonucleotide primers (primer set 1, 2 or 3).
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2.3.4 p15ink4b is a direct target of the ZNF217 complex.
Among the ZNF217 gene targets identified, we focused our initial investigation
on the p15ink4b tumour suppressor gene. p15ink4b is a member of the INK4 family of CDK
inhibitors which causes cell cycle arrest by directly inhibiting cdk4 and 6 (Kim and
Sharpless, 2006). Inactivation of p15ink4b has been found in a wide spectrum of cancers,
suggesting that direct silencing of p15ink4b by ZNF217 may contribute to its oncogenic
properties (Latres et al., 2000; Melendez et al., 2000).
As shown in figure 2.7, downregulation of ZNF217, or LSD1, using siRNA
resulted in significant increases in p15ink4b levels. To confirm binding of ZNF217 to the
INK4b promoter and more accurately define its binding site, we performed ChIP analysis
in MCF7 cells using pairs of oligonucleotides encompassing approximately 150 base pair
intervals (Figure 2.8A). The promoter arrays used in the ChIP-DSL screen consist of
unique 80 mer sequences located within 1 kb upstream from the transcription start site for
each gene, therefore we restricted our analysis to this region of the p15ink4b promoter.
Chip analysis indicated that ZNF217 is highly enriched within a region of the promoter
encompassing nucleotides (nt) -566 to -426 (Figure 2.8B). In addition, both LSD1 and
CoREST were also found predominantly within this region confirming that the p15ink4B
gene is a target for the ZNF217 complex.
To determine whether the presence, or absence, of ZNF217 corresponded to
specific chromatin marks at the p15ink4b promoter, ChIP analysis was performed using
antibodies corresponding to acetylated K9/14 on histone H3 (K9/K14-H3) and dimethyl
K4 on histone H3 (dimetK4-H3), which are generally associated with transcriptionally
active genes, as well as trimethyl K27 on histone H3 (trimet K27-H3), a marker for

Figure 2.7: The p15ink4b gene is regulated by the ZNF217 complex.
(A) Western blot of p15ink4b protein following ZNF217 knockdown in MCF7 cells. MCF7
cells were transfected with siRNA recognizing ZNF217 (siRNA1). Cells were incubated
for 72 hr prior to analysis of cell extracts by western blotting using ZNF217 or p15ink4b
antibody. (B) Real-time PCR analysis of the p15ink4b gene following knockdown of
ZNF217 or LSD1 using siRNA. MCF7 cells were transfected with siRNA recognizing
ZNF217 (siRNA1) or LSD1. RNA was then prepared, reverse-transcribed and real-time
analysis performed. Each bar represents the mean comparative expression relative to cells
transfected with control siRNA of two independent experiments.
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Figure 2.8: The p15ink4b promoter is a direct target of the ZNF217 complex.
(A) Schematic representation of the human p15ink4b promoter showing the nucleotide
sequence encompassing the Smad binding element (SBE1) and the FoxO3 binding
element (FoxO). The underlined sequences represent consensus ZNF217 binding sites
identified in (29), double line; and (12) single line. (B) ChIP analysis of the p15ink4b
promoter. MCF7 cells were crosslinked with 1% formaldehyde and ChIP was performed
with either control antibody (IgG) or the specific antibody (IP) indicated on the left. The
recovered DNA was then assayed by PCR using pairs of oligonucleotides encompassing
specific regions of the p15ink4b promoter (primer set 1, 3 or 4). (C) ZNF217-dependent
changes in histone marks across the p15ink4b promoter. MCF7 cells were transfected with
siRNA recognizing ZNF217 (siRNA1). After 72 hr, cells were crosslinked with 1%
formaldehyde and ChIP was performed with either control antibody (IgG) or the histone
modification-specific antibodies indicated at the bottom of the figure. The recovered
DNA was then assayed by realtime PCR using pairs of oligonucleotides encompassing
specific regions of the p15ink4b promoter as indicated in Figure 2.6A (primer set 1-4).
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transcriptional repression (Baylin and Ohm, 2006; Berger, 2007; Ting et al., 2006).
Realtime PCR analysis identified several significant changes following ZNF217
knockdown. First, a statistically significant increase in acetylation was observed at nt 566 to -426 (primer set 3), containing the ZNF217 binding region. However, the major
changes were found downstream of the ZNF217 complex binding site, at nt -340 to -204
(primer set 4). These included a dramatic increase in dimetK4-H3, which would be
consistent with the loss of LSD1. Surprisingly, in the presence of ZNF217, this region
was found to be highly acetylated at K9/14 on histone H3 and following ZNF217
knockdown, a complete loss of acetylation at K9/14-H3 was observed, despite the
observation that p15ink4B is highly expressed (Figure 2.8C, Figure 2.9).
Previous studies have shown that TGFβ stimulates rapid binding of SMAD, FoxO
and CEBPβ to the p15ink4b promoter resulting in transcriptional activation of the p15ink4b
gene (Gomis et al., 2006a; Gomis et al., 2006b). Interestingly, the ZNF217 binding
region of the p15ink4b promoter encompasses both, a SMAD binding site flanked by a
forkhead binding element at nt -504 to -538. Based on the proximity of the ZNF217
binding region to the SMAD binding site, we speculated that binding of ZNF217 and
SMADs may be mutually exclusive and that coregulator exchange, in response to TGFβ,
is a prerequisite for transcriptional activation of the p15ink4b gene. However, in
preliminary experiments upregulation of p15ink4b gene in response to TGFβ was not
observed in MCF-7 cells (data not shown). Therefore, to examine dynamic changes in
ZNF217 complex assembly at the ink4b gene promoter, we used the HaCAT keratinocyte
cell line, a well established model for TGFβ-responsive events. For these experiments,
HaCAT cells were stimulated with TGFβ and promoter occupancy was assessed by ChIP

Figure 2.9: ChIP-PCR analysis of the p15ink4b promoter.
Antibodies against trimet H3K27, dimetH3K4 and AcH3K9/14 were used for ChIP
experiments and the p15ink4b promoter was analyzed by conventional PCR using the
indicated primers A) ChIP-PCR analysis of the p15ink4b promoter following ZNF217
knockdown in MCF7 cells using siRNA B) ChIP-PCR analysis of the p15ink4b promoter
following stimulation of HaCAT cells with 150 pM of TGFβ for 90 min.
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assay using specific antibodies recognizing either ZNF217 or SMAD2. As shown in
figure 2.10A, p15ink4B protein levels are strongly upregulated upon TGFβ stimulation.
Importantly, ChIP analysis indicated that stimulation with TGFβ for 90 minutes resulted
in a rapid loss of ZNF217 and a concomitant increase in SMAD2 binding from the same
region of the p15ink4b promoter (Figure 2.10B).
To examine the effect of TGFβ on specific chromatin marks, HaCAT cells were
stimulated with TGFβ for 90 minutes and ChIP assays were performed using antibodies
recognizing acetylated K9/K14-H3, dimethyl K4-H3 and trimethyl K27-H3 (Figure 2.9,
Figure 2.10C,). The major changes were again confined to the nt -340 to -204 region of
the p15ink4b promoter, and included increases in dimethylation at H3-K4 and
deacetylation at K9/K14-H3. Collectively, these results suggest that loss of ZNF217, and
TGFβ stimulation result in similar changes chromatin modifications at the p15ink4b
proximal promoter.

2.4 Discussion
The ZNF217 gene codes for a Kruppel-like transcription factor and represents a
strong candidate oncogene associated with the 20q13.2 amplification. Insights into the
mechanism of ZNF217 have come from studies which have identified ZNF217 as a major
constituent of several related transcriptional repressor complexes containing HDAC2 and
LSD1 (Cowger et al., 2006; Hakimi et al., 2003; Lee et al., 2005; Shi et al., 2004; Shi et
al., 2005; You et al., 2001). Thus, ZNF217 may promote the development of cancer by
inappropriately targeting histone modifying enzymes to genes which are essential for

Figure 2.10: TGFβ-inducible release of ZNF217 from the p15ink4b promoter.
(A) Western blot of cells following stimulation with TGFβ. HaCAT cells were stimulated
with TGFβ. After various intervals following stimulation, cell extracts were prepared and
western blotting was performed using antibodies against p15ink4b or tubulin. Lane 1(-)
cells receiving no TGFβ were grown for 48 hr prior to lysis. (B) ChIP analysis of TGFβstimulated HaCAT cells. HaCAT were stimulated with TGFβ for 90 minutes. Cells were
then crosslinked with 1% formaldehyde and ChIP was performed with either control
antibody (IgG), SMAD2 or ZNF217 antibodies. The recovered DNA was then assayed by
standard PCR (right panel), or by realtime PCR using pairs of oligonucleotides
encompassing the ZNF217 binding region of the p15ink4b promoter (primer set 3). (C)
TGFβ-dependent changes in histone marks. HaCAT cells were stimulated with TGFβ for
90 minutes. Cells were then crosslinked with 1% formaldehyde and ChIP was performed
with either control antibody (IgG) or the modification specific antibodies indicated at the
bottom of the figure. The recovered DNA was then assayed by realtime PCR using pairs
of oligonucleotides encompassing specific regions of the p15ink4b promoter as indicated
(primer set 1-4).
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normal cell growth and differentiation. In the present study, we have used global genomic
approaches to identify genes which are directly regulated by ZNF217.
Using ChIP-DSL we were able to identify over 1400 gene promoters bound by
the ZNF217 transcription factor in a native chromatin context.

Furthermore, in

conjunction with siRNA knockdown and microarray analysis, we established that 54
genes are directly regulated by ZNF217. Thus, for the vast majority of the target genes
identified, changes in gene expression were not correlated with ZNF217 promoter
occupancy in MCF7 cells. This is not entirely unexpected as gene expression is dictated
by the repertoire of transcription factors and coregulators that transiently occupy target
promoters, and not by a single factor.
While this manuscript was in preparation, a genome-wide ChIP-chip analysis
identified approximately 1045 genes, bound by ZNF217, in MCF7 and Ntera2 cell lines,
with approximately 745 genes common to both cell types (30). However, only 54 of the
target genes identified were found to be directly regulated by ZNF217. A comparison of
target genes identified in our study, and the study of Krig et al., indicated 7% overlap (73
genes), and of the 54 genes directly regulated by ZNF217, only 4 were found in our
ChIP-DSL analysis. These differences are most likely attributed to variations in
experimental design, the specific antibodies used which may recognize different epitopes,
and more importantly, differences in the microarray platforms used. Unlike the more
conventional ChIP-chip approach which uses ligation mediated PCR (LM-PCR) to
amplify the immunoprecipitated DNA, in ChIP-DSL, the DNA is not directly amplified
but is used only as a template for annealing of complimentary oligonucleotides
corresponding to specific promoter regions. Consequently, this greatly reduces the
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complexity of the hybridization mixture and may avoid certain biases inherent in the LMPCR strategy. However, ChIP-DSL can only identify targets found within 1 kilobase of
the transcription start site. Thus, ZNF217-dependent regulatory sites located many
kilobases upstream would not be detectable by ChIP-DSL.
Surprisingly, 45 of the 54 target genes we identified are downregulated upon
ZNF217 knockdown suggesting that ZNF217 may also function in transcriptional
activation. This finding is consistent with recent ChIP on Chip studies of other
transcriptional repressor proteins. For example, using ChIP-DSL, recent studies have
demonstrated that LSD1 is recruited to target genes which are transcriptionally active as
well as repressed (Garcia-Bassets et al., 2007; Kwon et al., 2007). LSD1 has been shown
to function in both, transcriptional repression by demethylating H3-K4, and in activation
of specific genes by removing the dimethyl mark from H3-K9 rather than H3-K4.
Although the underlying mechanism for defining LSD1 specificity is unclear, in vitro
studies have suggested that LSD1 activity is allosterically regulated through interaction
with other proteins such as CoREST, BHC80 and the ligand-bound androgen receptor
(Lee et al., 2005; Metzger et al., 2005). In addition, surrounding histone marks found at
specific promoters may also play a role in substrate recognition by LSD1 (Forneris et al.,
2006; Forneris et al., 2005). Thus, the substrate specificity of LSD1 may be an important
determinant for defining the transcriptional activity of ZNF217 at selected targets.
To obtain insight into the mechanism of repression of ZNF217, we focused our
analysis on the p15ink4b gene. The p15ink4b gene is found within a 35 kb stretch of DNA,
the INK4 locus, which also contains p16ink4A and p14ARF a splice variant of
p16ink4A. The entire locus has been found frequently deleted or mutated in many types
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of cancer (Ghiorzo et al., 2004; Sill et al., 1995). Interestingly, we did not detect changes
in expression levels of either p16ink4A or p14ARF, based on the microarray expression
analysis, indicating that the repressive effects of the ZNF217 complex are specific for
p15ink4b.
In many epithelial cell lines, p15ink4b is rapidly upregulated in response to TGFβ
and under normal growth conditions, contributes to the TGFβ−dependent cytostatic
program. Previous studies using HaCAT cells have shown that the induction of p15ink4b
occurs predominantly at the level of transcription through a dual mechanism involving
downregulation of c-myc and the recruitment of activating transcription factors to the
promoter region (Gil and Peters, 2006; Seoane et al., 2001; Staller et al., 2001). Myc acts
as a negative regulator of the p15ink4b gene by preventing the transcription factor Miz1
from activating p15ink4b transcription (Seoane et al., 2001; Staller et al., 2001). The
addition of TGFβ suppresses myc expression, depleting the cellular pools of myc
available for binding to Miz1 which, in turn, relieves active repression of the p15INK4b
gene. Concurrently, SMAD proteins, as well as other transcription factors, bind to
specific DNA elements in the promoter region and, in association with Miz1, elicit full
activation of the p15ink4b gene (Feng et al., 2002; Feng et al., 2000).
The identification of the ZNF217 complex as a negative regulator of the p15ink4b
gene in breast cancer cells adds an additional layer of complexity in our understanding of
the molecular events regulating p15ink4b gene transcription (Figure 2.11). In MCF7 cells
the levels of p15ink4B are virtually undetectable and downregulation of ZNF217 using

Figure 2.11: Model highlighting the role of ZNF217 complex in p15ink4b expression.
In normal proliferating epithelial cells, the ZNF217 complex is bound to the p15ink4b
promoter and expression of p15ink4b is repressed. Stimulation with TGFβ causes a release
of the ZNF217 complex and a concomitant binding of activating transcription factors
which include SMADs (SM2/3 and SM4), CEBPβ, FoxO3 and SP1. Additionally,
associations between adjacent transcription factors, as well as downregulation of Myc
following TGFβ stimulation, may result in full activation of the p15ink4b gene.
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siRNA resulted in a dramatic increase in p15ink4b protein levels, indicating that loss of
ZNF217 alone was sufficient to relieve repression of the p15ink4b gene in this cell type.
ChIP analysis indicated that the ZNF217 binds a region of the promoter that has
previously been shown to encompass a SMAD binding element flanked by a FoxO site
(Gomis et al., 2006a; Gomis et al., 2006b). Recent studies have shown that upregulation
of p15ink4b, in response to TGFβ, is dependent on rapid binding of both SMAD proteins
and FoxO3 to their respective sites. Interestingly, a CAGAAA and an ATTCAA motifs
directly overlap the SMAD and FoxO3 binding sites, respectively. Both of these elements
have been identified as putative consensus ZNF217 binding sites in independent studies
(Cowger et al., 2006; Krig et al., 2007). Based on these observations, we speculated that
TGFβ-dependent activation of the p15ink4b gene is dependent on release of ZNF217. This
was indeed confirmed in HaCAT cells where treatment with TGFβ resulted in a rapid
loss in ZNF217 and a concomitant increase in SMAD2 binding, at nt -566 to -426, which
preceded increases in p15ink4b protein expression. Collectively, these findings establish
the ZNF217 complex as a novel suppressor of the p15ink4b gene (Figure 2.11).
We have also examined the relationship between promoter occupancy by ZNF217
and changes in chromatin modifications at the p15ink4b promoter. Following ZNF217
knockdown, a dramatic increase in dimethylation of K4-H3 was observed at nt -340 to 204. Dimethyl K4-H3 serves as a major substrate for LSD1, and suggests that targeting of
LSD1 may depend directly on ZNF217 recruitment. Unexpectedly, we have found that 340 to -204 is also highly acetylated at K9/K14 of histone H3, when the p15ink4b gene is
not expressed, and is deacetylated upon ZNF217 knockdown. Although deacetylation of
histones is generally associated with transcriptional silencing of genes, several reports
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have demonstrated a requirement for HDAC activity in transcriptional activation. For
example, analysis of the IFN-β promoter has shown that deacetylation of specific lysine
residues serves as a prerequisite for transcriptional activation (Agalioti et al., 2002).
Similarly, removal of yeast repressor proteins RPD3 and SIN3 resulted in decreased
transcription in a number of genes and increased silencing (De Rubertis et al., 1996). One
possibility is that hyperacetylation at K9/K14 is required for binding of repressor proteins
containing specific recognition motifs, such as bromodomains, which bind to acetylated
lysines with high affinity. For example BRD4, a bromodomain-containing transcriptional
adaptor protein, inhibits HPV transcription by binding to acetylated lysines on histone H3
and blocks recruitment of the core transcriptional machinery (Wu et al., 2006).
Consequently, the loss of acetylation at K9/K14, and increases in dimethyl K4-H3,
following ZNF217 release, may function cooperatively to target additional proteins to the
p15ink4b promoter which, in turn, may increase the accessibility of the chromatin to the
transcriptional machinery and facilitate transcriptional activation of the p15ink4b gene.
Similar changes in chromatin marks were also observed in HaCAT cells
following stimulation with TGFβ. Importantly, the changes we have observed coincide
with the release of ZNF217, indicating that loss of ZNF217 and stimulation with TGFβ
are most likely part of a concerted signaling mechanism regulating the p15ink4b gene. The
differences in the magnitude of the changes in covalent modifications between MCF7 and
HaCAT cells may be attributed to differences in cell types, as well as experimental
conditions. Covalent modifications related to a specific transcriptional outcome often
involve repetitive cycles of association and dissociation of transcription factors and a
large number of coregulator proteins in a sequential manner (Metivier et al., 2003).
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Consequently, 90 minute following TGFβ stimulation may not be optimal for the
establishment of specific changes in chromatin structure, even though increases in
SMAD2 binding and loss of ZNF217 are clearly evident by this time point. Nevertheless,
the changes in chromatin marks, following loss of ZNF217, or stimulation of cells with
TGFβ are quite striking and suggest that the -340 to -204 region is dynamically regulated
and most likely plays a critical role in determining expression of the p15ink4b gene.
Many tumours and cancer cell lines develop resistance to the growth inhibitory
effects of TGFβ which in some cases results from loss-of-function mutations in TGFβ
receptors or SMAD proteins (Pardali and Moustakas, 2007). However, the majority of
tumours which have lost TGFβ−dependent functional responses retain an intact TGFβ
signaling mechanism suggesting that specific downstream defects may be involved. This
may include overexpression of specific proteins resulting in a deregulated transcriptional
response at TGFβ-dependent target genes. The c-ski oncoprotein which is overexpressed
in a subset of leukemic patients, negatively regulates TGFβ signaling by interfering with
the formation of SMAD complexes at target genes resulting in abnormal silencing of
transcription (He et al., 2003; Luo, 2004; Luo et al., 1999). More recently, it has been
shown that excess levels of the C/EBPβ isoform liver enriched transcriptional inhibitor
protein (LIP) may, in part, account for the loss of TGFβ responsiveness (Gomis et al.,
2006b). C/EBPβ consists of multiple isoforms, a liver-enriched transcriptional activator
protein 1 and 2 LAP1/2, and LIP which lacks regulatory domains found in LAP and
functions as a dominant negative for C/EBPβ-dependent transcription. LAP binds
directly to the p15ink4b promoter and is required for induction of p15ink4b gene in response
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to TGFβ. A high LIP/LAP ratio has been reported in some metastatic breast cancers and
lowering of the LIP/LAP ratio by overexpression of LAP restores both TGFβ-dependent
induction of p15ink4b and the growth inhibitory response to TGFβ. Finally, it has been
shown that human mammary epithelial cells, aberrantly expressing ZNF217, become
immortalized and develop resistance to the growth inhibitory properties of TGFβ (Nonet
et al., 2001).
The identification of the p15ink4b gene as a direct target for the ZNF217
corepressor complex represents a potentially novel link between amplification of ZNF217
and the loss of TGFβ responsiveness in breast cancer. The proximity of the ZNF217
binding region to the SMAD binding is consistent with this hypothesis, and suggests that
the balance between coactivators and corepressor proteins at the level of gene
transcription represents a critical regulatory mechanism and an important determinant of
cell growth.
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Chapter 3: TGF-β-Dependent Active Demethylation and
Expression of the p15ink4b Tumor Suppressor Are Impaired by
the ZNF217/CoREST Complex
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3.1 Introduction
Transforming growth factor β (TGFβ) is an essential cytokine that coordinates a
complex antiproliferative program that includes induction of the cyclin dependent kinase
(cdk) inhibitors p15ink4b and p21cip1. The p15ink4b is a tumour suppressor and a component
of the ink4 locus, which also contains the p16ink4a and ARF genes. The regulation of
p15ink4b involves several interrelated mechanisms which operate primarily at the
transcriptional level. One mechanism involves silencing by the c-myc oncoprotein which
is recruited to the p15ink4b promoter through interactions with Miz-1 and represses its
transactivation properties. TGFβ suppresses myc expression, which relieves repression of
Miz1 (Seoane et al., 2001; Staller et al., 2001). At the same time, SMAD proteins are
rapidly recruited to the promoter, along with other sequence-specific transcription factors,
resulting in activation of p15ink4b gene. The Corepressor of Rest (CoREST) complex also
plays a role in silencing of the p15ink4b gene in some cell types (Thillainadesan et al.,
2008). This complex consists of the ZNF217 oncoprotein, and at least 4 additional
proteins: the histone deacetylase 1/2, the lysine demethylase 1 (LSD1), the Corepressor
of Rest (CoREST) and the C terminal binding protein 1 or 2 (CtBP 1/2) (Cowger et al.,
2007; Lee et al., 2005; You et al., 2001). The ZNF217 gene is found at the core of the
20q13.2 amplicon (Collins et al., 1998) and is amplified and overexpressed in many
cancers ranging in amplification frequency from 10 to 40% (Bar-Shira et al., 2002; Li et
al., 2007a; Rooney et al., 2004). Several studies have shown that overexpression of
ZNF217 is associated with cellular immortalization, increased cellular proliferation and
resistance to TGFβ (Krude, 1999; Li et al., 2007a; Nonet et al., 2001; Sun et al., 2008;
Thollet et al.).
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Aberrant transcriptional silencing of p15ink4b involving promoter DNA
hypermethylation is frequently associated with hematologic and other cancers
(Aggerholm et al., 2006; Papageorgiou et al., 2007; Tsellou et al., 2005). Nevertheless, in
many cell types TGFβ as well as other stimuli rapidly induce p15ink4b expression
suggesting that mechanisms are in place for reversing DNA methylation (Gomis et al.,
2006a; Gomis et al., 2006b; Warner et al., 1999).

DNA demethylation can occur

passively when newly synthesized DNA remains unmethylated following DNA
replication, or by an active mechanism which is replication independent and involves
enzymes that act directly on 5-methylcytosine (5mC). For example, the interleukin-2
promoter undergoes rapid DNA demethylation following T lymphocyte activation in a
replication independent manner (Bruniquel and Schwartz, 2003). In MCF7 cells, the
pS2/TFF1 gene undergoes cyclical demethylation and remethylation shortly after βestradiol treatment which coincides with estrogen receptor binding and activation
(Metivier et al., 2008). While a unified mechanism responsible for active demethylation
has not been definitively established, one mechanism which has recently gained
momentum involves base excision repair (BER) initiated by the DNA glycosylases,
thymine DNA glycosylase (TDG) and methyl-CpG binding domain 4 (MBD4). It has
been postulated that these enzymes may directly cleave the glycosidic bond between the
5mC and deoxyribose creating an abasic site which is then removed and repaired by the
BER machinery. However, while MBD4 has been shown to excise 5mC under some
conditions (Kim et al., 2009), in the majority of studies demethylation involving TDG
and MBD4 requires enzymatic conversion of 5mC to a more favourable substrate. For
example, the activation-induced deaminase (AID) or Apolipoprotein B mrRNA editing
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enzymes (APOBEC 1-4) can deaminate 5mC to thymine to generate a G:T mispair (Wu
and Zhang, 2010). TDG and MBD4 have a high affinity for G:T mispairs and excision of
the mispair initiates BER which effectively replaces the 5mC. This mechanism is
supported by recent findings in zebrafish where active DNA demethylation is mediated
by the cooperative activities of AID, MBD4 and an auxiliary factor GADD45α (Rai et
al., 2008).
Another

mechanism

may

involve

the

oxidation

of

5mC

to

5-

hydroxymethylcytosine (5hmC) catalyzed by the Ten Eleven Translocation (TET 1-3)
proteins (Wu and Zhang, 2011). It has been postulated that 5hmC is an intermediary
metabolite which can be deaminated to 5-hydroxmethyluracil (5hmU) creating a 5hmU:G
mismatch that is efficiently recognized and excised by TDG (Cortellino et al., 2011;
Hashimoto et al., 2012).

Alternatively, a more recently implicated mode of TET-

mediated demethylation involves the conversion of 5hmC to 5 formylcytosine (5fC) and
5 carboxylcytosine (5cC) (He et al., 2011; Ito et al., 2011; Krude, 1999; Maiti and
Drohat, 2011). TDG possesses robust activity against both 5fC and 5cC which could
account for the relatively low levels of both derivatives in the mammalian genome.
Collectively, these findings suggest that active DNA demethylation is a multi-step
process that links TET-mediated oxidation of 5mC to the BER pathway initiated by the
TDG and MBD4 DNA glycosylases.
In the present study we have examined the mechanism of dynamic DNA
methylation and demethylation of the p15ink4b promoter in response to TGFβ. Using
ChIP-seq we demonstrate that the p15ink4b tumour suppressor gene is a target for the
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ZNF217/CoREST complex and that promoter hypermethylation and silencing is, in part,
dependent on an association between DNMT3A and ZNF217/CoREST. TGFβ stimulates
active demethylation of the p15ink4b promoter by a mechanism involving loss of the
DNMT3A/ZNF217/CoREST complex and recruitment of SMAD2/3, the CBP
acetyltransferase and TDG or MBD4 to the same promoter region.

Remarkably,

overexpression of ZNF217 largely inhibits active DNA demethylation and expression of
p15ink4b by preventing recruitment of the DNA demethylation machinery. Collectively,
the present study suggests that active DNA demethylation involving BER is an essential
step in p15ink4b induction and that deregulation of this mechanism may contribute to
aberrant silencing of this tumour suppressor gene in cancer.

3.2 Materials and Methods
3.2.1 Plasmids, Antibodies, and Reagents.
The ZNF217 antibody was generated as described (Cowger et al., 2007). The
antibody used for ChIP experiments involving TDG was prepared as described (Mohan et
al., 2007). For immunoprecipitation and western blotting experiments (Figure 3.6E) the
antibodies used are described in (Mohan et al., 2007; Hardeland et al., 2002). p15ink4band
p21cip1 RNA levels were quantitated using Taqman (Applied Biosystems). The mouse
TDG cDNA was prepared as described (Mohan et al., 2007). Recombinant Flag-tagged
TDG was generated using the Bac-to-Bac baculovirus expression system (Invitrogen)
exactly as described. Human TGFβ1 was purchased from R&D Systems (Cat# 100-B001). L-mimosine was obtained from Sigma. A list of commercial antibodies,
oligonucletide primers and siRNAs used in this study can be found in Table 3.1, Table
3.2 and Table 3.3.
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Table 3.1: Antibodies used in this study.
Antibody

Cat#

Supplier

CoREST

BL1039

Bethyl Laboratories

CtBP1

612042

BD-Western Blotting

CtBP1

sc-11390

Santa Cruz Biotechnology, Inc. ChIP

LSD1

A300-216A

Bethyl Laboratories

DNMT3A

sc-20703

Santa Cruz Biotechnology, Inc.

SMAD2/3

sc-6202

Santa Cruz Biotechnology, Inc.

CBP

sc-369

Santa Cruz Biotechnology, Inc.

AID

sc-14680

Santa Cruz Biotechnology, Inc.

TDG

Tini and Scharr

Tini and Scharr Lab

APE/REF1

Tini(sc-17774)

Santa Cruz Biotechnology, Inc.

DNA Ligase
I

sc-47703

Santa Cruz Biotechnology, Inc.

DNA Polβ

sc-48810

Santa Cruz Biotechnology, Inc.

MBD4

A-1009

Epigentek

ZNF217

Torchia

Torchia Lab

Phospho-Rb

# 9308

Cell Signalling

5mC

ChIPgrade

Millipore

5hmC

39770

Active motif
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Table 3.2: qPCR primers used for detection of methylation and chromatin
immunoprecipitation of the p15ink4b and p21cip1 promoters.
Reverse 5’  3’

Methyl-specific p15

TTGGCGTATGCGT
TTTAGTATT

AACTAAACCAAA
AAACCGACGT

-194/-76

Unmethyl-specific
p15

TTGGTGTATGTGT
TTTAGTATT

AACTAAACCAAA
AAACCAACAT

-194/-76

p15 Bisulphite
sequencing
p15 MeDIP/ChIPb
p15 upstream
MeDIP/ChIPc

a

Coordinatesa

Forward 5’  3’

Name

GAGTTGAGGGTAG TTTTCAACTAAA
TGGTGAATATTT
CCAAAAAACC

-298/-71

CATGATTCTCGGG
ATTTTTCTC

-598/-458

GACAGCTCTGCA
CCTGTCAT

CTAGGAAATGGGG CCCCCAAATCCC
GTTGGAT
TGTAGAAT

Unmethyl-specific
p21

TTGTGATAAGGA
GATTTTAGGGAAC

p21 MeDIPd

GAGGAAAAGCAT
CTTGGAG

ATCACTATACCG
ATAAAAAAACGA
A
AAATAGACGGGA
GCAACG

-1463/-1285
+784/+890
+1421/+1534

Measured in base pairs from transcriptional start site.
Primers to detect mid region of the p15 promoter following ChIP/MeDIP.
c
Control primers used to detect upstream region of the p15 promoter following
ChIP/MeDIP.
Underlined and bolded nucleotides represent CpG sites that were targeted.
d
(Koinuma et al., 2009)
b
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Table 3.3: Silencing RNAs (siRNA) used in this chapter.
siRNA

Cat#

Supplier

CtBP1

J-0008609-11

Dharmacon

DNMT3a

sc-37757

Santa Cruz Biotechnology, Inc.

MBD4

sc-37763

Santa Cruz Biotechnology, Inc.

ZNF217 #1

CUSTOM

GCAAAUAACCUCAUCUGUAUU

mTDG

TINI

Dharmacon

Control Pool

D-00180-10-20

Dharmacon

APOBEC2

sc-95404

Santa Cruz Biotechnology, Inc.

AID

CUSTOM

UUCAAAAAUGUCCGCUGGGCUU
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3.2.2 Cell Culture, Adenovirus Infections, and Transfections.
MCF7 and HaCAT cells were maintained in DMEM containing 10% FBS. For
experiments involving TGFβ treatments, HaCAT cells were grown to approximately 60%
confluency and serum starved for 24 hrs. Cells were then washed with PBS and
resuspended in DMEM containing 10% FBS in the presence of vehicle (4 mM HCl
containing 0.1% human BSA), or 150 pM TGFβ1 for the indicated time period prior to
analysis. For adenovirus infections, HaCAT cells were infected with a recombinant
adenovirus expressing ZNF217 (1x106 PFU) or GFP, in media containing 8ug/ml
Polybrene, for 24 hrs prior to analysis. All siRNAs were delivered into cells using
Oligofectamine (Invitrogen) according to the manufacturer’s recommendations. Unless
otherwise indicated, cells were harvested 72 hrs after siRNA transfection. Protein extracts
were made and western blotting was performed as described (Thillainadesan et al., 2008).
Western blots were quantitated by densitometry using the software ImageQuant 5.1.
Unless otherwise indicated, the data was normalized using alpha-tubulin.
3.2.3 Flow Cytometry.
MCF7 cells were transfected with either control or ZNF217 siRNA for 72 hours
and then treated with 1µg/ml of Nocodazole (Sigma). At the indicated time points post
nocodazole treatment cells were fixed in ethanol, washed twice in PBS containing 1%
FBS and stained with propidium iodide. Single cells were gated out and %age of cells in
G1, S or G2/M phase was determined by DNA content using the cell cycle analysis
module (Watson-Pragmatic model) of FlowJo (Tree Star Inc.).
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3.2.4 Chromatin Immunoprecipitation Assay.
ChIP, ChIP-ReCHIP and DNA immunoprecipitation assays were performed as
described (Thillainadesan et al., 2008). For ChIP-ReChIP assays, protein-DNA
complexes were eluted in 25 µl 10 mM DTT incubated at 37° C for 30 min. The eluted
DNA was diluted 10 fold in ReChIP buffer (20 mM Tris-HCl [pH 8.1], 0.1% Triton X100, 2 mM EDTA, 150 mM NaCl) and incubated with a second antibody (1.5 to 4 µg)
overnight. Antibody-protein complexes were immunprecipitated using protein A
Sepharose beads (Upstate) for 2 hrs at 4° C. The beads were washed once with wash
buffer I (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, 150 mM NaCl),
wash buffer II (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, 500 mM
NaCl), and Tris-EDTA buffer. DNA extraction, de-crosslinking and purification were
done as previously described (Thillainadesan et al., 2008). Sequential ChIP with two
specific antibodies was always matched with a control sequential ChIP performed with
the first specific antibody and a second non-specific IgG antibody. The chromatin
immunoprecipitation assay used prior to deep sequencing analysis was modified slightly.
Sonication conditions were altered such that the majority of the genomic fragments were
in the 250-350 bp range. In addition, Protein A/G magnetic Dynabeads (Invitrogen) were
utilized for immunoprecipitation of the protein DNA complexes.
3.2.5 DNA immunoprecipitation Assay
MeDIP was conducted as previously described (Cortazar et al., 2011). Genomic
DNA was isolated using the GeneElute Mammalian Genomic DNA miniprep kit (Sigma
G1N70) and sonicated using a Bioruptor (15s ON/30s OFF) for 15 min to yield DNA
fragments in the range of 200bp – 600bp. 4µg of the fragmented DNA was diluted in
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450µl of TE and heat denatured at 95°C for 10 min followed by addition of 50 µl of cold
10X immunoprecipitation buffer (100mM sodium phosphate pH 7.0, 1.4 M NaCl, 0.5%
Triton X-100). The DNA was incubated with 10 µg of ChIP grade anti-mC antibody
(Millipore cat# MABE146) and 1/500 dilution of the anti 5hmC antibody (Active motif
cat# 39770) for 2 hr at 4 C. The antibody/DNA complex was captured using magnetic
protein G beads for 2hr at 4°C and washed three times with 700 µl of 1X IP buffer. DNA
was eluted in elution buffer (50
mMTris -HCl pH 8.0, 10mM EDTA, 0.5% SDS and
0.25 mg ml−1 proteinase K) for 3hr at 50 C. Input DNA as well as the IP samples were
purified using the PCR purification kit (Qiagen) and quantitated by realtime PCR.
3.2.6 In vitro glycosylation assay
The in vitro DNA glycosylation assay was performed essentially as described
with slight modifications (Cortellino et al.; Hardeland et al., 2000). The substrate DNAs
consisted of T/G mismatch oligonucleotides CAATCCTAGCTGACACGATGTGGCCA
ATGGC ATGACT (top) and GAGTCATGCCATTGGCCACATTGTGTCAGCTAG
GATTG (bottom), hemi-methylated oligonucleotides CAATCCTAGCTGACACGATG
TGGCC AATGGCATGACT (top) and GAGTCATGCCATTGGCCACATmCGTGTCA
GCTAG GATTG (bottom), or symmetrically methylated oligonucleotides CAATCC
TAGCTGACAmCGATGTGGCCAATGGCATGACT (top) and GAGTCATGCCATTG
GCCACATmCGTGTCAGCTAGGATTG (bottom). Prior to annealing, the bottom strand
oligonucleotide was radiolabelled at the 5’ end with T4 polynucleotide kinase
(Fermentas) and γ-32P-ATP (3000 Ci/mmol). The annealed substrates (1 pmol) were
incubated for 30 min at 37°C in a reaction buffer consisting of 25 mM HEPES pH 8.0, 1
mM DTT, 0.1 mg/ml BSA, 1 mM EDTA]

and various concentrations of purified
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recombinant FLAG-TDG (100-500 ng) in a total volume of 20 µl. For some experiments,
the reactions were combined with ~10 µl of TDG immunopurified from transfected
HaCAT cells. The reactions were terminated by the addition of 2 µl of 1 M NaOH
followed by incubation at 95 C for 5 min. Gel loading buffer (90% formamide , (1:1/ v:v)
was added to each sample and subjected to 8.0 M urea/20% PAGE. The gel was then
dried and analyzed by autoradiography.
3.2.7 Dot Blot Analysis
Genomic DNA was quantified using a nanodrop spectrophotometer (ND-1000)
and 300ng of DNA along with two subsequent serial dilutions (1/10) were used for the
experiment. DNA was then denatured at 99°C for 5min in a 0.1M sodium hydroxide
solution and neutralized on ice using 0.1vol of 6.6M ammonium acetate. 5µl of the
denatured DNA was manually spotted onto an AmershamHybond-N+ membrane and
dried in a hybridization oven at 80°C for 10min. The DNA was then UV-crosslinked
using a transluminator for 90 sec and blocked overnight at 4°C in blocking buffer (10%
milk, PBS-T (PBS+ 0.1% Tween-20). The membrane was incubated with 10 µg of anti
5mC antibody (Millipore 33D3) diluted in 10ml of blocking buffer for 2hr followed by
two washes with PBS-T. A mouse secondary antibody conjugated to a horseradish
peroxidase enzyme (HRP) was incubated with the membrane for 45min followed by three
washes with PBS-T. The chemiluminescent signal was detected and by ECL
(Amersham). To confirm loading the same blots were also staining with 0.2% methylene
blue for 30 min.
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3.2.8 Immunoprecipitations
HaCAT cells were harvested at approximately 60% confluency and whole cell
extracts (WCE) were prepared as described (Thillainadesan et al., 2008). Approximately
750 µg of WCE was incubated in the presence of 5µg of TDG antibody overnight at 4°C.
The following day immunocomplexes were captured using Protein A/G agarose beads,
washed four times with lysis buffer (50mM Tris pH 8, 0.3M KCl, 0.5mM EDTA/EGTA,
0.25% NP-40) and complexes were analyzed by SDS-PAGE and western blotting with
the appropriate antibodies. For experiments involving overexpressed TDG, 293
embryonic cells were transfected with 10µg of Flag tagged TDG with SuperFect
(Qiagen). The following day, cells were treated with 150pM TGFβ for 90min and WCE
were prepared. TDG was immunopurified using Flag Sepharose and the immune
complexes were then tested for glycosylase activity.
3.2.9 Genomic Sodium Bisulphite Analysis.
Genomic DNA was isolated from cells using DNeasy Tissue (Qiagen cat# 59104)
and bisulphite converted using EpiTect Bisulfite Kit (Qiagen cat#69504). For sequencing,
bisulphite converted DNA was PCR amplified using methyl sequencing primers and
cloned directly into TA cloning vector (Invitrogen Cat# 45-0046) and sequenced using
the T7 primer. For methylation analysis using PCR, bisulphite converted DNA was
subjected to methyl and/or unmethylated specific quantitative PCR as indicated. The
quantitative reactions were carried out as previously described (Thillainadesan et al.,
2008) using Brilliant SYBR® Green mastermix (Agilent Technologies cat# 600548) and
quantitated with a Mx3000P (Stratagene) real-time PCR instrument.
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3.2.10

ChIPseq Analysis.
ChIP assays were performed using either ZNF217 or CtBP1 antibodies. The

ChIP-DNA

was

sequenced

at

the

University

of

British

Columbia

(http://www.cmmt.ubc.ca/ facilities/services/sequencing) using the Illumina sequencing
platform. Approximately, 2.1 million raw reads for ZNF217 and 1.7 million raw reads for
CtBP1 were obtained. Each read corresponded to approximately 75bp of DNA. The
obtained reads were screened using PERL scripts that eliminated reads based on the
following criteria; reads that were shorter than 75bp, reads that had gaps and reads that
had repeat nucleotides longer than 10bp. The later criteria for eliminating repeat sequence
is based on the fact that larger than 10bp repeats were not found within the genome
according to blast results (http://www.ncbi.nlm.nih.gov/blast) and the repeats may have
been a result of sequence duplication events. The obtained reads were then aligned using
Bowtie 0.12.5 with Hg19 human genome. Alignment using Bowtie, resulted in 85.8%
and 87.3% of aligned reads to the Hg19 human genome for ZNF217 and CtBP1,
respectively. Peaks were identified using CisGenome (Ji et al., 2008) and MACS (Zhang
et al., 2008).
Negative binomial model was used to calculate the expected percentage of
windows that contained a certain number of reads. Percentage of false positive rate was
calculated by dividing the observed number of windows by the expected number of
windows containing the same number of reads. A false positive percentage of 6.3% and
5.1% corresponded to a read number of 8 for ZNF217 and CtBP1, respectively. A cut-off
value of 8 reads was used to control for false positives peaks.
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3.3 Results
3.3.1 ZNF217 Is Essential for Recruitment of the CoREST Complex to the
p15ink4b Promoter.
To define the genome occupancy of ZNF217/CoREST complex, we performed
ChIPseq in MCF7 cells using antibodies directed against ZNF217 and CtBP1 (Table S2
from Thillainadesan et al., 2012). Examination of the normalized genome-wide
distribution of ZNF217 indicated that only 2% of ZNF217 binding could be annotated to
promoters of specific genes within 1 kb of a transcription start site (TSS), suggesting that
the ZNF217/CoREST complex plays a role in repression at a distance (Figure 3.1 and
Table S1 from Thillainadesan et al. 2012). Approximately, 65.7% (FPR of 3.0%) of
CtBP1 binding sites were found to overlap with ZNF217 binding which is consistent with
earlier observations using ChIP on chip (Krig et al., 2007) and indicate that both
constituents are recruited as a complex to the majority of genomic sites. Of the 1202
CtBP1 binding sites annotated within 50 kb of a TSS, 979 (81.4%) binding sites are also
bound by ZNF217 (Figure 3.2). Comparison of the ZNF217 and CtBP1 binding sites to a
microarray expression analysis of ZNF217–depleted MCF7 cells (Thillainadesan et al.,
2008) identified several common genes involved in cell cycle control. Importantly,
ZNF217/CtBP1 binding was detected in a region of the p15ink4b promoter that overlaps
directly with a previously identified regulatory region containing a SMAD/FoxO binding
site (Figure 3.3A and 3.3B) (Gomis et al., 2006b; Seoane et al., 2001; Staller et al., 2001;
Thillainadesan et al., 2008). Knockdown of ZNF217 did not affect expression of p16ink4a
or ARF based on microarray analysis suggesting that repression by ZNF217 is selective
for p15ink4b in the ink 4 locus (Krig et al., 2007; Thillainadesan et al., 2008). To confirm
the ChIPseq data, we examined occupancy by the CoREST complex following

Figure 3.1: Genomic analysis of ZNF217 binding in MCF7 cells.
(A) Pie chart indicating the genomic distribution of ZNF217 binding in MCF7 cells. (B)
Pie chart indicating the distribution of ZNF217 binding based on the distance from a
transcription start site.
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Figure 3.2: Overlap between ZNF217 and CtBP1 binding.
(A) The pie chart indicates the overlap in binding sites between CtBP and ZNF217. Peaks
were considered overlapping if individual peaks were located within 500 bps of each
other. (B) Pie chart indicating overlap in neighboring genes. The neighboring genes were
annotated within 50 kb from the TSS and the percentage of genes common to ZNF217
and CtBP1 are indicated. (C) Venn diagram indicating the number of genes annotated for
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Figure 3.3: Transcriptional repression of the p15ink4b gene by the ZNF217/CoREST
complex.
(A) ChIP-seq tracings for CtBP1 and ZNF217 at the ink 4 locus. The square indicates
enrichment of ZNF217 and CtBP1 to the same region of the p15ink4b (CDKN2B)
promoter. Genes have been correlated to fit the UCSC annotations. (B) ZNF217 is
required for targeting the CoREST complex. MCF7 cells were transfected with the
indicated siRNA and ChIP-qPCR analysis of the p15ink4b promoter was performed using
the indicated antibodies. Error bars indicate standard error of the mean. (C) Western
blotting analysis of specific proteins (as indicated on the left) from MCF7 cells following
transfection with siRNAs for ZNF217 or CtBP1. (D) Knockdown of ZNF217 causes an
increase in the percentage of cells found in G1. Cells were transfected with the indicated
siRNAs and treated with nocodazole for 24 hrs. The percentage of cells in G1 was then
determined by flow cytometry. Shown is a representative experiment from 3 independent
experiments as depicted in Figure 3.4. (E) Knockdown of ZNF217 causes a decrease in
phosphorylated Rb. MCF7 cells were transfected with the indicated siRNAs. Endogenous
Rb status was analyzed by western blotting using the indicated antibodies as shown on
the left. The amount of phosphorylated Rb (pRb) was quantified using densitometry and
normalized to total Rb and Tubulin.
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knockdown of either ZNF217 or CtBP1 (Figure 3.3B). The recruitment of CtBP1 and
LSD1 was reduced by approximately 60% following ZNF217 knockdown, whereas
knockdown of CtBP1 did not affect recruitment of either ZNF217 or LSD1 suggesting
that ZNF217 is required for targeting of the ZNF217/CoREST complex.
We also examined the occupancy by c-myc which is a well-known negative
regulator of the p15ink4b gene. c-myc represses p15ink4b expression by inhibiting
transactivation of Miz1 at the core promoter region further downstream of the ZNF217
binding site (Seoane et al., 2001; Staller et al., 2001;). However, in MCF7 cells, c-myc
was found on the promoter regardless of the presence of ZNF217 suggesting that its role
in regulating p15ink4b is independent of the ZNF217/CoREST complex (Figure 3.3B).
Expression analysis indicated that knockdown of ZNF217 resulted in robust activation of
p15ink4b expression in MCF7 cells (Figure 3.3C). In contrast, knockdown of CtBP1 did
not stimulate expression of the p15ink4b gene suggesting that CtBP1 may not be essential
for repression, or a compensatory role may be provided by the homologous protein
CtBP2.
3.3.2 ZNF217-Dependent Repression of the p15ink4b Gene Is Essential for Cell-Cycle
Progression.
The p15ink4b gene is a cyclin dependent kinase inhibitor that forms a complex with
cdk4 or 6 and prevents their activation resulting in inhibition of cell cycle progression at
the G1/S transition. To assess the role of ZNF217 in cell cycle progression we performed
flow cytometry and as expected, knockdown of ZNF217 increased the percentage of cells
remaining in G1 relative to control (Figure 3.3D and Figure 3.4), and caused an eightfold reduction in phosphorylated Rb levels (Figure 3.3E). These results suggest that

Figure 3.4: Cytometric analysis of MCF7 cells.
MCF7 cells were transfected with scrambled siRNA or siRNA targeting ZNF217. After
72 hrs cells were treated with nocodazole. At the indicated time points post nocodazole
treatment cells were fixed in ethanol, washed twice in PBS containing 1% FBS and
stained with propidium iodide (PI).
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Figure 3.5: Knockdown of ZNF217 or DNMT3A causes DNA demethylation of the
p15ink4b promoter.
(A) Knockdown of DNMT3A using siRNA. MCF7 cells were transfected with the
indicated siRNA and after 72 hrs, cell extracts were prepared and western blot analysis
was performed with the indicated antibodies. (B) DNA methylation analysis of the
p15ink4b promoter. MCF7 cells were transfected with the indicated siRNAs, DNA was
extracted, and the core CpG region of the p15ink4b promoter was analyzed by sodium
bisulphite sequencing. The human p15ink4b promoter with the CpGs indicated in Roman
numerals is shown. White and black circles indicate unmethylated and methylated
cytosines, respectively. (C) Methylation-specific PCR of the p15ink4b promoter. Samples
were treated as described in (A) and then analyzed by PCR using specific
oligonucleotides recognizing the methylated sequence contained within the core CpG
island. Error bars indicate standard error of the mean. (D) ZNF217 and DNMT3A cooccupy the p15ink4b promoter in MCF7 cells. ChIP or sequential ChIP (ChIP-ReChIP)
was performed with the indicated antibodies. The IgG control values for ChIP were
subtracted from values obtained using specific antibodies. Error bars indicate standard
error of the mean.
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repression of p15ink4b by ZNF217/CoREST prevents inhibition of cyclinD-cdk4/6
complexes thus allowing for increased phosphorylation of the retinoblastoma protein
(Rb) and G1/S phase progression.
3.3.3 Methylation of the p15ink4b Promoter Is Dependent on the ZNF217/CoREST
Complex.
The human p15ink4b promoter contains a CpG island within 1 kb of the
transcription start site which is highly methylated in many cancer cell lines (Aggerholm
et al., 2006; Papageorgiou et al., 2007) and also contains the ZNF217/CoREST binding
region (Figure 3.3A). To assess whether the ZNF217/CoREST complex influences the
DNA methylation of the p15ink4b gene, we carried out knockdown experiments and
assessed the methylation status of the p15ink4b promoter by sodium bisulphite sequencing
and methylation-specific PCR. Knockdown of ZNF217 resulted in dramatic promoter
demethylation (greater than 95%) which coincided with increased p15ink4b expression
(Figures 3.5A-3.5C). To determine the mechanism involved in maintaining the p15ink4b in
a hypermethylated state, we initially examined the role of the de novo methyltransferase
DNMT3A which is often associated with repression at specific genomic loci (Hervouet et
al., 2009). Knockdown of DNMT3A using siRNA reversed hypemethylation of the
p15ink4b promoter although the reversal was not complete suggesting that other DNMT
family members may also be involved. Sequential ChIP analysis (ChIP-reChIP) using
ZNF217 and DNMT3A-specific antibodies indicated that both proteins co-occupy the
same region of the promoter in MCF7 cells (Figure 3.5D). These results suggest that the
ZNF217/CoREST complex and specific DNMTs combine to generate a hypermethylated
state resulting in repression of the p15ink4b gene.
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3.3.4 TGF-β Stimulates Active Demethylation of p15ink4b via Recruitment of TDG.
To examine whether the p15ink4b promoter undergoes signal-dependent, temporal
changes in DNA methylation, serum-starved HaCAT cells were treated with TGFβ for
various time periods followed by sodium bisulphite sequencing and methylation-specific
PCR. In untreated cells, the core CpG island is highly methylated and demethylation was
detected within 20 minutes after TGFβ treatment while nearly complete demethylation
was evident by 3 hours (Figure 3.6A and 3.6B). Similar results were obtained by
methylated DNA immunoprecipitation (MeDIP) using a mC-specific antibody (Figure
3.7). Furthermore, DNA demethylation in response to TGFβ was not inhibited by
pretreatment of HaCAT cells with the DNA replication inhibitor L-mimosine (Figure
3.8). The rapidity of this response in quiescent cells, and the observation that both TGFβ
and L-mimosine arrest HaCAT cells at G1 (Krude, 1999; Warner et al., 1999) strongly
indicates that DNA demethylation is active, as opposed to passive demethylation that
requires DNA replication. ChIP analysis of the p15ink4b promoter in HaCAT cells treated
with TGFβ demonstrated loss of ZNF217, CtBP1 and DNMT3A and a concomitant
increase in SMAD, CBP and TDG binding to the same promoter region (Figure 3.6C).
These results are consistent with earlier findings demonstrating that TGFβ-dependent
activation of p15ink4b promotes recruitment of SMAD2/3 and p300 (Seoane et al., 2001;
Staller et al., 2001). The coregulator exchange was detected as early as 20 minutes
following TGFβ treatment and preceded the large changes in TGFβ-dependent DNA
demethylation. ChIP-ReChIP indicated that on the p15ink4b promoter, TDG associates
with SMAD proteins as well as CBP (Figure 3.6D and Figure 3.14). Consistent with

Figure 3.6: TGFβ-dependent demethylation of the p15ink4b promoter.
(A) TGFβ stimulates DNA demethylation of the p15ink4b promoter. HaCAT cells were
treated with TGFβ for the indicated time periods and the p15ink4b promoter was analyzed
by sodium bisulphite sequencing. White and black circles indicate unmethylated and
methylated CpGs, respectively. The human p15ink4b promoter with the CpGs indicated in
Roman numerals is shown. (B) PCR analysis of the p15ink4b promoter. Samples were
treated as described in (A) and then analyzed by PCR using specific oligonucleotides
recognizing the unmethylated sequence within the core CpG island as indicated by the
arrows in (A). (C) TGFβ stimulates a coregulator switch at the p15ink4b promoter. HaCAT
cells were treated with 150 pM TGFβ for 20 minutes or 90 minutes and ChIP-qPCR was
performed with the indicated antibodies. IgG control values for ChIP were subtracted
from values obtained using specific antibodies. Error bars indicate standard error of the
mean. (D) TDG associates with both CBP and SMAD 2/3 in response to TGFβ. HaCAT
cells were treated as in (C) and ChIP was performed using a single antibody, or the
combination

of

antibodies

(ChiP-ReChIP)

indicated

on

the

left.

(E)

Co-

immunoprecipitation of endogenous SMAD 2/3 and TDG. HaCAT cells were treated
with TGFβ for 90 minutes and whole cell extracts were prepared. SMAD 2/3 was then
immunoprecipitated and western blotting performed using the TDG antibody.
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Figure 3.7: Time dependent demethylation of the p15ink4b promoter in response to
TGFβ.
Serum starved HaCAT cells were treated with TGFβ for the indicated times, cells were
then harvested and methyl DNA immunoprecipitation (MeDIP) was performed using a
5mC-specific antibody. The p15ink4b promoter was quantified by qPCR. The control (C)
was assayed 360 min after vehicle treatment.
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Figure 3.8: PCR analysis of the p15ink4b promoter.
Cells were serum starved or grown in the presence of L-Mimosine (0.5 mM) for 24 hr
prior to TGFβ treatment for 90 minutes. DNA was then isolated sodium bisulphite treated
and the p15ink4b promoter was analyzed by qPCR using oligonucleotides recognizing the
unmethylated sequence within the core CpG island.
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these findings, we were also able to coimmunoprecipitate endogenous TDG and
SMAD2/3 from whole cell extracts using TDG-specific antibodies from both control as
well as TGFβ-treated cells (Figure 3.6E). These results strongly suggest that that TDG,
SMAD2/3 and CBP form multiprotein complex(es) and that targeting of this complex
represents a critical step in the induction of p15ink4b expression. We also examined the
methylation status of the p21cip1 gene. The p21cip1 is also a critical regulator of cell cycle
progression and is also activated at the transcriptional level by the canonical TGFβSMAD signaling pathway (Gomis et al., 2006a). Treatment of either serum starved or Lmimosine-treated HaCAT cells with TGFβ for 90 minutes resulted in rapid DNA
demethylation of the p21cip1 promoter and a concomitant increase in expression based on
qPCR analysis (Figure 3.9).
To assess if TDG is required for TGFβ-dependent demethylation of the p15ink4b
promoter, HaCAT cells were transfected with TDG-specific siRNA prior to treatment
with TGFβ for 90 minutes. TDG knockdown in HaCAT cells abrogated promoter
demethylation and decreased p15ink4b mRNA levels by approximately 50% in response to
TGFβ treatment (Figures 3.10A-3.10D). These findings demonstrate that TDG regulates
TGFβ−dependent promoter demethylation and expression of the p15ink4b tumour
suppressor gene.
We also performed dot blot analysis of bulk genomic DNA using an anti-5mC
antibody to examine whether TGFβ causes global changes in DNA demethylation.
Although only semi quantitative, we consistently observed a 2-3 fold decrease in DNA

Figure 3.9: Active demethylation of the p21 gene.
(A) Schematic diagram of the p21 gene. p21 contains one CpG island which extends
from the promoter, through exon 1 (E1) and into the first intron. (B) Methylation analysis
of the p21 gene. HaCAT cells were serum starved or pretreated with L-Mimosine for 24
hrs prior to treatment with TGFβ for 90 minutes. DNA was isolated, sodium bisulfite
treated and the p21gene was analyzed by qPCR with primers recognizing the
unmethylated CpG island (784/890). (C) MeDIP analysis of the p21 gene. Cells were
serum starved and then treated with TGFβ for the indicated times. (D) RNA analysis of
the p21 gene. HaCAT cells were treated with TGFβ for 3hrs, RNA was extracted and the
p21 gene was analyzed by qPCR. Error bars indicated standard error of the mean.
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(A) Knockdown of TDG using siRNA. HaCAT cells were transfected with the indicated
siRNA and after 72 hr cell extracts were prepared and western blot analysis was
performed. (B) TDG knockdown inhibits TGFβ−dependent DNA demethylation. HaCAT
cells were transfected with the indicated siRNAs and then treated with TGFβ for 90
minutes. The p15ink4b promoter was then analyzed by sodium bisulphite sequencing.
White and black circles indicate unmethylated and methylated cytosines, respectively.
(C) Methylation-specific PCR of the p15ink4b promoter. HaCAT cells were treated as
described in (A) and analyzed by methylation-specific PCR. Error bars indicate standard
error of the mean. (D) Knockdown of TDG inhibits p15ink4b expression. HaCAT cells
were transfected with the indicated siRNA and then stimulated with TGFβ for 6 hrs.
RNA was then extracted and analyzed by qPCR. (E) Dot blot analysis of genomic 5mC.
HaCAT cells were treated with TGFβ for 90 minutes. Bulk genomic DNA was isolated,
sonicated, crosslinked to nitrocellulose membrane and probed with a monoclonal
antibody specific for 5mC. Recognition of DNA by the anti-5mC antibody is shown in
the top panel, loading control is shown by the methylene blue stain in the bottom panel.
The blot was quantitated by densitometry and a representative experiment is shown from
two independent experiments.
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methylation 90 minutes after TGFβ treatment (Figure 3.10E). Remarkably, demethylation
was reversed following knockdown of TDG suggesting that the effects of TGFβ on DNA
demethylation are genome wide and extend beyond selective promoters.
3.3.5 TGF-β Treatment Stimulates Conversion of 5mC to 5hmC at the
p15ink4b Promoter.
Recent studies have shown that knockout of TDG in mice causes promoterspecific DNA hypermethylation and is embryonic lethal (Cortazar et al., 2011; Cortellino
et al., 2011). However, we and others have been unable to demonstrate that purified
recombinant TDG possesses intrinsic 5mC demethylase activity in vitro (Figure 3.11 and
(Cortazar et al., 2011; Cortellino et al., 2011). One possibility is that 5mC is deaminated
to thymine by the AID/ABOBEC class of proteins. This would generate a G:T mispair
that can be recognized and excised by TDG and subsequently repaired by the BER
machinery. Alternatively, mounting evidence suggests that 5mC can be oxidized to 5hmC
by TET proteins. Although 5hmC is not a substrate for TDG, it may be deaminated by
AID/APOBECs to 5hmU which is recognized and excised by TDG (Cortellino et al.,
2011). In this model, we would predict that knockdown of TDG or AID should lead to
the accumulation of 5hmC. To assess whether hmC is generated at the p15ink4b promoter,
we performed DNA immunoprecipitation assays using antibodies specific for 5mC
(MeDIP) or hmC (hMeDIP). Surprisingly, TGF
 treatment following TDG knockdown
decreased 5mC levels further (greater demethylation was observed) whereas the 5hmC
levels accumulated in the same experiment (Figure 3.12A and 3.12B). A similar trend
was observed following the combined knockdown of AID and APOBEC2. These results
are consistent with a mechanism suggesting that 5hmC represents an intermediary

Figure 3.11: TDG lacks 5mC DNA glycosylase activity.
Base release assays were conducted with synthetic DNA duplexes containing either a
CG/GT mispair, hemimethylated (CG/GCm) or fully methylated (mCG/GCm) CpGs, in
the presence of increasing concentrations of purified recombinant TDG generated using
baculovirus (A).

Shown in (B) is a denaturing polyacrylamide gel with the intact

substrate and cleaved protein indicated at the top and bottom of the gel, respectively. (C)
Cells were transfected with Flag-tagged TDG and after 24hrs were treated with TGFβ for
90 minutes. Cell extracts were prepared and TDG was immunopurified and tested for
base cleavage activity. Western blot of the overexpressed and immunopurified Flagtagged TDG recombinant protein is shown on the right.
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product during active demethylation at the p15ink4b promoter. ChIP analysis demonstrated
that AID is recruited to the p15ink4b promoter in response to TGFβ and sequential ChIP
assays using AID and TDG-specific antibodies confirm co-occupancy suggesting that the
activities of TDG and AID may be functionally coupled (Figure 3.12C).
Finally, we have also found that the BER enzymes, apurinic/apyrimidinic
endonuclease-I (APE-1), DNA ligase I and polymerase (Pol) B are recruited to the
p15ink4b promoter following treatment with TGFβ which is consistent with the
requirement of the BER pathway for active promoter demethylation (Figure 3.12D).
Like TDG, MBD4 possesses a similar DNA glycosylase activity at G:T mispairs
and also plays a role in active demethylation at selective targets (Kim et al., 2009).
Remarkably, knockdown of MBD4 also reduced TGFβ-dependent demethylation
consistent with the recruitment of this factor to the p15ink4b promoter (Figures 3.13A3.13C). However, ChIP-ReChIP assays indicated that MBD4 does not co-occupy the
p15ink4b promoter with SMAD2/3 suggesting that the roles of MBD4 and TDG may be
functionally redundant but that their mechanism of recruitment differs (Figures 3.13C and
Figure3.14).
3.3.6 ZNF217 Overexpression Abrogates p15ink4b Promoter Demethylation and
Expression.
Based on the overlap between ZNF217/CoREST and SMAD/CBP/TDG
binding, we speculated that overexpression of ZNF217 may prevent DNA demethylation
by interfering with coregulator exchange in response to TGFβ. To test this hypothesis, we
infected HaCAT cells with a ZNF217 expressing adenovirus and examined the status of

Figure 3.12: TGFβ-dependent demethylation of the p15ink4b promoter involves
conversion of 5mC to 5hmC.
(A) Schematic diagram of the p15 promoter with the CpG islands indicated as a closed
ball and stick. (B) DNA immunoprecipitation analysis of the p15ink4b promoter. HaCAT
cells were transfected with the indicated siRNAs and then treated with TGFβ or vehicle
for 90 minutes. DNA was isolated and DNA immunoprecipitation assays were performed
using 5mC or 5hmC-specific antibodies. Aliquots from the same DNA samples were
used to perform MeDIP and hMeDIP. The data is expressed as the ratio of the percentage
of input DNA from the TGFβ treated and vehicle treated cells from three independent
experiments. (C) AID is recruited to the p15ink4b promoter. HaCAT cells were treated
with 150 pM TGFβ for 20 mins or 90 mins and ChIP-ReChIP assays followed by qPCR
were performed with the indicated antibodies. (D) Components of the BER machinery
are recruited to the p15ink4b promoter. Experiments were performed as described in (B)
and ChIP assays were performed with the indicated antibodies. Shown are the ChIP
assays from samples treated with TGFβ for 90 mins. No significant change in recruitment
was observed 20 mins following TGFβ treatment (data not shown). Error bars indicate
standard error of the mean.
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Figure 3.13: MBD4 is required for TGFβ-dependent DNA demethylation.

(A) Knockdown of MBD4 using siRNA.

HaCAT cells were transfected with the

indicated siRNA and after 72 hrs. cell extracts were prepared and western blot analysis
was performed.
demethylation.

(B) Knockdown of MBD4 inhibits TGFβ−dependent DNA
HaCAT cells were transfected with the indicated siRNAs and then

stimulated with TGFβ for 90 mins. The p15ink4b promoter was analyzed by sodium
bisulphite sequencing. White and black circles indicate unmethylated and methylated
cytosines, respectively. (C) Methylation-specific PCR of the p15ink4b promoter. HaCAT
cells were treated as described in (A) and analyzed by methylation-specific PCR. Error
bars indicate standard error of the mean. (D) MBD4 and TDG do not co-occupy the
p15ink4b promoter. HaCAT cells were treated with 150 pM TGFβ for 90 minutes and then
ChIP or ChIP-ReChIP assays were performed with the indicated antibodies. Error bars
indicate standard error of the mean.
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Figure 3.14: Quantitative ChIP-ReCHIP analysis of the p15ink4b promoter.
HaCAT cells were treated with TGFb for 90 minutes and ChIP or ChIP-ReChIP assays
were performed with the antibodies indicated and quantified by qPCR. In (A) ChIPReChIPs were performed using antibodies against SMAD and TDG (also shown by
conventional PCR in Figure 3D) (B) ChIP-ReChIPs were performed using antibodies
against SMAD and MBD4. IgG control values were subtracted from values obtained
using specific antibodies. Error bars indicate standard error of the mean.
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the p15ink4b gene (Figure 3.15A and 3.15B). Overexpression of ZNF217 by
approximately 3-fold, resulted in a 60% reduction in TGFβ-dependent induction of the
p15ink4b gene and inhibited promoter demethylation based on methylation-specific PCR
(Figure 3.15C). To examine the consequences of ZNF217 overexpression on promoter
occupancy, we performed ChIP analysis on transduced HaCAT cells which indicated that
ZNF217 reduced the recruitment of SMAD2/3 and TDG to the p15ink4b promoter (Figure
3.15D). Collectively, these results indicate that overexpression of ZNF217 is sufficient
to impair TDG-dependent DNA demethylase activity by preventing recruitment of
critical components required for active DNA demethylation and transcriptional activation
of the p15ink4b gene.

3.4 Discussion
The p15ink4b gene is a key regulator of cell proliferation that inhibits cell cycle
progression by blocking the activity of cyclin dependent kinases 4 and 6 (Kim and
Sharpless, 2006). Herein we demonstrate that transcriptional silencing of the p15ink4b gene
by the ZNF217/CoREST complex involves promoter hypermethylation mediated in part
by recruitment of DNMT3A. Furthermore, we show for the first time that the
TGFβ/SMAD pathway triggers active demethylation and gene expression by targeting
the BER enzymes to the p15ink4b promoter. Importantly, overexpression of the ZNF217
oncogene, which is associated with a loss of proliferative control in breast and ovarian
cancer, inhibits p15ink4b expression by impairing the TGFβ-dependent recruitment of
cofactors involved in active demethylation. These results highlight the dynamic nature of

Figure 3.15: Overexpression of the ZNF217 oncogene inhibits TGFβ−dependent
DNA demethylation of the p15ink4b promoter.

(A) Overexpression of HA-tagged ZNF217 in HaCAT cells. HaCAT cells were infected
with the indicated adenoviruses (GFP or ZNF217). After 24 hrs, extracts were prepared
and western blotting was performed with the indicated antbodies. (B) Overexpression of
ZNF217 inhibits p15ink4b protein expression. (Left) HaCAT cells were infected with the
indicated adenoviruses and after 24 hrs cells were stimulated with TGFβ and western
blotting was performed using the indicated antibodie shown on the left. (Right) The
amount of p15ink4b protein expression was quantified using densitometry and normalized
to Tubulin. (C) Overexpression of ZNF217 blocks TGFβ-dependent demethylation. Cells
were infected with the GFP or ZNF217adenoviruses then stimulated with TGFβ as
described for 90 minutes and the p15ink4b promoter was analyzed by methylation-specific
PCR. Error bars indicate standard error of the mean. (D) Overexpression of ZNF217
inhibits recruitment of SMAD2/3 and TDG to the the p15inFk4b promoter. HaCAT cells
were infected with the GFP or ZNF217 adenoviruses and then stimulated with TGFβ for
90 minutes. ChIP-qPCR was performed using antibodies recognizing SMAD 2/3 or TDG.
Error bars indicate standard error of the mean.
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DNA methylation/demethylation and suggest that coregulator balance is a critical
determinant of the methylation status of the p15ink4b promoter, and possibly other tumour
suppressor genes (Figure 3.16).
Recent in vivo studies in mice have established the importance of DNA
glycosylases and BER in active gene-specific demethylation. Tdg knockout mice display
embryonic lethality and gene expression defects involving hypermethylation of numerous
developmentally regulated genes, as well as the loss of active chromatin marks and the
accumulation of repressive marks at selected genes (Cortazar et al., 2011). These findings
are consistent with a central role of TDG in gene-specific demethylation as well as in
other epigenetic events such as the recruitment of transcriptional cofactors CBP/p300.
Interestingly, differential gene expression analysis of Tdg null MEFs revealed that
p15ink4b is significantly downregulated suggesting that cell cycle defects may also
contribute to the phenotype observed in the knockout mice (Cortellino et al., 2011).

3.4.1 Involvement of 5hmC in TGF-β-Dependent Active Demethylation.
A controversial issue in recent studies has centered specifically on whether DNA
glycosylases can directly excise 5mC from DNA, or if enzymatic conversion of 5mC is
required prior to its removal. Our data suggests that 5hmC is generated in response to
TGFβ and that both 5mC and 5hmC levels decreased at the p15ink4b promoter following
TGFβ treatment. However, under TDG-depleted conditions, 5hmC levels accumulated
suggesting that TDG most likely functions at a step downstream of 5hmC formation.
These effects were not apparent when using bisulphite genomic sequencing because

Figure 3.16: Model depicting the mechanism of TGFβ-dependent demethylation of
the p15ink4b promoter.
In normal proliferating epithelial cells, the ZNF217/CoREST/DNMT3A complex is
bound to the p15ink4b promoter along with c-myc and the promoter is hypermethylated
(filled circles). Stimulation with TGFβ causes release of the ZNF217/CoREST/DNMT3A
complex and c-myc and a concomitant binding of activating transcription factors in
association with CBP/p300, TDG and AID. 5mC is then oxidized to 5hmC and may
undergo deamination by AID/APOBEC proteins to generate 5hydroxyuracil (5hU) which
is then processed by TDG and repaired by the BER enzymes (APE1, DNA polymeraseβ
and DNA ligase) which reintroduce an unmethylated cytosine (open circles).
Alternatively, TGFβ may stimulate recruitment of MBD4 which triggers active
demethylation.
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5hmC does not undergo a C-to-T transition after bisulfite treatment, and thus cannot be
distinguished from 5mC by that technique (Huang et al., 2010). The accumulation of
5hmC was also observed following the combined knockdown of AID and APOBEC2,
although the effects were not as great as those observed following TDG knockdown.
Additionally, ChIP analysis suggests that AID and TDG co-occupy the same region of
the p15ink4b promoter in response to TGFβ suggesting that deamination may also be
required at selected TGFβ-dependent targets.
The involvement of AID/APOBEC2 suggests two possible scenerios for
deamination-dependant demethylation at the p15ink4b promoter. First, deamination of
5mC to thymine could generate a G:T mispair which is then recognized and processed by
TDG. Such a mechanism infers that deamination and TDG-dependant glycosylation
would have to be tightly coupled in order to explain the lack of accumulation of G:T
mispairs following knockdown of TDG. A deamination-coupled mechanism is supported
by transgenic studies in zebrafish embryos where the presence of a G:T base pair
intermediate could only be detected when a catalytically inactive MBD4 mutant was
coexpressed with AID ( Rai et al., 2008).
Secondly, it has been postulated that 5hmC can be deaminated to produce 5hmU
and the resulting 5hmU:G mispair is subsequently repaired by DNA glycosylases and the
BER pathway (Cortellino et al., 2011). Although biochemical evidence for the
deamination of 5hmC is lacking, recent studies have demonstrated that combined
overexpression of TET1 and AID cooperate in demethylating a 5hmC containing DNA
duplex (Guo et al., 2011). Furthermore, TDG and MBD4 exhibit robust activity against 5
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hmU (Cortellino et al., 2011; Hashimoto et al., 2012). Thus, the observation that 5hmC is
generated at the p15ink4b promoter and accumulates under TDG depleted conditions
makes this mechanism plausible.
Our results do not discount the possibility that a deaminase-independent
demethylation pathway may also play a role in active demethylation of the p15ink4b
promoter. 5hmC can undergo iterative oxidation to 5fC and then to 5cC and TDG
possesses robust excision activity towards both metabolites (He et al., 2011; Ito et al.,
2011; Maiti and Drohat, 2011).
3.4.2 Requirement for TDG or MBD4 in Active Demethylation.
A surprising result of our study was that knockdown of TDG or MBD4 prevented
TGFβ-dependent active demethylation suggesting a requirement for both DNA
glycosylases at the p15ink4b promoter. Furthermore, ChIP assays indicated that TDG and
MBD4 were targeted to a similar region of the ink4 locus and with similar kinetics based
on two different points. However, the fold enrichment of the ChIP-reChIP analysis was
not greater than that observed for each individual ChIP suggesting that MBD4 and TDG
do not co-occupy the same promoter region. This suggests that the activities of TDG and
MBD4 with respect to DNA demethylation are redundant based on our assay conditions
and consequently different population of cells may utilize either TDG or MBD4. A
partially redundant role for TDG has also been reported in zebrafish embryos where
active DNA demethylation is mediated by the cooperative activities of AID, MBD4/TDG
and GADD45α (Rai et al., 2008). However, this conclusion must be interpreted with
caution since we have not performed an extensive analysis of MBD4 occupancy at the
ink4 locus and the mechanism of MBD4 recruitment is not entirely clear. Unlike TDG,
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the recruitment of MBD4 does not appear to involve direct binding with SMAD2/3 upon
treatment with TGFβ. Therefore, it is possible that TDG and MBD4 activities are
cooperative at some level. This is also supported by the significant differences in their
substrate specificities (Cortazar et al., 2007). For example while both TDG and MBD4
recognize AID-generated 5hmU (Hashimoto et al., 2012), MBD4 does not recognize 5fC
or 5cC which have been shown to be efficiently processed by TDG (He et al., 2011; Ito et
al., 2011). MBD4 also contains a methyl-CpG binding domain (MBD), that is not found
in TDG, and which could play a major role in targeting MBD4. Thus, in response to
TGFβ, the recruitment of chromatin remodeling factors along with the accumulation of
activating histone marks may create a nucleosome free area at the promoter to facilitate
binding of MBD4 and, in association with AID and GADD45, promote active
demethylation. This mechanism may be facilitated by TDG which can be targeted
indirectly to promoter regions by interacting with SMAD2 or 3, CBP or its close
homologue p300 (Chiang et al.; Kim and Um, 2008; Li et al., 2007b; Neddermann et al.,
1996; Tini et al., 2002). The association between CBP/p300 and TDG has been well
documented and the TDG knockout studies in mice supports a mechanism whereby
recruitment of CBP/p300 to retinoic acid receptor (RAR) target genes is dependent on
TDG (Cortazar et al., 2011; Cortellino et al., 2011; Tini et al., 2002). The present work is
consistent with this hypothesis as we have found an association between TDG, SMAD2/3
and CBP on the p15ink4b promoter.
Post translational modifications (PTMs) may also play a critical role in the
activities of MBD4 and TDG. A recent study has shown that MBD4 is found in a
complex with the vitamin D receptor and the protein kinase C (PKC)-dependent
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phosphorylation of MBD4 potentiates its DNA glycosylase activity for 5mC at the
CYP27B1 gene promoter (Kim et al., 2009). This was not observed for TDG despite the
fact that TDG is also a substrate for PKC (Mohan et al., 2010). In our experiments,
overexpression and immunopurification of TDG from TGFβ-treated cells did not
stimulate glycosylase activity towards 5mC. Nevertheless, the NH2-terminal domain
(NTD) of mammalian TDG is essential for tight binding to abasic sites and processing of
G:T mispairs and undergoes a variety of post translational modifications that dramatically
alter interactions with DNA and accessory factors (Mohan et al., 2010; Mohan et al.,
2007; Tini et al., 2002). Consequently, PTMs may also play a central role in the substrate
recognition and targeting by TDG as well as MBD4 and warrants further investigation.
3.4.3 Implications of Active Demethylation in TGF-β Signaling Event.
Active demethylation may have important ramifications with respect to global
TGFβ signalling. A CpG rich region of the p21cip1 promoter also undergoes active
demethylation in response to TGFβ signalling. Furthermore, we observed significant
demethylation of bulk genomic DNA from TGFβ-treated cells which surprisingly was
TDG-dependant, based on dot blot analysis. Although this may appear somewhat
paradoxical when considering the effects observed at the p15ink4b promoter using MeDIP,
bulk genomic DNA consists mainly of repetitive elements and transposons and
consequently the effects of TGFβ on gene-specific promoter methylation may be
different.
Many cancers lose TGFβ dependent functional responses, which in some cases
results from a loss of function mutations in various components of this pathway. More
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frequently however specific downstream defects are involved. For example, similar to
ZNF217, the c-ski oncoprotein is overexpressed in a subset of leukemic patients and
negatively regulates TGFβ signaling by interfering with the formation of SMAD
complexes at target genes resulting in abnormal silencing of transcription (Lu and Chen,
2003). Overproduction of TGFβ has also been found in many tumours and is associated
with induction of epithelial-mesenchymal transition and increased tumour invasiveness
(Derynck et al., 1987). Thus, deregulated TGFβ production may contribute to the
abnormal DNA methylation patterns associated with malignant transformation.
It has recently been shown that the loss of the Adenomatous polyposis coli (APC)
tumour suppressor gene causes upregulation of components of the DNA demethylase
machinery resulting in hypomethylation of numerous developmental genes and impaired
differentiation (Rai et al., 2010). We have identified signal-dependent mechanisms
responsible for epigenetic regulation of the p15ink4b gene which rely on the exchange of a
promoter-bound silencing complex with activating transcription factors and components
of an active DNA demethylation machinery consisting of DNA glycosylases, other BER
enzymes and accessory factors. These findings highlight the expanding role of DNA
glycosylases and BER in epigenetic regulation and identify important molecular
mechanisms that may be targeted by oncogenic processes.
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4.1

Discussion: Overview
ZNF217 is a Kruppel-like transcription factor and is a constituent of a core

transcriptional repressor complex consisting of LSD1, HDAC 1/2, CoREST and
CtBP1(Vandevenne et al., 2013). ZNF217 is found within the 20q13.2 region that is
frequently amplified in cancers and amplification and overexpression of ZNF217
represents a marker of poor prognosis (Littlepage et al., 2012). Overexpresssion of
ZNF217 in normal HMECs leads to cellular immortalization, loss of senescence,
increased proliferative capacity and TGFβ resistance which are all hallmarks of cellular
transformation (Littlepage et al., 2012; Nonet et al., 2001). In this thesis, I have used
global genome-wide approaches to identify novel transcriptional targets for ZNF217 in
MCF7 cells. I identified the p15ink4bgene as a direct target for ZNF217. I showed that
p15ink4b is regulated at the transcriptional level by a dyamic interplay between the
ZNF217 repressor complex and components of the TGFβ signaling pathway. During the
course of my analysis I uncovered a novel mechanism of TGFβ signaling involving
active DNA demethylation. I further demonstrated that ZNF217 overexpression impairs
the TGFβ dependent transcriptional activation and expression of p15ink4b by blocking
DNA demethylation.

4.2 Global Approaches to Identify ZNF217 Targets
Chromatin immunoprecipitation (ChIP) in conjunction with technologies to assess
genome-wide occupancy, represent powerful approaches to identify transcription factor
binding sites. In chapter 2, I employed a variation of the ChIP-on-chip approach, ChIPDSL, to identify gene promoters that are bound by ZNF217. ChIP-DSL provides several
advantages over the traditional ChIP-on-chip approach. First, traditional ChIP-on-chip
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utilizes random oligonucleotides to amplify the ChIP-DNA and this could introduce
amplification biases in the technique. ChIP-DSL reduces this bias by using the ChIPed
DNA as templates for the selection of predesigned oligonucleotides which are then PCR
amplified using the same pair of specific primers. Second, by using unique predesigned
oligonucleotides, the approach avoided repetitive sequences that are abundant within the
human genome and can interfere with hybridization to the microarray. Third, ChIP-DNA
that was not completely de-crosslinked would be more tolerable since the ChIP-DNA was
not directly used for PCR amplification which is traditionally used for the ChIP-on-chip
approach (Kwon et al., 2007).
Using ChIP-DSL, I identified 1431 gene promoters as ZNF217 targets but only 9
were found to be directly repressed by ZNF217 and 45 targets that were activated. The
relatively low number of promoters was surprising because we expected ZNF217 a large
set of genes to collectively confer oncogenesis. However, a limitation of ChIP-DSL is
that it identifies binding sites that are only found 1 kb upstream of the TSS and studies
examining genome-wide binding of other TFs such as ERα have shown that only 3-8%
of the ER binding sites are found within 1 kb and approximately only 4% of the targets
were transcriptionally regulated by ERα (Kwon et al., 2007). Furthermore, a recent
genome analysis using 125 different cell and tissue types have annotated DNase I
hypersensitive sites (DHSs) within the human genome that indicates euchromatic regions.
These regions were found to encompass many regulatory genomic elements including
enhancers, promoters, insulators, and silencers. This analysis indicates that with respect
to the TSS, approximately 3% of DHSs are localized to the TSS, 5% within 2.5Kbs and
95% are positioned further away (Thurman et al., 2012). The ChIP-DSL approach would
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have failed to identify many targets where ZNF217 binds to promoter regions that are
greater than 1 kb from the TSS.
To circumvent this problem, I used ChIP sequencing (ChIPseq) to identify
ZNF217 binding sites genome-wide at single nucleotide resolution. The single nucleotide
resolution consequently allows for easier validation and characterization of putative DNA
binding motifs following mapping of the DNA to the genome. ChIP-DNA with a high
degree of repetitiveness can also be better represented using ChIPseq compared ChIP-onchip method since the ChIP-on-chip method relies on hybridization to complementary
strands. Futhermore, ChIPseq has a very large dynamic range with the capability to detect
regions of DNA bound lightly and regions with highly enriched binding. For ChIP on
chip approaches, abundantly bound ChIPed DNA can often confer intense signal that
generally has a bleaching effect and sparsely bound regions are too low for detection
(Park, 2009). Due to the dynamic nature and high resolution mapping of the binding site,
bound regions can be quantitated to confer strength of binding. Using this approach I was
able to expand the number of genes whose promoters were occupied by ZNF217 (within
5Kb from TSS). I also mapped the binding sites of both ZNF217 and CtBP1 throughout
the genome which indicated a significant overlap and this observation is consistent with
earlier biochemical assays showing that they are components of the same complexes
(Cowger et al., 2007; Quinlan et al., 2006). Surprisingly, only a small overlap between
ChIP-DSL and ChIPseq was observed and the reasons for this are unclear but may be a
result of the differences between the two assays, as discussed above. Nevertheless, both
assays confirmed the binding of ZNF217 to a similar region of the p15ink4b promoter.
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Importantly, the ChIPseq analysis excluded binding to the other regions at the ink4 locus,
highlighting that the binding is unique to the p15ink4b gene.
The identification of p15ink4b is consistent with the FACS analysis which
demonstrates that ZNF217 overexpression facilitates the transition of cells from G1 to S
phase and is in agreement with published reports in other cell lines indicating that
overexpression of ZNF217 causes an increase in cell proliferation (Thollet et al., 2010;
Vendrell et al., 2012). Silencing of ZNF217 in MCF7 cells also dramatically decreased
the phosphorylation of the Rb protein suggesting that ZNF217 promotes the transition
through G1/S by maintaining Rb in a hyperphosphorylated state. It is possible that the
hyposphosphorylated state of Rb and the G1 arrest observed following ZNF217
downregulation could be as a result of p15ink4b expression (Figure 4.1).

4.3 Transcriptional Regulation ofp15ink4b
The p15ink4b gene is part of the ink4 locus, which is encoded on chromosome
9p21, and also contains p16ink4a and p14ARF genes. p15ink4b and p16ink4a are often silenced
through DNA hypermethylation and co-deleted in many cancers (Simboeck et al., 2011).
The expression of genes in the ink4 locus provides an effective barrier against cellular
hyperproliferation that is associated with many cancers and as a result, the transcription
of the locus is tightly regulated. For example, the polycomb group complex consisting of
PRC1 and PRC2 are important repressors of the ink4 locus in many cell types (Bracken et
al., 2007). Surprisingly, knockout of p15ink4b in mice did not result in tumor formation
and MEFs were still responsive to TGFβ signaling. This suggests that there may be
compensatory mechanisms. However, deletion of both p16ink4a and p15ink4b significantly

Figure 4.1: Model of p15ink4b regulation by ZNF217 and TGFβ.
Normally, the p15ink4b promoter is bound by the ZNF217 repressor complex and its
expression is repressed. The repression is mediated by the removal of H3K4me by LSD1
and H3K9/14Ac by HDAC1/2 and promoter hypermethylation at the CpG island by
DNMT3A. TGFβ stimulation releases the ZNF217 repressor complex and promotes the
binding of SMAD/TDG/CBP activation complex to the same region of the promoter.
TDG along with AID and TET facilitates active DNA demethylation of the promoter and
CBP acetylates the histones leading to the activation of p15ink4b. p15ink4b can inhibit
cyclin D-CDK4/6 complex. This results in the hypophosphorylation of Rb and inhibition
of the cell cycle at G1. However, overexpression of ZNF217 can prevent the binding of
SMAD/TDG/CBP complex to the promoter leading to the repression of p15ink4b. This
can lead to the activation of cyclin D-CDK4/6 resulting in the phosphorylation of Rb and
ultimately G1/S transition. Black circles represent DNA methylation. Blue and Red
circles indicate H3K4me and H3K9/14Ac. Green arrow represents activation of the cell
cycle. Red arrow indicates inhibition of the cell cycle.
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increased the tumor incidence suggesting functional redundancy (Krimpenfort et al.,
2007; Ortega et al., 2002).
Expression of p15ink4b is regulated primarily at the transcriptional level and is cell
type specific (Figure 4.1) (Siegel and Massague, 2003). The p15ink4b proximal promoter
contains two SMAD binding regions (SBR), SBR1 (-538/506) and SBR2 (-443/-385).
SBR1 is flanked by the fork-head binding element. TGFβ treatment promotes binding of
the SMAD2/3 and SMAD4 heterodimers to the promoter and, along with FOXO factors,
facilitate the transcription of p15ink4b. ZNF217 binds within −566 to −426 of the p15ink4b
promoter which contains the ZNF217 consensus binding sites that overlap with the
SMAD2/3 and FOXO binding elements suggesting that binding between the SMAD2/3
and ZNF217 is mutually exclusive.
A complementary mechanism has been postulated for p15ink4b regulation in some
cell types and involves the MIZ1 transcription factor which binds to the Inr element
found at the proximal promoter region (-150/+75) and activates p15ink4b(Figure 4.1).
MIZ1 is repressed by the interaction with MYC, which prevents recruitment of
coactivators, such as p300 (Staller et al., 2001). TGFβ treatment promotes the
downregulation and dissociation of MYC from MIZ1, relieving the repression, and along
with binding of SMADS, FOXO and SP1 transcription factors facilitates the activation
of the p15ink4b gene.
In this study, knockdown of ZNF217 caused a robust increase in p15ink4b
expression but did not affect the occupancy by MYC at the promoter, demonstrating that
ZNF217-mediated repression of p15ink4b is not dependent on MYC binding. Although the
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reason for this discrepancy is unclear it is possible that ZNF217 and MYC occupy the
promoter of p15ink4b and repress its expression in distinct cell populations. Alternatively,
ZNF217 and MYC may both be required for the repression of p15ink4b and the loss of
either protein can lead to the relief of repression. Based on the established role that MYC
plays in regulating p15ink4b in some cell types, this observation will require further
investigation.

4.4 ZNF217 Represses p15ink4b through Chromatin Modifications
Treating cells with formaldehyde crosslinks protein-DNA and protein-protein
interactions, so it is formally possible that ZNF217 could bind to the p15ink4b promoter
through association with other transcription factors and that CtBP1may bridge this
association through its PXDLS binding cleft (Quinlan et al., 2007). However, the
ZNF217 binding region at the p15ink4b promoter contains both of the consensus binding
sites identified for ZNF217. Furthermore, I have demonstrated that knockdown of
ZNF217 causes the loss of promoter occupancy by the other constituents of the ZNF217
complex such as LSD1 and CtBP1 whereas CtBP1 knockdown did not affect the
recruitment of either ZNF217 or LSD1. This suggests that ZNF217 is required for the
recruitment of the chromatin modifying enzymes to the p15ink4b promoter and ZNF217’s
recruitment is independent of CtBP1. Consistent with this, recent crystallographic studies
demonstrate a direct interaction between ZNF217 and DNA (Nunez et al., 2011;
Vandevenne et al., 2013).
I have also demonstrated that the binding of the ZNF217 complex is associated
with the lack of activating chromatin marks that coincide with the inactive state of
p15ink4b. In proliferating MCF7 cells H3K4 is unmethylated and knockdown of ZNF217
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caused a dramatic increase in H3K4me2 and a modest increase in H3K9/14 acetylation at
the proximal promoter region of p15ink4b. Surprisingly, there was a robust decrease in
acetylation following ZNF217 silencing near the TSS that coincided with transcriptional
activation of p15ink4b. H3K9/14 acetylation is normally associated with transcriptional
activation and the reasons for this paradoxical result are unclear. It is possible however,
that the H3K9/14 acetylation at the TSS serves as a docking site for certain BRDcontaining proteins that facilitate repression. Alternatively, activated gene promoters
recruit many proteins such as the GTFs to the TSS and it is possible that downregulation
of ZNF217 does infact increase histone acetylation but our ChIP assay was unable to
detect this modification due to masking by the occupying proteins (Agalioti et al., 2002).
Our analysis was limited to the region encompassing the ZNF217 binding site.
However, it has been documented that these marks can rapidly spread over extended
regions in either direction. During thymocyte maturation, the silencing of the mouse
terminal transferase (dntt) gene was initiated by the removal of H3K9Ac and H3K4me
and a gain of H3K9me at a specific region of the promoter (~200bp) at approximately
50bp upstream of the TSS. The pattern of these repressive marks then spread rapidly over
large regions of DNA upstream and downstream from the TSS to a maximum distance of
approximately 12Kbs (Su et al., 2004).
The spreading of these marks may be mediated by chromatin modifying enzymes
that can recognize and bind a specific histone tail mark. For example, G9a/GLP proteins
bind H3K9me1/2 through a hydrophobic ANKYRIN (ANK) domain and can place
mono- or di-methylation marks on adjacent nucleosomes through the catalytic SET
domain. G9a/GLP-mediated initiation and spreading of these marks has also been
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observed on the Oct3/4 genes (Collins and Cheng, 2010). Kinetic ChIP experiments
following TGFβ treatment could be useful in assessing whether activating chromatin
marks that nucleate at the p15ink4b promoter is spread over the entire ink4 locus.

4.5 Role of Methylation in Transcription
In chapter 3, I demonstrated that expression of the p15ink4b promoter is
dynamically regulated and involves active DNA demethylation in response to TGFβ
signaling. In dividing HaCAT cells, the expression of p15ink4b is minimal and its proximal
promoter is methylated and occupied by the ZNF217/DNMT3A repressor complex.
A point of controversy in recent years has been whether transcriptional repression
is a direct consequence of DNA methylation, or whether DNA methylation is a secondary
mark that serves to reinforce the state imposed by repressive chromatin modifications.
However, multiple studies have demonstrated the dominancy of DNA methylation in
transcriptional repression. Treatment of cells with 5-azacytidine results in activation of
several repressed genes (Jones, 1985). Transfection of a methylated DNA template, but
not the unmethylated template, results in the assembly of highly compacted chromatin
structures that are nuclease-resistant and coincides with transcriptional repression
(Buschhausen et al., 1987; Keshet et al., 1986). Equivalent transcription was observed
immediately after injection of methylated and unmethylated DNA in Xenopus oocyte
nuclei. However, following assembly of chromatin, the methylated DNA conferred
transcriptional repression coinciding with nuclease resistance (Kass et al., 1997). These
studies suggest a direct causal relationship between DNA methylation and transcriptional
repression.
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However there are also studies which suggest that DNA methylation is a
secondary effect that occurs as a consequence of changes in chromatin marks and serves
to reinforce this repression. The hypoxanthine guanine phosphoribosyltransferase (hprt)
gene on the X chromosome is methylated after X chromosome inactivation (Lock et al.,
1987). Several studies in cancer cells have demonstrated that repression by the PcG
complex, through methylation of H3K27, precedes DNA methylation (Gal-Yam et al.,
2008; Ohm et al., 2007; Schlesinger et al., 2007). Embryonic carcinoma cells that
differentiate following retinoic acid treatment show that the repression of the pleuripotent
genes begins with the appearance of a nucleosome at the oct4 enhancer and nanog
promoter followed by the occupancy by DNMT3A and DNA methylation (You et al.,
2011). It is clear from all of these studies that although DNA methylation and histone
modifications are carried out by different sets of enzymes, there is a tight relationship
between these two epigenetic marks that is important for defining transcriptional
outcome. My analysis of the p15ink4b promoter demonstrated that both chromatin tail
modifications and DNA methylation associated with the transcriptional state of the gene
and based on the observations presented above, both of these marks may mutually confer
a transcriptional state at p15ink4b.
Methylation of H3K4 inhibits DNMT binding and prevents de novo methylation
of the underlying DNA. Consequently, H3K4me is permissive for transcriptional
activation and is often enriched in the promoter regions of actively transcribed genes
(Chotalia et al., 2009; Meissner et al., 2008; Ooi et al., 2007). In our study TGFβ
treatment of HaCAT cells resulted in the release of DNMT3A from the p15ink4b promoter
which coincided with the increase of H3K4me2 mark suggesting the possibility that the
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increase in H3K4me2 mark inhibited the binding of DNMT3A. In contrast, knockdown
of TDG prevented TGFβ mediated DNA demethylation at the promoter and conseqently
inhibited the expression of p15ink4b. These observations imply that DNA methylation can
act as both an instructive mark and an epigenetic mark to reinforce repression of an
already inactive chromatin however it is most likely the cross-talk between DNA
methylation and chromatin that collectively confer repression.

4.6 ZNF217/DNMT3A Complex Methylates the p15ink4b Promoter
In MCF7 cells the CpG island at the p15ink4b promoter is hypermethylated and
p15ink4b is silenced.

However, downregulation of ZNF217 caused a dramatic DNA

demethylation of the promoter which coincided with robust expression of p15ink4b.
Downregulation of DNMT3A resulted in only a partial decrease in promoter methylation.
The reasons for this are not entirely clear but can be attributed to the functional
redundancy between DNMT3A and DNMT3B (Kaneda et al., 2004). Using ChIP-reChIP
assay, I demonstrated that DNMT3A and ZNF217 colocalize to the same region on the
p15ink4b promoter. These results suggest a mechanism whereby ZNF217 may recruit
DNMT3A and methylate the promoter (Figure 4.1). The formation of chromatin
modifying complexes containing DNMTs has been previously observed. For example
DMNT3A/B interact with EZH2 of the PRC2 complex and this interaction is responsible
for targeting DNMTs to PRC2 target genes (Vire et al., 2006). Interestingly, about 49%
of genes that are hypermethylated in colon cancer are targets for PcG complex and the
PcG targets are 12 times more likely to acquire hypermethylation in colon cancers
(McGarvey et al., 2008; Widschwendter et al., 2007).
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It has been demonstrated that deregulated targeting of methyltransferases
correlates with hypermethylation at promoters in cancers. For example, upregulated
expression of DNMT3B1 within the Apcmin/+ background exacerbated colorectal cancer
and correlated with hypermethylation of tumor suppressor genes (Linhart et al., 2007).
Hypermethylation of CpG islands at promoter regions of genes and hypomethylation at
repetitive elements are hallmarks of cancer (Jones and Baylin, 2002). These observations
suggest a potential link between DNA methylation and ZNF217 that may play a role in
promoter hypermethylation in cancers where ZNF217 is overexpressed.

4.7 The Mechanism of DNA demethylation at the p15ink4b promoter
Serum starvation causes cells to enter a quiescent state (G1/G0) resulting in
growth arrest (Khammanit et al., 2008). Under these conditions, my result demonstrates
that the p15ink4b promoter is hypermethylated. My results also indicate that the treatment
of serum starved HaCAT cells with TGFβ triggered DNA demethylation at the p15ink4b
promoter as early as 20 mins after treatment and demethylation was nearly complete by 3
hrs following treatment. The rapidity of this response suggests that DNA demethylation
at the p15ink4b promoter cannot occur through the passive mechanism which requires
DNA replication. However, it has been demonstrated that a small percentage of cells may
still undergo cell division following serum starvation (Khammanit et al., 2008). Therefore
to confirm that the passive mechanism is not responsible for demethylation of the p15ink4b
promoter, I treated HaCAT cells with L-mimosine which has been shown induce growth
arrest at late G1 phase of the cell cycle before initiation of DNA replication (Krude,
1999). Treatment of cells with TGFβ following treatment with L-mimosine still resulted
in DNA demethylation. However, I also observed DNA demethylation of the promoter in
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cells treated with L-mimosine alone. L-mimosine is toxic to cells suggesting that the
observed demethylation at the p15ink4b promoter is as a result of treatment with this amino
acid since toxicity may upregulate cell cycle inhibitors including p15ink4b in an attempt to
halt cell division (Jenkins et al., 2011; Tsai and Ling, 1971). These observations
collectively support an active DNA demethylation mechanism at the p15ink4b promoter
following TGFβ stimulation.
Two

interrelated

mechanisms

have

been

postulated

for

active

DNA

demethylation. One mechanism is mediated by the AID/APOBEC enzymes that catalyze
deamination of 5mC to T. This generates a G:T mispair which is then cleaved by TDG or
MBD4 and then reverted to G:C pairs by components of the BER machinary (Rai et al.,
2008). The other mechanism involves hydroxylation of 5mC to 5hmC by the TET
enzymes. The 5hmC intermediate is oxidized further by the TET enzymes to generate
5fC and 5caC which are recognized and removed by TDG and the BER machinery (Guo
et al., 2011a).
ChIP analysis demonstrated that treatment with TGFβ increased recruitment of
AID to the the p15ink4b promoter. However, knockdown of AID did not abrogate DNA
demethylation in response to TGFβ but knockdown of both AID and APOBEC2
demonstrated a modest decrease in TGFβ dependant DNA demethylation. This suggests a
deamination-coupled mechanism which is supported by transgenic studies in zebrafish
embryos where the co-expression of AID/APOBEC2 and MBD4 is required for
demethylation of an ectopically introduced methylated DNA template (Rai et al., 2008).
However, DNA immunoprecipitation analysis of the p15ink4b promoter indicated
enrichment in 5hmC from TGFβ treated HaCAT cells when either TDG or the
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deaminases (AID and APOBEC2) were silenced using siRNA. This result suggests a
mechanism whereby 5mC is converted to 5hmC prior to removal. However, given the
involvement of AID/ABOBEC2 we favor a mechanism whereby 5hmC is deaminated to
5hmU which is then excised by TDG or MBD4. Recent studies have demonstrated that
combined overexpression of TET1 and AID cooperate in demethylating a DNA duplex
and that 5hmC proved to be a more effective substrate for the deaminases than 5mC (Guo
et al., 2011b). Consistent with this, it was demonstrated that in the parietal cortex of
psychotic patients upregulation of TET1 and downregulation of APOBEC3A/3B
correlates with increased 5hmC levels (Dong et al., 2012). In addition, TDG and MBD4
have robust glycosylase activity against 5hmU:G mispair (Cortellino et al., 2011;
Hashimoto et al., 2012a; Morera et al., 2012). However, a recent study has called into
question the ability of AID to process 5hmC (Nabel et al., 2012). They demonstrated that
AID/APOBECs have decreased deamination activity against 5mC compared to C and no
detectable activity against 5hmC in vitro. This was attributed to the bulkiness of the
hydroxymethyl group which disfavored deamination activity.
5hmC represents 0.3-0.7% and 4-6% of all cytosines in neurons and ESC,
respectively, suggesting that 5hmC may be a bona fide epigenetic mark, in addition to
being a metabolic intermediate (Kriaucionis and Heintz, 2009; Szulwach et al., 2011;
Tahiliani et al., 2009). Furthermore, genomic analysis reveals that 5hmC is found at
regulatory regions such as promoters near TSSs, enhancers and exons (Ficz et al., 2011;
Pastor et al., 2011; Stroud et al., 2011; Wu et al., 2011). 5hmC levels also correlate well
with DNAase I hypersensitive regions and it is often found adjacent to transcription
factor binding sites. Ultimately, 5hmC is associated with transcriptional activation (Yu et
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al., 2012). In contrast, the derivatives of 5hmC (5fC and 5CaC) are much less abundant
consistent with the theory that the 5hmC mark may play a more direct role in
transcription (Ito et al., 2011). 5hmC could activate transcription by preventing the
binding of the repressive methyl binding proteins such as MeCP2 (Valinluck et al., 2004).
However, a recent analysis has shown that MeCP2 binds to 5hmC and facilitates
transcription whereas binding to 5mC by MeCP2 promotes repression. In accordance
with these observations the authors propose that 5hmC is a stable epigenetic mark that
confer transcriptional activation (Mellen et al., 2012). At the p15ink4b promoter, it is
possible that conversion of 5mC to 5hmC in response to TGFβ treatment may provide an
initial rapid transient mechanism to activate transcription, perhaps through switching the
activity of MeCP2 that is already bound to the promoter from a repressor to an activator.
The sustained treatment with TGFβ could result in full demethylation leading to the
expression of p15ink4b for longer time points which is required for the maintenance of the
cells in a quiescent state. Further investigation is required to decipher such mechanism.
Our results do not discount the possibility that multiple demethylation pathways
play a role in active demethylation at the p15ink4b promoter. Structural analysis has
demonstrated that TDG is a highly versatile enzyme, capable of cleaving the glycosidic
bond of several intermediate derivatives of 5mC that is mispaired with G including T, U,
5hmU, 5fC and 5CaC (Hashimoto et al., 2012b). The generation of these metabolic
intermediates is believed to be very rapid and transient. Unfortunately, the availability of
techniques and products, such as modification specific antibodies, to quantitatively detect
many of these metabolic intermediates with high sensitivity are somewhat limited.
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Consequently the relevancy of many of these intermediates must await further
clarification.

4.8 The Activation Complex; SMAD/TDG/CBP
We have identified a novel activation complex consisting of SMAD2/3, CBP and
TDG, that assembles at the p15ink4b promoter in response to TGFβ (Figure 4.1). Τhis
complex is required for the active DNA demethylation and coincides with occupancy by
several BER enzymes. Our immunoprecipitation assay suggests that SMAD2/3 and TDG
physically interact and our ChIP-reChIP assay demonstrates that TDG interacts with both
SMAD2/3 and CBP at the p15ink4b promoter. Studies using breast cancer cells have
shown that TDG associates with CBP and the coactivator SRC3 in response to β-estradiol
treatment and these associations are required for DNA demethylation of the PS2
promoter (Chen et al., 2003; Lucey et al., 2005; Tini et al., 2002). More recently, it has
been demonstrated in MEFs that TDG associates with both the liganded RAR and p300 at
some RAR target genes. Furthermore, the authors demonstrated that the recruitment of
p300 to the RAR is dependent on TDG (Cortellino et al., 2011). Although we have not
examined the assembly of the SMAD/TDG/CBP complex, it is possible that TDG may
act in a similar manner to recruit CBP to the SMAD heterodimers.
A surprising result of this study is that TDG and MBD4 both appear to mediate
the active DNA demethylation and activation of p15ink4b gene and are targeted to the
same region of the promoter in response to TGFβ. However, based on ChIP-reChIP
analysis, we did not observe an interaction between MBD4 and SMADs or MBD4 and
TDG at the p15ink4b promoter suggesting that MBD4 may work independently of TDG
and SMADs. It is possible that TDG and MBD4 are functionally redundant and mediate
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the actions of TGFβ in different cell populations. Although they are non-homologous
proteins, the catalytic activities of TDG and MBD4 are very similar. Another possibility
is that the promoter may be initially targeted by the SMAD-TDG-CBP complex
promoting an open chromatin conformation which then facilitates the binding of MBD4
through its methyl binding domain. Binding of MBD4 may promote a more complete
demethylated state of the promoter and since coregulator binding to the promoter is
dynamic, MBD4 may also ensure that the CpG sites remain demethylated by
counteracting the activities of DNMT containing complexes, such as the ZNF217
complex.

4.9 ZNF217 Overexpression Impairs TGFβ Induced Coregulator
Exchange
HaCAT cells are immortalized keratinocytes which contain normal physiological
levels of ZNF217. To examine the consequences of ZNF217 overexpression on TGFβ
responsiveness of p15ink4b, I transduced ZNF217 in HaCAT cells using adenovirus.
ZNF217 overexpression inhibited the promoter demethylation and expression of p15ink4b,
compared to the mock transduced cells, following TGFβ treatment. ChIP analyses
demonstrate an increase in ZNF217 occupancy at the p15ink4b promoter and a reduction in
occupancy by SMAD2/3 and TDG. However, no change in the cellular levels of TDG or
SMAD2/3 was observed following overexpression of ZNF217. Taken together, with the
observation that ZNF217 and SMAD2/3 have overlapping binding sites within the
p15ink4b promoter, these results suggests that ZNF217 interferes with coregulator
exchange and this imbalance inhibits p15ink4b expression (Figure 4.1).
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Deregulation in DNA methylation/demethylation has recently been documented
in vivo using zebrafish where, the loss of the APC tumour suppressor gene causes
upregulation of the DNA demethylase machinery (MBD4/TDG, AID and GADD45) and
prevents differentiation of intestinal stem cells resulting from a concomitant
hypomethylation of key intestinal genes (Rai et al., 2010). Similar findings have been
observed in human colon adenomas obtained from patients that harbor mutations at APC.
This study complements our findings and suggests that oncogenic events leading to the
dysregulation of active DNA demethylation could have broad implications in cancer
progression.

4.10 Summary and Model of Transcriptional Regulation at p15ink4b
The p15ink4b gene is a CDK inhibitor and an important component of the TGFβ
cytostatic response. In this study, I demonstrate for the first time that promoter
hypermethylation and transcriptional silencing of the p15ink4b gene involves an
association between the ZNF217 complex and DNMT3A/B. Occupancy by the ZNF217
complex also leads to a repressive chromatin landscape at the promoter. Treatment with
TGFβ triggers the release of the ZNF217/CoREST/DNMT3A complex and the
concomitant binding of an activation complex that includes SMAD 2/3, TDG and CBP.
The association of this complex with the promoter is required for the TGFβ mediated
active DNA demethylation and activation of p15ink4b. Additional constiuents may be part
of this complex and could be required to mediate the active DNA demethylation
including AID/APOBEC and possibly GADD45α. Collectively, this complex may
regulate transcription of genes by simultaneously acetylating histone tails and
demethylating the CpG dinucleotides at the promoters of genes (Figure 4.1).
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Our data also shows that active DNA demethylation at the p15ink4b promoter
involves conversion of 5mC to 5hmC which suggests the involvement of TET proteins in
this mechanism although this has not been formally demonstrated. Indeed, our dot blot
analysis demonstrated a global DNA demethylation in response to TGFβ stimulation and
this demethylation could be at promoters of genes, such as p15ink4b and p21Cip1, affecting
transcription or at repetitive sequences/transposons. Finally, I have shown that
overexpression of the ZNF217 oncogene, which is associated with a loss of proliferative
control and TGFβ resistance in breast and ovarian cancer, inhibits p15ink4b expression by
impairing the TGFβ-dependent recruitment of the activation complex. These results
highlight the dynamic nature of DNA methylation/demethylation and suggest that
coregulator balance is a critical determinant of the status of the p15ink4b gene (Figure 4.1).
In many cancer cells, it is possible that ZNF217 overexpression sequesters a
limited pool of the other constitutents of the ZNF217 complex recruiting them to
promoters of genes where they would not be bound under normal physiological
conditions. This can severely upset the normal delicate coregulator balance leading to the
aberrant transcriptional regulation of target genes. FACs analysis demonstrates that this
deregulation of genes can result in the bypassing of the major check-point at G1 phase of
the cell cycle and lead to the promotion of G1/S transition ultimately causing increased
cell division when ZNF217 is overexpressed. ZNF217 transduced cell lines also
demonstrate resistance to the anti-proliferative effect mediated by TGFβ. p15ink4b
provides a potential link to the increased G1/S phase transition and TGFβ resistance seen
following the overexpression of ZNF217 (Figure 4.1). ZNF217 may target additional
gene promoters in a similar fashion and deregulate their expression to collectively
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provide tumors having the ZNF217 overexpression with TGFβ resistance, increased
proliferation, resistance to apoptosis, EMT and metastasis, ultimately leading to the poor
prognosis that is associated with its overexpression.

4.11 Significance and Future Directions
In cancer, aberrant DNA methylation is thought to be an early indicator of the
disease and global methylation changes are often observed as a result of epigenetic reprogramming (Novik et al., 2002). The recent identification of active DNA demethylation
mechanims has provided a new level of complexity in gene regulation and establishes a
new role for this mark as a dynamic regulator of transcription. However, the exact
mechanism of DNA demethylation remains unclear and will require further studies.
To complete our understanding of the TGFβ pathway, additional targets for the
activation complex SMAD/TDG/CBP needs to be elucidated. Since advanced techniques
are becoming more available, global approaches such as ChIPseq in conjunction with
RNAseq should be utilized to isolate a subset of targets that are bound by the components
of this complex and transcriptionally activated in response to TGFβ. In conjunction with
this, methylation status at the gene promoters can also be assessed using genome-wide
MeDIP assays.
Our knowledge of the mechanism employed by ZNF217 to transcriptionlly
repress genes may allow for better treatment strategies for ZNF217 amplified cancers.
For example, HDAC inhibitors may not be effective in ZNF217 overexpressed cancers
since the mode of transcriptional repression by this complex also involves histone tail
demethylation and DNA methylation (Gryder et al., 2012). Drugs that target all three
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enzymatic activities associated with the ZNF217 complex, histone deacetylase, histone
demethylase and DNA methyltransferase may be required to effectively treat tumors that
have the ZNF217 amplification. In the future, ChIPseq in conjunction with RNAseq for
ZNF217 needs to be conducted to expand the number of genes that are regulated directly
by ZNF217 to completely understand the oncogenesis associated with ZNF217
overexpression. Furthermore, the identification of additional targets for the SMAD
activation complex and ZNF217 can be compared to isolate a complete set of genes that
confer resistance to the anti-proliferative effects of TGFβ when ZNF217 is amplified.
Collectively, this study provides a comprehensive understanding of the
mechanisms that underlies the transcriptional regulation of genes by TGFβ and how this
regulation is affected by oncogenes.
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